var title_f1_23_1392="Intraabdominal desmoid tumor in familial polyposis CT";
var content_f1_23_1392=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F54879&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F54879&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intraabdominal desmoid tumor in familial polyposis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 347px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Computed tomography (CT) scan through the mid-abdomen demonstrates a large well-circumscribed soft tissue mass arising in the mesentery (arrow); the mass represented a desmoid tumor (aggressive fibromatosis).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_23_1392=[""].join("\n");
var outline_f1_23_1392=null;
var title_f1_23_1393="Sertindole: International drug information";
var content_f1_23_1393=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"13\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Sertindole: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F9659605\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antipsychotic Agent, Atypical",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F9659606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of schizophrenia",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F9659608\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: Oral: 4-24 mg/day; maximum dose: 24 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821077\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9659609\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: 4 mg, 12 mg, 16 mg, 20 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10388 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-61.234.146.186-AFBC45AB80-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_23_1393=[""].join("\n");
var outline_f1_23_1393=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9659605\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9659606\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9659608\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821077\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9659609\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10388\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10388|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_23_1394="Blanket phototherapy PI";
var content_f1_23_1394=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F73723&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F73723&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Baby getting home light therapy for jaundice",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Wikipedia under the terms of the GNU Free Documentation License, Version 1.2 of any later version published by the Free Software Foundation.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_23_1394=[""].join("\n");
var outline_f1_23_1394=null;
var title_f1_23_1395="Pulm AVM CT III";
var content_f1_23_1395=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F53034&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F53034&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Patient with Weber-Osler-Rendu syndrome presents with bilateral AVM's",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 265px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A CT scan demonstrates a right upper lobe AVM.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_23_1395=[""].join("\n");
var outline_f1_23_1395=null;
var title_f1_23_1396="Stasis dermatitis with bulla formation";
var content_f1_23_1396=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F78581&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F78581&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Stasis dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A bulla is present within an area of stasis dermatitis on the lower leg.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from:",
"     <a href=\"file://www.visualdx.com\" target=\"_blank\">",
"      www.visualdx.com",
"     </a>",
"     . Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_23_1396=[""].join("\n");
var outline_f1_23_1396=null;
var title_f1_23_1397="Fluocinolone, hydroquinone, and tretinoin: Patient drug information";
var content_f1_23_1397=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"15\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Fluocinolone, hydroquinone, and tretinoin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/39/13940?source=see_link\">",
"     see \"Fluocinolone, hydroquinone, and tretinoin: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F172279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Tri-Luma&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10112082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10025610\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691349",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower the color of freckles on the skin.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10025609\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702138",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to fluocinolone, hydroquinone, tretinoin, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697143",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a sulfite allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10025614\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696604",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       After stopping this drug, some of the color change may come back.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696955",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Some weather conditions may irritate your skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696817",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use coverings (bandages, dressings, make-up) unless told to do so by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10025615\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698029",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698191",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Itching.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10025617\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10025612\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694420",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on 30 minutes before you go to bed.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean affected part before use. Make sure to dry well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin and rub in gently.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695526",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Practice good skin care and avoid the sun.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10025613\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696441",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put on 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10025618\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699391",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a refrigerator. Do not freeze.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10025619\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11736 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-A7B94B43F3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_23_1397=[""].join("\n");
var outline_f1_23_1397=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172279\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10112082\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025610\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025609\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025614\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025615\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025617\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025612\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025613\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025618\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025619\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?13/39/13940?source=related_link\">",
"      Fluocinolone, hydroquinone, and tretinoin: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_23_1398="Ileocecal tuberculous enteritis";
var content_f1_23_1398=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F83832&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F83832&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 533px\">",
"   <div class=\"ttl\">",
"    Ileocecal tuberculous enteritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 513px; height: 413px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGdAgEDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD3v4nePtL+HWg2+ra1b31xbz3S2ipZojOHKO4JDMoxhD39K8z/AOGpPBn/AECPEn/fiD/49Sftm/8AJMtI/wCw1F/6Inry34G/CPwz448Car4g8S6lqtl9hvJYWNrLGsaxJDHIWO6Njn5279AOKAPU/wDhqTwZ/wBAjxJ/34g/+PUn/DUngz/oEeJP+/EH/wAeri/hd8JPhj8SdMvLzQdU8YQi0mEMsN3JbJIMrlWwsbDaecc/wnivmuM5RSx7Ak0AfZB/ak8Fjk6T4kA9TBb4/wDR1dxpvxOOpQJNaeDfE7I6CQbjZIdpGRkNcgj8a8E/Zs+GaXlxb+LfEkDrbAn+zYX4ErDrMR3UcgA8E88ivooWtvbWz3FviYgkE55PrXNVruDtE6aNKMvjKt38RpbSLzZ/BniVY9wXcHsSAffFzxSJ8SJGk8seDfEofg7WaxB56dbmqus6ZeX7wT2MmxJF8maFjjI68/59KnVRHbpJPKCHXbJOT9zaOP1xWP1mfkdSwlJq93/XyH/8LHk3sv8AwhviTcoDH57Hoe//AB80g+JTFVYeD/EeGbaD5lj1/wDAmsjWWuHuYxHBHNaPschWxlkY7lz2HtVB5I0jkjtyY9zkqmfuZPCmoljJrt/XzOillkKnf8P8joB8U0Of+KQ8SjBIOWsh04/5+aQ/FRASD4R8SZHX5rL/AOSa5JZCVWWXkr9055I7ZqGW581doGCByc1l9fqdl/XzO2OSUOrf4f5HXt8WoFGT4T8SY+tl/wDJNN/4W7bZx/winiT87L/5JrhZchyFxtBHAOaYWaVcHjtyKPr9Xsv6+Zf9h4fpKX3r/I79vi1brt3eFPEY3HAy1kMnr/z800/F22BwfCniTPXrZf8AyRXBNKUQ7uWHBOOcVVdvmIY/N27Zqvr1Tsv6+YLI8P8AzP8AD/I9EHxisyQB4V8SZ+tn/wDJFH/C47P/AKFTxL/5J/8AyRXme7JIUnrzng09GIJQglj0Xrn6UfXqnZClkmHS+KX3r/I9Ib4yWSkA+FfEuT/15/8AyRTl+MNoxwvhTxKT6f6H/wDJFebPG2XGORgMM8qeoz9aYzCEF2zuj549aPr1Tsif7Fw9tJP8P8j0qP4x2Us0kMXhbxJJKiFyiGzZsDrgC45PsOaD8ZLJVJbwt4kXBI+b7GDkckY+0dfbrXlccsi6d5VqyFQ+5X/iTLAkA9fpVuGJYNRmdZpJ0dgAz/eY/wC1n+Ic/Wn9en2Rk8mpLq/w/wAj0ofGG0Ybh4U8SkYBz/off/t4qIfGnTy20eF/Em4f9ef/AMkV5ukHlvKFnbdBbN5m47guG4fHp0B9PpUcaedD5jtGVbo6HOCR0/Oq+uT7Ij+yqPd/h/keoN8ZLFVDN4W8SBScAk2fX/wIqGT42abECX8MeJAB7Wf/AMkV5Y5cZiIaR84xjgkUnlC4w43puB2bhwccY/OmsZPsiHltBdX+H+R6efjppIIB8NeJcnkfLac/+TFQzfH3RIYmlk8OeJgigk4jtScDrwJ815Fa3EVy8sUsTJIq4YOMEex/+tVS6UxybXUbSOTjqKpYqXUxlgKW0W/6+R6eP2o/BhXI0jxJj/rhB/8AHqX/AIaj8Gf9AjxJ/wB+IP8A49XzR460I288mo2sbmJuZl/un+8PauQJyRg5FdsZqSujy6sHTlys+xv+GpPBn/QI8Sf9+IP/AI9W94F+Pnhjxp4rsPD+madrcN5eb/Le5hiWMbI2kOSsrHoh7da+Gq9O/ZnP/F8vDH+9c/8ApLNVEH1N8TPjN4f+HevwaRrNjq9xczWq3atZxRMgRndQCWkU5yh7elcn/wANReDf+gR4k/78W/8A8ery/wDbG/5Knp3/AGBof/R9xVqL4UeCrTw/4El1B/GN9rHimzjmht9Nlswok8lJHGZVUKPn4yx6UAejf8NReDf+gR4k/wC/Fv8A/HqP+GovBv8A0CPEn/fi3/8Aj1eV+KPhn4LHwa1Pxt4WvvEhltZkgFvqTwYD/aEicMEj5wGOCrYz+VeJW0fnNz9wdT/SgD7DT9p3whIqlNG8SkN0/cW/P/kapP8AhpjwngH+xfEvIz/qbf8A+PV8loDlgOTnn6e1OUAMFjAZywUAfxH0/wA9qnmLULn1kf2mPCYGToniXHr5Fv8A/HqRf2mvCLHC6N4kY+ghtz/7Wr530zQ4IAj3m24uduSpxsT12+v1NayQxkbI0Tb3CgD+VZSrWOqGDctz3kftH+GTjGg+Jueg8m3/APj9B/aO8MjP/Ei8S8cf6q2/+P14BLAAzcZJ4OBx+lRyW8kilURjt4dhjHTuf6UvbM0WCXc+g/8Aho7wz/0AfE3/AH5tv/j9TR/tC+H5G2p4e8TE5x/qrbr/AN/6+forZA4l8r96Npzkbc46n04/lVq1t4440knYqr8jaP3jknAyD2xz+VT7d9C1gIvqe8j9oLQCFI8PeJTubYMR2vJ9P9fVj/he2j7gv/CN+JdxOANtp/8AJFeCqFtXdkbb5SkKFAPQ8c9+CcmtO5thHJIp2hyCXPPyr2AzyCaTxDRosth1bPav+F46VtVv+EZ8SgNyMraDP0/0ipR8a9OIz/wi/iX06Wf/AMkV5Ei7rdGU+WXJCZGSCOMH6mrkMIYhhjk5JB7EUvrLNf7Lpd3/AF8j1MfGewPTwv4k/wDJP/5IqRfjDaEkDwr4kOOv/Hn/APJFeaJD8uQMj1JAxVmOFQRyDxnI70vrMiv7Jpd3+H+R6F/wuG05/wCKU8S8DJP+h8f+TFIfjFZgZ/4RXxJ/5J//ACRXCiPClNpyTyg6Uu3dzH9eeABnBP4UniZLoH9k0+7/AK+R3P8AwuG0Gc+FPEwwM9LPp/4EU1/jLYoMt4W8SDp/z5//ACRXnjCW4uFSNQVIzjOflH8Wfeli0x5EVbiVpXwWRI2xjn+uaSxUuxf9j0bayf4f5HfN8bNNU4PhnxGD/wBuf/yRUZ+OOlDr4a8R/wDkn/8AJFcYNHiWXKQxhjgbupH+BqUaKhTLhdpHpmj61LsQ8ppL7T/r5HVSfHfRowS/hzxIADjIW0PP/gRVST9ojw7Hnf4f8TL9Ybb/AOP1yWo+E4ZlLeUFJ6MBgiuM1nwhd27M1swdf7rDkD6dDWkMQ29TnqZdCOzZ6w37SnhVcZ0TxJz0/dW3/wAfqsf2ovBoJB0jxKCDjBt4P/j1fPF7p0lu4SaEocknK1zGqWbffVW8xRyp9P8AGt4zuedUouB9X/8ADUXg3/oEeJP+/Fv/APHqP+GovBv/AECPEn/fi3/+PV8dA8daWtDE+xP+GovBv/QI8Sf9+Lf/AOPV3nws+KWi/Eo6oNDtNStjp3leb9tjjXd5m/bt2O3/ADzOc47V+f8AX05+xN/rvGv+7Y/+3FAH1DRRRQB4J+2d/wAkx0j/ALDUX/oieuP+Bmg6z4o/Z18U6H4dubS1u7/WHgkmuWZVWEw2/mY2qSSVyMe55rsP2zv+SY6T/wBhqL/0RPXxrsU8lQT9KAPvDwJ8MtQ8D/EKXUtK1Rbvw/d6ZFZ3UV1sScSwgLEyrFGqFQgC888knNfOP7Onwo/4TnUv7W12Nx4bs2AKjj7XKMfux32jPzH8O9c58Gvhpd/EbxJ9mRWt9HtcPfXiqDsU9EX1dscenJ9q+6/DHh/TfDGhWmkaHbC10+2GI4wckc5JJPJJJyTSAnltLWGzjighjgiSPy4wiALGo4AA6Ae1cjLfafpfl2MkzO8rMZDF/Bg9a7a6DMqps3xucOc/dWvMRpkWqXEc0dv5MyySC5AJPmbfukem7kmuLEJrVHZhWnozqxE87LIbkh41A+XowODn8RVHVIh5F7GYQV3GUR54bHUfy4q/JAiTWhD7W4cjOCRjAFcr4g8Q28UtxancskbOpCf3jxn64zXLJpI66UXKXulO/wBQygEbYUqJDtPUkdPrkc1zzX7K79VZgGBxwATzV6+NvFaFoVBhKecjjnd/e4+tUruK1s4UZlMgjXdIAeAu7Cn865rXZ9FRlCEbdSOWaYxM0g2oTjjspPcfWnGUwjy8bTt69hVb+1YZpRtUqw3beOCG7H8arPcMxBcYYnbyKTWpupXNE7m3EHIOCcdaJAUDJnOeQR1pkFzG6o64Y4H86juZ9zMoxxyDTsNSsMlYlNxDHHHuahGMqWOcDIbHT2qKbKFmMh3qyhlHVVPRj7dqgF0/kiRo1Kk8cdfWpY9d0aaxLNNCr/JHI+3djpxUdsTcWLqwKExlMnGA2cc+n+B9qqX920iEKvlbVBjYD+IHI+o9vemC7aa7nubaAW9sSHa137trH7wQ9due34VSVzCcmpWZLFbuvnT3k0vnoyJuB3Aqowyt344we4qO7t55JWSLOOrDHX02+x9K2japIrrHlnmUET9Q3pvHbjIzVHU0a1S0ZhKIJdkczRj54iGGSPcDp6092T7RQ3MeKzxciNcxMW2NvztQ+jeladjbx3Tyh5PLkjQbQ3ILqchW9iOh9av39tEt7PKksV9HuV3liO1bhOgP+y2Oo9RUUkYtmMh/dx8quDzz0z+lO1tDJ1XUXumdc6dD9tluPPkjuPJ82GMc72BGY29Qy5Hp6060tHbV3FhHCqSqXSEMACCM7Mn+Ids1JdXMKOs0YQuwUkLnAYdSAemeuOh68VUWcXIZpVXywGQsODg9qtO+hhJSWrKep38gkhntYmKSQlgqqQ0br14/ofWnW093dWs9nPC+GzJHID0J7j0NOm1S3tXidY2mKLgFvU/1qhc+Jc2u2KNFkIb7p6r/AIiq6HLUkV2t5ZLgCXzJPkK4VtrjA6571EkJ+zHzWZguMM/BFIuoySCNonVlY8ORy3rTpZC8UpLnBHKnpVeph7S+hnXTHy3WRQ8W0jDDII7g15n4n0cWFz51qji0k5w3WM/3T7elevSR2EmlMqwy/wBoPKrCcNuikj/iVh/CR2IrC1XTorqzlikjDwgYZfX8f6+tdFCpyPXYxrU1Vj5nkVenfszf8ly8MfW5/wDSWauB1vTH0262ks8D52SEcn/ZPuPWu9/Zlz/wvHwx35uef+3Wau9O6ueU007M6z9sb/kqenf9gWH/ANH3FeqN4Gv/ABb4J+EF/Z2ejaha6PpkMtzY6pIyR3Ae2iAHEUg4IzyvpXlf7Y3/ACVPTv8AsCw/+j7ivCREhIGxPypiPrfx/wCEb/wh+zf4usNUuoHa51GK7itrVmaCyje7gxBEWAJVceg69PX5fhUBQq/dGTj/AOv3qG3s4FbCou7+8VHH+FbMNqBwScZ4AzkYqJSNadNyKIQMCWG0DkDIzx9K3/DenFZxczIV8viHI6HjLfWptO0xNqySrkqPfIHPP1rpNPtFKxovMf3Qo4JHfn+lYSnZHo0cPYdZwCRJGKBgAuMjG7nr6n6Vd8rOSkaoOAML196vwWq7V3DJAxz049qspbYALDg4H/1uKw5j0I0zHNs284Bwe3Q0kdszEqwBHB6HjH8zxW39mAKsYxuJ4z296RoD0C/eBBIOML3/AA9anmLVG5hfZlSbCrGo7k8D2AHcn+lJNGGujvflgCozy+Tz9D61s3Nm0gXZgeWMxk87iOMAewPfiqS2kcse9kYByVx0JI79O54wKm9jdUSttJGEZV2jblV7dj6mrVpl5kRicFTkHn3J/GnrARj5QSMAZ9cVKsO3CxACRcFu+0k5x7Ck2aqnysSJmiGWUvuOT6j6fQ1u2pU2kQTmPAAI6jHHPaqMMCfPuQAICUzyNxbj69zU9rIwkt4TIISZkSSTZxEjMoZ8D0BJ9qhPWxc42941kwDgDGBnjqDUseUk2kHrgHv+PpVfWJNL07xBeS2919o0OyuA7x7ws1zCV+fY5xuVZWjXscbgM81Tsb+Q26qAhuIhhtykESE5wVODxnuOgFaTTjqzDD1o1pcsU16m5iBdAmSTzz4jkuoILOHcFjuHdzhVHZCv3i54IzxxWZdyh/OhjYqI5HRkzyHVipAI+9yD9aqyXCziQ8FgQQXY5XvkHqDnkVGrYB8rCRgl1wOeOpJ+naoq1lJKysb4fCTpzbcrpm7pACJORHhHCBWx94r94fhnJrSiC4IEQB3YAOPlyM5H4VieH3L3u0SSiKJjJnqvI5/kBg8V1drbLGCApwxZgx5IJOcDj8PpUQloXVjyNpksAjBKgAAYC8YB54qZSqN8i7lIyqsBkc8j6Vdt7IMcbEG7k5H6VqxaTbuoMiISeM4/StYxkzzaleMHdmCvluW2oOnFR3FlDKpDQHAA5HOPxrp4tCt22SeV1GOD1H0qVdBhXBVpOOPv5/yK15JHNLFUu55L4i8O2l1HIJbZGDdyOcV5f4n8HtHG0lqAcZIBr6Yv/DnmKdrErj0rjdc8N3EYdlh3KeSAKpSlFmbjTqrQ+RdZsXtpWYIy4++pGCD6j2rO6+n4V7j4z8LQ3Qkmhj2XCA4B4zgdDXjGo2TWkxUoVAOGQj7ldcJ8x5Vai6bKtfTn7E3+u8a/7tj/AO3FfMVfTn7Ev+t8a/7tj/7cVoYH1FRRRQB4J+2d/wAkx0j/ALDUX/oievlr4e+D9S8deKLTRdJQ5kO+efGVt4hjdIfpkcdzgCvrT9rDR7/X/BPh7StIt3ub+712KOKJe5+z3HJ9ABkk9gCa6H4K/DC2+HPh6SB5Y7nV7pg15dIvDAZ2oncKAfzJoA2/ht4G0zwD4ai0nRg0gLebPcSffnlPBdvy4HauvxxTFOEGOQKcWGQO5oAhk4LMeECVR+zpBGZIoEGNxI9eKm1IvJbyJCNzdGGcY460yaQizJQdNvJ7qcZNc1Rp7lq6OQ8XP5MMd9Hn7RYvu8vOFZ2XGD7DivINY1QS6xHLp9oySTIHaJ5N2ZCMMR7Hn6V7FqwS4luPlLqt0ZJEP8QIwp+lcZNYWZu7pIUjDxlVTdyQT1H0PSvKqTSlY9rCPlSkYlpqcdlFZ2N6nyo4BwCcMc8j1Gah1N7gXiW5ZfJmjSC5IAKlPMB49gcHNZV9PPPqFjZSIwksmlSOUdSud20+uDnmtPWJrZbAo8vkyxoZIyP4uOV96V+XY7XLmRduNK+yXN/bTTYltpBD8o+XYD94+nGDWTfFgSyAshwD9RxuqV9SZ4kdkeJ5497xucsw46n0qEytOQOikdfSh6s2pVJJe8zP80KAY2dQe2ajDl5FdnOAeoPNWbm0CRZhcnA3DIziq8Lbg3nIULcqMYzT5TpVZM0zumZAJkjlYOQ3qgGQn4nP41BawqQyRyHYTu2sfmUe3uKrEEu2xGKKB1NWdwjMbhcsucDv7nNJxD2rexp2scVzHGsrZyxXdnGTWxpYil0qG1NtbHyo3hExHLjeDuOO49R61yFmBDdWs1tI5VZC7ox459PwrobS6SKJhEpRGz8o9+o+lCfKZTpuo1cvlltrweVuG1cFW6/T6UTGJoctK2CdrHbnOfUe3rWbeu2Rhi2cKCev1pI7mUZCuAQ4ZwejY/pUJpGyotiyMEhbyY4drDy5VjOcEdG/Gsu7nZlGWLAcA5yAfSpZWYKTEu2XOQynr35ouPNeF2iiU3I2/u243A+n9DTvcGlTV2ZB3zOUGVbHLDoKbql5Hp8H2aIb3YY59auaQGudUmgeJhBGh81yCCp9PeuQ8U6msczNjdtfauDyQK2grvQ87EV7sp3F1KWZrjLIRyucY+lQvfxptzhmQ5x6e4rImu5rwkk+XERkLnt6U9LbzEwOAQVJHX6V0qCPOnUuzVi1SNFIUFos8AcY9asf2mmHUjD8bVPG4GqC2rSoQsYLDsenFLNaxxSIIn8yPG1snIVsdiece1NwRlzGtY3SFmB3IxGcHpgdqkNw7kiBFUnG5X6c+lYoMkeWDnA429SKtWs5EbBFZscuG69e1Q4lJlbXdLg1CBrWWNkLNuDD+FvVaf8As9WE2nfH7w5BOOjXJRwMB1+yzcirsryKs0ku+aFPnIVeYwCOSfQ10nwpt4W+NHhe5VcMtxcIpz/C1nOSPzArooTafKzLEU1KPOjO/bGJ/wCFq6Yq8s2jQgD1/fz15BbWA2jc25s9T0r279rGJZPivYM2AV0WDBPvPcV5jYWqP0yRzyvJronO2hy0qfMRWNj94dwc+uT7+pratrJWZVUZLcZ7BQeeOtSWlmQMMMAYwmep9/TFbllblWB6u/Q9DWDmejTp2GQWu1hy64O4bevH1/OtqwtT5ZPygs3GBjj6UxLYKrEBt6kcN1J/z3rWs4mEfzEbzksO5rnctTupxUSSOHaPlPAzzjp7VIIz5wUZXYQDj19KuW8TFVBAyx4Geen8qlitgoYdzyf6nFSdMSmlvvCnv1yfrT3tVIyVJGfunqfbNX44y6bzuGeDz1AqWW3KSMGAyCMjoAccGlsbJWMtUyDkDIUnC9c+1ZjxRtkDB28BgemeoHr7mtu6Hl27ttVmTgc4Bc96zIXnkizgCNW2pwPTn6dqzkzrp07oqvayF8Bd3zbiQOMVASzgYG1c7SynqT0q6wYklizMM5bOe+AB+FWYERJwrK2QCGxjA2jqf0yalyNvZ8quyvbw7YGEhby3IXI5CDOevqOfzqSSR4o1MEaHzJk2mYnYmWA3SFedoByce/1rRhsDOIElQo8sixxxqfm3N298+o/lzXQeGvDUmuaNfNBqKRarBMTDbSL+6MWBtJI5yefmBwDwQcVrTpubucOKxVOjFqT3OduH09fCerabJZQ38+oSsLDUQ+Xl8qX/AFzgDEUat8yIOqgDkkms3UbyUzXupX0xmaSSITzy/wCsmcpkngABEjXceMAEDnNdpaeEoZrcFnm3yYZxkAB8c8DvjvTT4Vtfskkc4N3Az+S2eCT18vPb1/Ct6ic0oyWxw0uShHmhK8n3Of03Q766lFrLbvZkqjuZhhyjqSrYGfQjBwQetabaVDphmk80XMxXy1QkBVBPJPqa6qcqJLmQtuvM5d/XIACj2XGPauN12C8lMkUUiRhCPKYYIXCtuyOpYsUIPQYNYunC51U8VVlH3/wNDTBHbz3K4jCo4BVR2xwPrXSQcmOI47Ekfw+mP61x9nb3X2u8uk3SRhIwyBuu2MAtk/xlstnpziuggugjbSSDuUcHHJXdj/PpWUfddkVU99J9TpIyu/g9GIIU9c8VqW8gOVY/KcEDpwMc/UVzUFwrqHViQQBgccE1pWlxk7jwxLMfatoTVzzK9BtHUwyggkYzyQR096nQAlsDaO+O5x1rHs7kgoAfTaf61pwyByQvGW9a7IO55FSDgThAzYxyRk1WntkZRldynqR2q55g4I/XrTMgow4yOFptJ7mSlJbHE+JPC1rqAfI2Pt+8or5z+KvgKWyaS4iUkAYOB94Y7+9fXkse4Z6gHGc1leIvCkGr28ke5fnXGHHGaUKbTujq9vCa5Zn533VuYGX+JGGRX0x+xL/rfGn+7Y/+3FeW/E7we/h+/kUgC1mb5SMjY349u1eq/sVRNDc+NkfqFseR0P8Ax8V0J3OKceV2Pp+iiimQcn42/wCRg8C56f2zJ/6bryuowpG08g81zHjPnxD4F/7DMn/puvK6nAHH4UACjb3J+tB7kdaT5gDjk0yWQptXksRk49B1pNgVrlnEhwPkwcn8OK565u7gWWx9wZcP8v8Ac9/pWveXa/Z2Lrw2d3PFYt7I0hKJgEOhJx972rhrtrY6aK6sydYnghjURP5a7jEWA5Ddcn1HNcvPbTtq8lzcCON0i2sEbIdh/F+PFb1zCkzSu6nazbic8BqxNQXy7hzExO87s9uR/iK8yzuenDRHP6mivFHJcYikG8lwOd3XFYuoMlzFbG7gG5MZOeVyOeK2dVufP+zqdu1yVcHselYF+sjzyxu2OdrZ68VLdjriwt52vHZNwmIcosjDG1B2q8PkVVJX0O09KyLZfLBC5CE5461fsfICTiRuRyMnOTUc7G+5fjQINyngjBB6U+YW7RhLiD2BUZqNEkES4HHfJ7VasLWS9huEWYwKI22MR0YDpmtaVTmJ9o4asySssDt8oaHaWIH3gB6028G1nQ5WRMMVIxwRwfxFd1eaBYHw/ouuQrlvs4iv1gYkM/lnkjsS3B9sVw08k97FKJgTcxxKVXPLqP4R7iuqpTcdysPilUdjPtGZZztYh92Qfb0rfikYgkYyD0xXOxiUnYQd69sYb8a1bbfIo3Aq/fbXPJnrwSbLzO0km7GCOcAdaTyWbfubbxnryBUXlSKBkOvOOPWkdGM6yOpDj72eAax6m9uxNdypb2qMgfewITCZBb+63oCOhqwkcd7NbYjdNgVtoOdvGSM+3b1qmjq7kvG/KlTg9R6H39KSS8SGzndC8TzFBg+q/wAq0ijz60WyLxVqAsbVra3lLyODukxg4968a1q5aS4MYbJUncfevQPHWoB5nll+VFjyfRq8s+0b5S20NuOetduHj1Z5WKtBWROkxUI7HaAOgPBrWtrp44Ts8t1d1O5wcx8dvXPf0qPchttkkEbBT9CKfp17HCssTwqYiR9wZYfjXSzgaujXsLhZJlDSKjJ1AycerD1qOCGRQpU703sXUnJz16/jVXUSAsl9DcM028FQIwcj+LJ7Eccd81PYXCTlQjhTgu2OhJ6jFSxJFieGSOQybQ5HBUHqPWqo8yJtwYl88k/3T2q5JDG0DuC4uVYMvP3xn/CovPcGeRs4Y7VKDOePSoLjqbWj6rc2+maoLe4gWC+VIJ4ioJaPOQR7Z9K2PhHx8VvB6gDatxcLn/t0uK4uyxE6KOVXp7V2Xwjf/i7vhJcAf6RcH/yTuKqn8aIqaQZqftK2y3PxVgBGSuj2x56Y8+6zXnVraxW4QKADnKn1PSvTv2irgw/FFU/d/vNFtR833v8AX3PT/PpXnULAhsOQW5IOMcenv/jWtV2kVhdYpGhZWw37zhiDt3fzAHatGK35wO4xz2+tJBEFc7vkAA28fy9a0Yk2hi2AFBJ9B71gelGKJ7M7MqyghsfNjIHH860Io+QqL34H4VFaw4jO8bnIzj07ircUW2VCmcHjGO1RbU3jFFlYX37PvFuhb071IqAZcrxjKg9+cAUtsCw+8evPv68/yq5CvmOMjG07hkdSKVjaKIo4cBfMALAcjsCaSRBG2Vwzbhg5+8fr6VawQCxB2N94d8Z5xUCxJcxJG8jG4Yb2Vfu/e7enHFZyNYmZ9ikvUEiELByA5/jOeWx39BV7+xNyru4jxjaRtAB/qa6C1gXYNuAANv8AugVZWHJVU53EAAdyegA/wrNRcy5YnkVjjn0cbiu4LkghMA9PeoVtXt7/AE64mg86CK4E88PA89cEBBnjAJU4PHBrrLm1KSyRsCJI2KsvTB64x/WqzwjawI3A44Pfmmo8ktVqN1VVhZvcpfDe6ttE1dBrAMuYvs8EoGVikLHdkn1BChuwX3ra8PzpcGWURiOM3ExRB2jdiQox0GDWLPZgkJyFJI24yQcYqEajJp0n78FIxEcEAhRIGVUBPpgsTXTCvJ6bHBWwdOLdRa3PSIUQBcLjIOAvGKxru6jR0XvJMSi5wpfHUZ/iwKwH8UyQ3kttskRY0kO0gEllz/h+orF8R6umqJbRQofuI8jA/cYjlAf5n1yOlXKqnGxlTwkuZXWhoreKsMUs7kCQbw5Gep4H41Kk1s8RMqqGDEYYZAb0rkLnUbh4oYpnLxkAPJjJYk5APYY5496YbqeK0mgj2Sp5pfzOrk8/MPp29a5Wd6pOKsj0fT7JDpuUwvmksuOx7Z/KsibCXGGBxnuP4hnp+tYej+M1gxBqqeUx+UuvTI7+1WL3VLKZkMN1DJGSNjK46/0qJLyJpKUZe8dLa7ECAMMjCg9/88itOIyF0KbQT/Cex64FcfZ3xCDJOOhwc1t2eoISrSNllxu2DG/noPf3pwdgrU3bQ6m3n+42CGdQQOm4dcVqWtwu5dxJJJ/OuQS5UCFDNuKgIp7kc4+nFaVrdEKpb1zj19fyrojUszzKuHbR1kc4JG76Z/Cpt69BnPTkcVzsUy9d+eOvqKvLcEg9TgcHNdCmefPDtGoZCMlhlunFNbUUiZd+TGR94dqzfOwFzIVOMEnp9arXcnls6k7QAGDAcEEA5+lP2jWqM/YqXus4D41aBa6ulykflsksay/L/C2cf/XrnP2QbeS11XxxbzriWMWSt7nNzzXd69CLi0YAEyA42j0/vfX2rI/Z+tltvGPjfaMCWCwf/wAeuh/SrpT5mViaKhBM9voooroOA5Txn/yMXgT/ALDMn/puvK6kYHeuW8Z/8jF4E/7DUn/puvK6nHNAB3waqXrKFIwSXG0EevpRIzpMxBYkg49B0x+uahnQlXy+DkBcn8zWc3oNK5lay8cVjHHGfnKnjvWZbtJ5LLK+X3k8dq09Qska5M8RJ8gBSgPUY71iXavbRvjH3949jn/CvNrSdztopctjMupwnncjZnPI9axry4Aj44Gc5qzqUvmguwA6la5zUH2mMbsHBGM9K4rnoQVzLvT5lw69Rv3DHr61nOWaSRmGXPUmtSYEE8855NVpFBDHGD1+ormqSZ2RiUi/LZA2j8Kkt0XaqsoK9T9Klgj3xTQnDOykrVYWb29tFLJJ8rqVIzzk96uGqKaLSyypFJukb5ULLx97FWrHU0a1VFGHdMkdBUVnqSzILabC3EfKsR+GPxqGa0lgYrGqvbuMqMYKH/Ctqa5TCrG5r7gscQLyBSPmCk4bPHI7kdqhnghbUoDGTtaFs4HRs46VlwXk0jQrMmxUP8HDAjoa3bTzDK1y2STktIeeCO9bSm7mUIcktDm5nb+0pGJ2lWx/jn61oWzRgA545yD2FZ+vuftbmLAURqhA6svXOfWqttdHCtnPGDWb1Peoy0uzqprqMweXEMIdrnPUMBjNZlxIzEkNnuazhfLyG6AZ/Cmfad5yDgMMgio5ToTjFaFuRvnBzkjnbnGaq3U27arO2c96asu4bWxg8j1NYXiLWI9Mt2kP+tIIjjOM59a1hHWxyV6kYq9zE+Id75l5FZLIPlG84/lXLQKvmfKuT7DOarzXEtxM0krF5JGyzE9KcsxgRdvyZ6+tepThywsfMV6vtJ3RdmnkyiySHCdADnGappK/mnacBjwDUMk7SsAQCPXPWlSXJ7fUHBqlEyc9NDd0iXzjNEoBnH+sQcBk9feplLRlZI9uE5IA6g1y8btFLHMrMrIwII6j/EV0hmeWIBuhIBIPvUTjY3p+8rG3bTQyqr7jjy9pXOKijRhJ5ke0yKrHDHIYdhUWkRElY2UuJGJx6AVoTx+TdZXYIHXHAwV9RWQ7WZXUCSFH4Ukcgc4Peuw+DjBvit4S4+b7TcZP/bncVzAjAXCZQjj610fweUD4xeFCP+e9xn/wDnqqXxoyrfAza/aVtzN8V7ZhIqAaPbA56kGe54A/CuHsYVyvzFo+DuzkHBrv/wBo1vL+KiSEZVdEtsqDyf39z0rhYGx9wbQe4PI+taVfiHhV7iN23DSD5NoB4GDk1oQI08S7wD69gTWZayjaGZV3KGAxxx6f561s2sipbKGAGVzk9vpWLdz0YFy1VVjBBJBPQnOT6mrMXJXHYjp3/wDrVUtpAcAMARzgmrEZJUnPC4JXFI6YyRowgqrKDyq4VsY4zV6IYBiHVcL1wSf/ANZ/SqFg4copQjgvwfToPatIY8xwQocEHdniobsaQaYOFDRqwB+f5iegXuMfrTbOIsrXGMeYwO1uqoMBV/qamt43llnn2gIxUx5OflGcZ9s54q9bwrFO0J25kBOG6sw6k/X+nFYpNs0c1FE0WBIF3YGeOfzq7FE1vb6VexzKLppJXYOMhSpwOPQDP1LCqcDHyyVGWRipBwce1W1AeMqdpUMpIbocYOD6g45rejJROHFQc1o/+D5E92JdX1G9udsEEkMcCeWxP7wknJB9AD+lVNSszZ3rWcsiSyiJpgYxxtGSTz3AGcflVuSW2js9Qmu2Iv8AMl0kgO1WGclQPVVA4PPNV7mONneGaMfK7I0bKB7EfiuQR3B962q8trtHFh6lRPlg7W6Mz44g00YyCTzk8c+n5H9ax9UbNpK0RYCZWZSwOBjgEe3oa3/LETDkFgW3HAO5ixJJ49wPwFUryBjC0YdlRCqIW/hCnKdf7pPFYSSPWhUno2jkdTA8+Wd1Bf5TIQMknA3H8TzVKRSLh1UsVdiCozgcD/DIrYu7eOCw2K/EaImSc/xDAJ71jXfmRqXhyHRwqsf4cdR+XGPeudb3Z6mjjoVJGeB5FbJHyyADHzqR0HvVW5vBDGwUgAHacrjn0qS/nKvu24RV2AH7rKTkEn2NQRIPNWWMZjjO/cDnkHlq1SOOpKxiXO64vh5hcRmMneRwB2B9vf3qtaC9i+1olqhYOXKbOB0zznIAAzjvW6La3mVZBIH8qRUkhC/65CCVPPIAILEjj5kXGam04qlrI7YGGYtkct9TWqgmefVxDF0/VJbSMRXxCSCQxhmBUMQM8fgR+Nb9tqSSqGjk56bCcVympQiN3kRj5RRQAx3KCPY9M1zst+2n3HluwFtKwJXOQR3I/u/SonS7DpY5XtI9jt75wvvjBJrZsb/5lzkNyOvPXOTXmUN+6xBopvnfKxKT94dhg9/c11GjLc+VIJ5xvMe6Jj0U+h/KsOVo7uaMjvrW6DxqVI+U4I9j0NXFuQwUbvvHFcbY3zwpElypXaNhZehPY4q+l5gt/skjjqCK0U7HPKipHSS3RGFHTkfX1qvqGovPJEzOSRGIwMdgew7k1nG5DDJ+8Mfr3rFv9SkgKtbuBOmSD/d7fyp87tYlYVN81tS7f3Ykk2uTtByVBx096v8AwcMTeOPF7wJsRrLTztznH7y8rkZrqOTTXZXP2nzgoXsUI/x4rq/gu8D+MvFX2YNtWw05W3DHzCS8zXThb8x52ZK0D1+iiiu88M5Txn/yMXgT/sNSf+m68rpZJ40BLHGDiua8Z/8AIxeBP+wzJ/6bryujmh3jKnDYOD6Z/wD10mArvuIQHBIzn0rJmkZraZimZIn+XHUgj/69XwMblc8uMk/Xispf3VrKSxYRnyXU8njp+lc9WRcCpq0mYl8t9tw6A5H8WRyPrxWFdXQM/kyKSrRCQc5zirHimdbURtGwWRMfP7A9KzfNWZ2DjGDtPGCoJ6j2Jry607ux6VGnZXMO/BMk21jiEbgPbvXO3EjPOQ2COmfauq1Dh5nlHRwCPb0rEubaMMTkbByD7VyNnoU0ZLksWOMtmoM4I9OhzVu62EPs53dPYVQmfEarIMFGO78aiUbnWoljTnhFxIG4ZkKjPYn3qu8bSobKcEGP5i/dR2IqN5l2sjINwPWmXE0jIzhxvyMgd19K1pws7hyjodtvO8dxjDEMswHUVZnu/s8pWKRZYmUMA/OPoayjNIZBbyYxF8ytjse1ZzPmVo2y3l9PpW3KTKnc6NNZiVxiGNpD94Y4ovNUkuIRGOEzkBRjPtXG3Vy6gbZdo5IGOauWd+Wt1kYsBjrjgetVyXOaUeV3L7ziSbbjlDyvZhTAkbFnjGwHjbn7tZs2owXUkigFNifJIOC5Pt3FVYdUzHkjL9GA7EU+Vo9GlXTSTN6OFPl3ZyOMHmopQYCFULIr9FHUGso63sQYfcV564/CsnU9fuZY2RWCgjGEHSnGF2KpW5epPrWptbySRxOyz+g7etcLqVw803zSPI+DlmOSPpU+ozzDDSMcnuetZZ67QT9RXdRppK54mLxDk+UmQtEVYmM5G4Y5/A0katIep2HqabEihgWOWIzj0qSXeEAUYB6mug4LDJECtsBGe+KlAwnQex71DGNpzwTUnJJJAOaAGsOvb2Fammyl4fLP3ozgj1HaspvvfSpbJzHPGzHMf3XB7571M1dGtOdmeh6TFGzI5ZmAxgA+1JcupmuI33BHCsC68IOmFNU9LuXht9xVWOcKxOMEHH/16m1W8+V0HH8GAc475/GuTqdKiUoLhiyDaXZco/PT3rtPg2B/wt7wn1/19wOf+vO4rgbJ2WYMCuWyeB055rvfg22fjB4T5/5b3HH/AG5z1rT+JGVfSLR0n7RbY+KQC/6w6JbbPr591Xn1jvZCZDlhw3otd9+0c3l/FNJgMsmi22FI4OZ7kVwERktIvLjw2JCSSe9aVPiFhfgRu2eZHKEEqpBJb/P0q8xKxE/eA549qytN8xcIxVjknAzkk9/8+laDSlQR1Lcjj/PArJpHpRZpQ7ABtJVWHAPf8a0LZmkZiRhjx1z/AJ6VmM24LyPNIXAxwT2/+vWnIqx3UqQl2iDbUcjkrn+dJlxNKJl3JIoHIVlyfu8VNK+YJdvLFcDB/nWRFO6jBxnBAq4soe3BQsd4w3HSsZHRBHW7XEMBjjLZJ3rEBnJU7do9S2BnsM0yBZniDO0YZZwxWMAqxWPBk3ddu7IUdOppdFukns4xgjYNvHcVdmKiJkAwhHQdMdhVKXu3Rz1KblO7GYUsOmG+YEHvjn681PbNg/N90djVJJd2UC/PHyqgckDvU8cm12Iy/GeO4H+c1KbNelmWplVx5ckYddvRuQ2SAR+XP0FSWdp9vmvrdgyvGhud6uAZByBGSegJ+Zm6nIGcVWikYlSGLdSPfirHl7IpgrFTLF5TMOu3rit4VVF6nBiKLa93coxtHIV2sN7KOPU7QePzqDUEWRVjcFlk3OfQBVzz9eg96vIm1o05aSSbbGgOSCTkKM9Pr6Co2BWVtyMrx/u2VhgqeuKzcU9baHTTqSfut6nPap9mRtPEkYMF4G8kA9lYAkj69D6Z6Vzd/avHMYCSGyVd+33id34jAzXWanbqZYnKsr2yySl1UMUQoVIUHocMce9Y2rQ+TePDKoVh5S5znG5VIX3IBAPvkisZxjbmR3YWrNSVOo7nGXHzs4XDKUwCeMndmpIwkf2h0UhnTypAOFIJ9DwBV7VbVQ8gA2uB5eewJ5z+dZZkUQ3KXHCxqDJwTgdMf0pwka4lWKt1I5haGAjDSCIEDBTYBk+ykHHvXM6lfyw3KhYvJZHby9jkgnplvbg11uqttWZpUWOYSq0gPUcBs8e361yOqxlLobgAgyx44x1GfXJNdEWeTWWhRt9Zny0t5N5of7pc/KPYDsKqapqltdNdK8kSRY/dBugGPb19ao6xGYSsiDZvbB55P1/Kp/h94di17XwLxT9gt08y4U8Fz/BHn3IyfbNbWVtTzlGTmlFXPVPCNiE07TXuNz3XkROzNydxUH/CvQtPt8oxkDZOSxI4JPc/U1iaHbNcXxkZQzEbmAGAMdfwHFdmipHF8m1mUfMcccd/1rjeuqPbXupIrxW4PHl/OzZ5H3QB1qOS2WIZRQSQSx9z3rURTksFOAuSSOpz0qK4iPQnqD/Ok1cSkzEuv3atsJxnj2Nc7ePJ5583HXA281019Ht34I78ZxXO34zeIAAEyQCBk5qeU3hOy1M+GY299ZXsuTFDdRSNgfwhxnA9v1r1jwHB9n+LnxBQIqK1vpzgKMDDNdHP615jcxqY3+XKnqPX0rtfgjcy3njXxjd3UrS3M1pp7Su3Unfdj+QHSu3DaaM8XNIN++tj2Oiiiuw8U5Hxw23XvApzj/idSDP/AHD7yumMm/dn7g6k+3X9a5rxuofxB4FVuh1qT/033ldECFgBAGMEEH8amTAiu3RNjOdgaQRjnrnpWVqhSKzuXUExlSWC989D+BqfVnhmggSRsKSsqP7rzVPUJxPHMiABFQx7uinI4FcVaZvTichqjmbTJnuXzHKu/wCXqr4Gce3pWU9+kjM8ZUyKiqpB/wBYvTB+lT6vMZrJraMMnkKm/wBVB6/jTr3So1RFh+VnUGMr2Pf8xzXjzd5XPYhZJIxry+aWPJ6BiMeorPuHBh/ducd89uauzqiST5XciAqD/WseT7uwdOuam9ztpxXQrtMVlY8AA7Qc1UuJfMZl2nAOD71JIcF02+5qFsFDnhmOTinBXOrlKzOWLZOeOaSJcRZQd+56UknBZi3HSp7JRM7Rlm2pjmuhBaxQm82Sdnt0JIwAf6VlySTJl2XaclTkdTXUxWz207At8jfe+tZevRgxJv8AuO2M46HtW0YnPKRzt8rRnefmVyDnPNSMPI0hzHIMbwGPc59O2Kj1CbfObaVedwDNnp6Uk++Ox8iaMnKjPYAjvWnLY451LMp3Bj3Bivyr2PYetVXDJIsnVX+YMD196VbpJV2ht3OD2P0FDskkTKScR5wVHINOz6nRGUWk0LIFlUFyCo6HvUbGKEhtql8evaqT3gtmKj5lIzhh0+lZd7qHmnCAgHjOauEG3cyrV4pWI9TnSe6O0BdvWq9um8u7Dp3zxSJltwUZABPvVhFZI8kAIBvYf0rrSsrHizlzyuRybRcgAjoM45p8+GiI5JU0yGPd8+07Tk+5omYlgq9F7UxkWM4weepFP4CFiOPUmlAwysoxTnG5jj1/KgdiMLuPUYpcgKxU8jt34pzYUDnmmtny3wvPqetAI6mzlBiAcK5Yq2D6/wCNWtUnkNqluz/uUkMiLgZyevNZ2nNlIEIyIwGJ96mv5SX54baMjPSuSS1O+GxBaEJMTnG3IBz1r0D4Kvu+MHhMAAATXHHf/jzn6157avjzHYkEcCu7+B0gPxh8KJnkTXGf/ASetIL30ZYhe5JnY/tEwiX4qRbvu/2RaKfxnuuv5VwlvELiMpjcwYqG7A/T64r0D9oX5viaUzgnR7THfpPdV5/p1x+/fem0Oc4/+v8A0rSp8RnhvgRYsbhw6u3ztJxyfvc8YFa8KeZlZMbwvHtnn+lZ+mxB4oZXIBhG1R+JrTT93LKpw4xkqT/Ks2d6kEhdYpzjzHRdwC8bgOQB78V05ikvtR1GG2jD3cq/a7LawEdwW+cxD0LISU9wQa5cgJMpyXY89Ocg9K2LT91Gx2OyggtHFJ5bAgcMGA4IODnnBFTFJPUKibV0EbxvEs8TFlYFlz19NrehBzn34p0cyjeoBwPQ/wAq2tU/szUFtruxeZdUuZVivFkURRuxU5n2DI3EgBiCBnmsm8gKs8TqUuIyQ6nhlYdjSqwSfkaUK/MrNWZo6XqBhn9c8jn866BL9ZVAz1PXPAz0riIn8mRGPKZxuHY9c1qpOdox97qffisHGx1aPU35bhI5d3mI23KkITnPqR6Y9KnExwNuFO04PcAn+XNc2Z+cscYP5jvWlYXZI8vIViuN3UFewxU6l8t0b8MgVgflXuuD+dW0kxIADn+Hk/nWNFLlURlG7kHjp6VNb3QVHZv4R94/zFNStuZyhc0ix8yMwOY5YslGGCVbBAPPHc9ajklMty5kVjJJI5ZsY5UDB+h/9lNRqwYxkZBOH3e1PlmUICc4Jxz1JI7e1axqaWZzSovmTjuZouy13IIIjIPLaQlVyRGq5z7Lg/Wufu4IdQjhuJZtr3G2COVJAPIjm+9Mc8ZCg4+tdDYMxvljWWS2F2ptZJ0A/dxkkk4ORztAz2qvNZLb3F5clPtLI+c4CiULhEO0DCgADpxxnFTyq3Oty3VanKnJW03Ry13CbuFpWiaISIJJEPBVugH5Y4/WsVof9JnFwmYmQxSuv3sdiPfmu+vtNxdTQrJHIqOQsyA7XbG9z1Prgc1h3VoI3b5SjHEjB+eR8u3+XNYyunqenCrGrSSTuYk9iqWrJcBJYggjZ04KjPU98YrjfENi1lqMcLkyh0BgmPR19PqPSvSlVjDJDPFyB8rg5yO4rE1nw8+o2slpa3AETHciSAt5bjujZyPpXRCasefWouO54/4hjj8pZBgLuJdcg47k/X2r0TwFpf2Hw9bbgGuLrF1Png5YfKPwXH4k1m3fw71OaGWbUrqKKAtjCfOWBPzY9Prz1ruNOiZ3O1fLUYVVznCg4A/IUVaitZGWGo2nzM6jRYxDGgOMsdzN65PI/wA9q17d83GfU8n/ABHesaOTYhJ5BbaoB5FXEmYhSp54AwPWsVI6pxudJLu27EOU2Dk9yTWddt+8bngcZ7Zqyl5lI1PDA7SVqK+8pkbcdwIIIFauz2OZNxKE0LC0u7h0xHCYo8MMEiTncB64A/M1zP2cvL5m0tHD8ztnhM8D9a3b+Yy4R2LMdoHplV2jA9cYrL+aNJ13sgJGIwOC3ofx5pyaeiFTU1fmZmXZUnHXnrXWfAY58W+Lv+vPT/8A0O7rkLx9oIz2rpv2eXMnizxozPk+RYrt/u7ZLtcfjjP/AAKt6C9448wl+7sz3Kiiiuw8Q47x/KINa8DSHoNbfP8A4AXla3mtIZGhKko2Pm6Edq574ppJJc+D1h5k/teQgfTT7w1U/tN7S0gaMEhiu7P8LZxg1w4ms4Tt5HRRp86uasssUUcFsS0iAlgG9skD8Rn8qjKCNJEEgaCb58N1UHjI+lUJ45prGWRlbz42OT34OVP0GamiKxmCGT5GVcc+h5/LNcfNfc6FHl0Ql5YW++9yCfOAkLAdvas6eErbqd/ywnIYdsdPwNbcI3ou1htGd2e394U6axBtVUEbWQFh2K4Nc1WnzbGsKrWjPOvEMqoSdgVssrg/xZ6GuVWbfcuBkof73UVoa1dLNdPEGJhWXbnvjpzWL/qJpOcjJAPqPWsfI9ujH3dSaUhmkk6dhxVRkMoXoCy8dqXd7AAtU+oSfPCIQAEFawikb3Zk3O8J5jgBQQpFdDpNvEtu7rgCUA59axb5fMtPOUEjeAwq9pNxHFCIkf7pJIb09q2REpaC3M21zxwGxk1ka1KTauGwB1HtUl+7m5LcjnhKztUuk+wTCYkMR3/lW8dTiqSsYd8/m35C/eKKuQO9a8cc+oQeXDFvzwSxwMAc1gaaA88zN8z7hkegxU+m639j01rq4lVLeOZljRR8z89K25b7Hnzlrqc9r1q+lX6whyRIpcMO2D0qBdX8tCrKxYdcYNVdb1WXVNQkuJAEB+4v9xaprHs2s4IBG/2NbqCtqZfWJR2HTztNM0mDj0ojiZxk5ye/pU0q7UwCN/V9vTkZFPtZGIEaHGecHvVRsjP3pO7ZHKghcFRgDByD1qwXH2VwuQZFIHGc1CpyWTPy08wrCXKEEFRnn7pqricbEQyLUnc3YAjoPWhYUdQ0eQDwc8ZNM6DHRMn8K2tIsLe50vU7m6unik09FkhtwmS+T1Of4T6ipKUbmUkbJhjE7knapAJGe4qSS1ljkZGXds43LyG+h7++Ola+g3Fot4slxc3VrBJE7mWBd5EwO6MeqqSMEjpxTJLu4vbprm8meLc7SMQoZQzHJwB1J7kd80D2MmSDHLgrgZ61C64TepBU5BPbNaUoIj81AFfPy49PpUEvkq7ROWVQu5lIyCT0AoW4mixp8oRoNwYllxg9xTrycGY/dHqPSqiE71yD8o47YFWrO3aefcwbZnHGM/hWMu52RlZE0cTpZlmzhuRXb/AkH/hcvhXIx+9uO3/TpP3rntVQL5ax5OAFIz0xXS/Aw5+MvhXHI864Of8At0nopu80Kv8AwpHbftBPs+LcIOdp0a2Jx3Anua4KBQbmIyLjfKc4XpuHHP4V2P7SjBfivbEtgDR7U+3+vue/41x7SbIpGVciMhhg8AZyP0rWp8Rz4d+4i7p0qRtcxNnAffnsM/0q9bu0m1Tgl0GAOevY1jtIDdBowhWaMocg4O3p/OrtpM0DLFID5gUbeeSM9frUHZAsQAtIzMMkO3mD0x3FbMMmIihPzP07Bs4/pWbZSIdSmZDuhchzx1GOePxq40O2I4YtjI4OeM4/DjFSzZs0C8mZRt3r0x2GD0Psc1duJWu7mGadc3CQiOST/nqij5Wb/aH3T6gCsu0l3mZZiN8QCH88g1cOJGXywwZ8KSy8Ee1SyJLW5B5ebckjOcsMDGRmpbSXb+7Y8AnB7cc1ZVAItpACqAcenaskSlHJKljjPA6kVDWpvCTZupCjRIWDYB+coeU98UzPkSHALIudvy4z74pkVz5c3IV1IBbGQsoIBOPzx9RU0hWRpQpEaNnaMk4H90e/PFTKNmaxmy7BIzeXsyWLdu5x6VJHIZVKkbV++V6bl7gVnWsxilIbdnbvjb0I4xWh8paHBLRQhVRj1wc5H6msmtDoUnsa1rOZBK7fLubCnsFxn+tSTOApJUEg+nPXoKz9LfZFEpI4LfkCcCr8CCaRfMDYU7xt/iI5oWxMko6lm3g8kNuA5HzEjr6ZFT79sPnFRtAHykYBPQZ/GpMBxxz5hyRT4wiRSQn5jtAPPXeSAv1xuP8AwH3rWN36HDWqJLme43VrE6fJZwSqGkktj5rAE5fIyR2VRnjuc9O9c3qcOIUk4LGVFkbuFLfMR+WPqRXTaizzMGlZpCkYiXgDCjsB+uaxLuNpfLtoQWnnkSKIKMknlv5AnmrqWctEGEbp0vfZx6l/KilkISQRvwowhdTiQLnqFJUVLZzERLDMpDZLZPBzjGc+lWZJLeWJI1GY4lkSFG4yGkJfjv8AMjZP+z9KrMHulnEYZri8QLHkYKEHHTtnt7c1g1Z6HpK86fvfI1L618zSJU3RkAbFPfgZP51j6ZGGM2OrEEcYPHFbcH73TdhAE7yeUsbHJDY6Z+gqhZoI2ZipWN1OPdu/8ql36mNN8rsW8mQhgCuePp2zVi3IRHYDhAT9KpJIu9+CFLE4Pv0JqUyFoGZTjBAz1J9/zpJXNHsXLOUmfJPHJz+HWknuOhP8KgEf0qrFKAMNkEcsfT2qMyhY1dun15PNWrmckiUuFkV25dGBUD1BzWdesT5jneXaTf0/iJ5qWebZxkBs4OKz7ycBJOTuxn3FaRMWilqMwLPzz6e1dh+zwQ3ijxgQMf6Lp/8A6HdV59fy/wAQHPB6Zruv2bSG8R+MCOhtrA8f711XTQ+I87H/AMM94ooorsPFOQ8d5/t3wLtXcf7bfj/uH3lVdW07zLt/JXMUpLHPABHIqx4+cx634Gcdtbcn6fYLzP6VoaigNnOpwqFjtI4PIyDn6iuLFq5tRk0zNlLR3s0qgGFog+PrwRWbZ6hbX+ovGw2BVx7Y9ap3dzcyRjYR5q5R8HisKxMkkNz9nwLgrtya851NND0IU1a7OytopYNUZW5gkADgDp6N+PSr14VsNOn3twkZAJOcDtUGhXCyJBDM2J44wpJ6OOvFZXj/AFI22iXESfNIzAY9qvTkuZwi3Ox5Nd5+0SY4cuSR2FVdqvfRxyHanU/lV27AWB5kbIyq4PvWbKuQJWOSCQR9DXIo6n0VNaJArEkR9Wyc9qiuJRDKdxzn9apXF8Y7lVYgD7ytj061SN8Z5Uc/dVicelamyibEjgBGwduc7QevtVaeM/a96MQrAr8tPcMQo3c/eHHQVBJKyOO6VURSiV7+4uYpQ7N5gGOTWXqk32i1DOPmzhsfzrWup4GjJzlW4IHUGub1q4SONo1xmRODn8K6KZ52Jj2M/wC1mO9uQvWRM5HB+7XLyOxijiySo+br0NaM0jCUNk7gAAT9MVldZWI7nHT0ruppWPIqt7FiK3P2E3G5TlzHsP3gQM7sf3e2fWpQQ7xk4VcEYz0HpTDLuTa3QDC4HrTpY2jXKvxuK9s5HtVsySJ5XhaxtY0g2zRGQyTE/f3HIGPbFVVLCMEp196tQz5jZ2SN3DIULDIXrkfTnqarAsqjk4X5enWpNLBGQm/crZPHHTHelWQLD5TcAkbMenvTMgLmQkD+dR7gfl/hz3p2JkyVm3kgKDjODU8880qRmcb1Vdikjrj3qokhDbRzx6VNAQodW6BdwHWixUWXlnf7MPu4YDOB29KYlw2TycDouePwqETbhkLt9Bmq4kwQfT270rCbLk8wRGOFbI7nGPes+SUlmJ4yfrSsxbqxzRGMyqCBjNUklqS32LS/fPfjp6VuaW8dtZu7qDIcMoz92seDAIyAQWzj1rTj3yASSEd9q9q55nbTWmpJPMZXLvjcxzj0rs/gZ/yWPwngYAlue/8A06T1xDgKRt6nqS1d18DVK/GDwnkD/XXH/pJPSpfEh1/4Ujqv2jwr/FRImIXzNDtwHP8ACfPuT/TH41wlruuraQOvlyMgRh3GBjOO/Irv/wBovj4r25zx/ZFrkeo8+6rgbB/LuiwAzHlsH+6xG4fgea3qfEcuH+BFiNlkhA+6zrkrj/loOCAffrj61cX5445Rj5WCnB6dv51UnjAtJ3JdNjZGQc5Bp4d4po5QW2zIGk284bGOn61mzpgzbjCxXiuMCKYbGI/vYrTkXMCjO2SRgo46Hoc++Kw7uQi3jdGUpvXkfoRWxbz+YYCWxhixH91/TNS9TXzIltJPMeRnUMCQzc847H1rWjlyRG4RJYz8pOcN7rnr9KjjPlohyfmJ3hu+ecCmXaeZZt5ZBaNQ6cc5HUA9qkvmuXROApU/JGy8Fz0Oenv9Kp6pGAS4A3FvmPof73FQ2Vz50UQZgQ4b5SOM5qSdyqOkrGSN1Ij9RjnafWk1cpXixkJ3MscRLSsSBGi5JI5IUDkn2HNXrSYSgsGyxG3AJ79s/jWSu6N42ORIOQwJBR+hII5GcmrcMhBGwdACnHI9aHqaJtvUvMwJwT3J+nt+dXLeRDCx3jBJGemMAcVlx4eN2BPcfXnIqxaS/ImSCvykgenQ1hJHRGRuQPiSMKfukN04IIzV/S2zJIS24fKOOx64FZCSZVcEbgGVc+g4/QVo2TgQqycZdicn3x/SptY1esTehkA2r3POBzzn+VXET5FYKOCzY9DjGc+wGPxrPtWBZcnHB49Kv2/zKSo5HPPTH+NaU5NbHnVkluV7yPeJGGWJjCBc7cENnP4jisnUGkS5tWgLKVcO0icMvUDH1yRn0rduGHlMEb5jnYSOCRw368VnOv7tunHPqOtVJvoVQs029TP0XQ7W/v2s0Agf7O7QOQCDznYD6c5IHOBVOeNmiZJImik6OhUghuRjsce/fFX54VeZcF0ZMSLLG+11cdCp7dPxHByDipNQeW+vnurpw1wyLGxC7QAM449eSar3eSz3NE6sa391mI0AntgUfJDFnCjBY7eAPfpUOS4huNrCMttDY4B5BFX4FaW6KQyRxALLciVz8qqqjd9ecAfU1QWUNaKI1MYnIcxMfuE9qhxbV2NVFztIryMAcg9//rU5pNsZHQ9CO2O9EwKuWGcD5Tn1qKZyH2seVAAHpWSRtzXJfMC7VLZ7knoajkkwVIOMdc+tUTPiQJng/Lg8/jRNKAx54XpjvVBIfcSjyYlJHmKHMrdM5PygfQd/U1k3khCksfkIxyeBViWTcOTycVQun4Yg8A4q0rmTaijO1GT5RyQcZIHYV6D+zA5k17xkxHBgsMfTddV5Xq1wfLcAce/SvSf2T5DLrXjZu3l2AGeuM3PWuqirSPKx0rwPoqiiius8g4/x6FbW/A4bODrMgP8A4L7ytR3Z92RhFx15BFZHxDO3VvBDHoNac/8AkheUy5vPsqQ7C77WbIP8Sk8/59q8/FztJI3pRutCGVVia7MahflJQk/xeh9f8awtJeS2K3ZCmCZwJR3ib+8fQV1DpHORC5VtwLhl6H1/HvVH7NHb3SyOMwzZV+ODnncR7/pivNnF3ujthUSVmYeri40+4ae3Yhkk+ZG/iwcjHpkVzvjHUxOWCHGG+bPvXb+ONPb+wTLbBjtG/cv3lx3HrxXlviEhrlmGMSxq2R06UpJrQ7cLyzdylcMZYk9D1qpPEfL3AnlTke4q3Gm5Ydp+QrnFSTRoEDAEZGBQnY9eC2OPu1fzDnGAec1DaWgfzN8oR2JVMnjPatvU4UVHJUdOQBnNZKRqySxyMcbgRVR1Okspefu7dLhCs0SmKRe/sajncBjtbdnjkVRu4Wb51ZiyMDljniq/7x1fe7qwPpVrQTjcbceXcNJFuVGH3cnvVHW4PNOWcmRIlK5XGDnlf8Kc8YPmCUZYDqR1qaVt9uYZmzGFEiEjPbtW1Nnn4mBzVtF9olaHjeemaxI1xd7JCVCsQxxyMVtsDDfRs3RiOR61R1eFxcSTqO+Wx/Ou6m0eJiI2ehCWHmkgZU5257VJI4YD3xnHXNVz80ec9fSnjgrjANabnPzdh8DbsIz7A3Geuwj+lSXciNetLDEsEUmCIlYsE45Gf1qucZJXj8KcrbshhjpxilYa8x7NvGdoBzjJ6UBTHjuQ2Tk9aSTCHOMgGljXg5yQc89aYmRSkSTM0W4Z7HqKkXIUc44/H6VHEp8zqQQOaGG0jdyD6UErQac4A5HvSg/KQPSlkycEjHbGeRSL27/WgYc4Oc4xU9rEw3EgYYck023QyMCQSgJrQggZ2AAwMYz0rOcjopUm3cfDF5sgKr8oxgetXxGVUEjljgKBSwxLGqhQOOc+tXraDjcwDHOR7Vg5HfGBAtp5ZZmG4kYyB39K7b4MRlfi74SyuB59x+H+hz1zccQJD4DnzMMpHYgn+ldR8ICR8Y/CacjZPcA9Of8AQ58fl0oo6zRlitKUkbX7STY+K8IP3W0W3BH/AG3ue/avPYpsXUMjMAu0xknsMjP17V2n7Ukpj+LVmAcFtEgGf+29x+defQTK8EZbIEbAttHVcnOB/T8q6p/EefQfuHTqfncgZcDGDg9Dxiqh/d/Ko/dRyDHovOcZ9OP1rTn0LWLDwnpOv3UAOm3ab3lhmEhtwxwnmgdCQe2cE4ODWfKoigCoSdgGw5OBzUNWN6ck9jS37I5Ay5t5gzZA+630+v8AOrE7MiwzOuyTOyRQOhxWXCQY2t+EQ9GPQ+n41fRhcwkybkZjtfjkYGM1Btc1ftP7iJN4YOAu7PU56j8M0gvkiVjMFYLuGCcbtvT86yQBGu50BaM+XIg5wM8MPrWijJNCWTDIynZ1I4osVe2pWcPFbpKqNvT52A6MCetbFu8UkKTopLMOh7Z6iqkTI0QJwR3JPQ1XnU2sYaEkDcwkQ8qMYwR/WlZIpS5tDRlwD22EZGex702xYxyKMnGTjcOo9BSRTiR4yVAJG3OepxULfJuC43AcH/PSky4voa7qYY3VeFYhsduKhWQJOHG3DcAHpjtz+VOVxNaoWBK471SnkCgDdj1B7c4z9KyaNYtp6nQRTEQxOXzGxJdR/D2wfy/WtCwkK26K2SwD9O53d65e0mIcodoUlSAOQecVrWEpRmTcRhyQT9P6VnJHXGZ1drKQ2cg9QOOMd62IZgsZbPOAQcVy1nLlkUFiWG1OOOea2Y32cjkKMEn1FEHYzrQUyWR8soByw+UYPAyc8emTk1akt2jsGn8rMbuBu7Ag4yaopJGmJWQZU7jnv9PetAak76MdPIQRsc7iDkLndtI9fetYRTu5M5KyqRsqcTLKDzDMwYvtAII4GPQevNMlIK5K/JnaRjqKtysGVcnJIPPqfWqlyDFA8ixPIwUkKOGJHAFTynRzN2uZsMD3t3b29oCZJThF2/eGcnjtjHPtVDWLSSz1OeKRBHPE2CgOck8gj2I5q6l+dN1tZbaZft9uNwUg7dhGCre2AffvWXrGpSahNJcyyrJLK4DuvAHooHYcU3ytEctXnvb3RRN5hYOoJIOPXPpWbJN8rK/LA5HHpVKTUALry3JU9s8ENUclwHUsxG1l6HtjqahLQ1Wg4Pgv82NzAc0+Y/OfY1UhO5OTuJOfpmgtumc88HkGnYbdxzSZZjnOB+VZWpS5Tg8Ejr9KsTPtjc84JJC+uDWHqMmASzD5c8ngdK0Wxz1JGHrlwBHIMZHoe3vXq/7HDiS/8bEdNtj2x3uK8J1+7IiYgkAkL1P417f+xYc3PjXnPy2POc97iumgup4+MnfQ+nqKKK6ThPFf2q9bv/Dngzw9q2jzCC+ttbjaNyoYc29wCCDwQQSCPQ034a+LbLx54aXUYAIZ42Ed1bF8tBIev/AW6qfqO1Z/7Z//ACTHSf8AsMxf+iJ6+WfAXjHU/BOvJqeksrgjZcW0n+ruI/7rD+R6iubE4dVo26mtKpyM+5LSQJPCjODJbtgEdNpOCPryDmtOFBMPspUE8mM+3b9f0rjfCniGw8R6Lb67p0jy2U6CNkbG6NsYYMB3U8fTBrrbNvNEZjbEqHzIyD94DgivHp3jLkkdU9VdFy7eNrGJGU7ZQwx6EDBFeIa9ALTxFaQFf9Hn+VFz904OR+dewavfOmnvJLF91yX2jp7ivJPFpaXVkk4dFIkjdfukevtmnWkmzrwF0Yls/kmIYzyfl9welT6hKgkby8GIgOG9Aev61RldvJkLHbPBLyufvJnrUOoPgOE6Z9e3Wsj3qctglPmQksfm7VlXCKGJUZbIz3rYijR4h82G+8KeYo18ySTgqu48cD3xWkdEbORiS2szCNogoOfmUjqKpvt82SNyVnGCQ38QPeu0utIurT7Ot9bSW5uYvOgJIPmIfQjjOCDiuf1ayURNMCW8sHdu7qev+NaNNaMUKqmtGc9JbuLncy/J0zn/ADxS/Zo4oVWJSybj5eT90nqv/wBata38sqQE3RjlT60ySPJlVQCjDJHv2/GrjoYV05HOT2MUsbwvxsOCRwUb1rKdTl4pwBNEMMn94eo9iK37k7JZJCC0qgKw7sPWs7V4WYLeQnPlgAnrla6YSPIq07PU5aeIWV40OSYmGV47elMI5GDj61s30Ud9CoyFkUgow7+1YgJ+ZX+Vw20r3Brqi7o4KkOVjlOD1496ldhhdp79KiC4bIGOccHNOZh5Zy21uw/xpmY+MiVTnhu5x0FPlJjT0J4X2qABmkAj6jgY6U+UMxBkxx+X/wCugZGiZKgAFjU1wjbVB6DpgYpUyGOxcnsP61K8OU3ysQVHOefypXArM3mMisoXbycc5p6xxsG5JwM8d6WKF5Aq9FPGR1q55SoI4AoyG5x1NJyLhC7LFrbJHAHdc4H3R1HsatwRJjcQvPIHem2tvLcyKqJuY/8AfK+/vWtBpqh98khYjn8BXNKSPRpwdhttbGZQeu0ABAcE1akC+bELd9xA4YjAUn/OKuwpGkYUnDAjgnqD3HpTHtwCY2w0zngA9B2wO+elYt3No6FdcQxs4BD8h1zyfQ10PweYt8ZfCpbG77Rccg8f8ec/A/Suf1WQadDdDUGML2gZZo3IOz0A9ST0xUf7P+q3Gq/HvwvJcYRU+0rHEpyEH2WaujDwbfMcGMqpQcXuzqP2tX2/FawG7a39jQEEdeJ7j9K8x0248xV3N8vylQf73Nd/+2QxT4raWynDDRocf9/568n02781S+FDlsMM/rXTUjrc4KNSy5Tsbd0glaeNF8xxtl4xuwc9upyO9aYn35EP7xVBJQ9zjoDWFay7lGDgY5IOcj0J/GrVtcs4kAU7wm5UJPzZ4AJ9a55TfU6oq2xs2FzvhbBzsYxuNvOByOPYGrv2hLK6YSyRpGVUM28FVOBg7ugGGGfSs77ORH/aFjKlzY7V+1FVIe1fuJo/vKueki5U4PI6VJ+7YRyZDRAjd5YyGBPJHY8YP9KLqNrlc19jqL7T77TI1n1bT7zToWPlrLPFtiyP9sZXB4wSRntWb50trMGi2qrE7wAcDn7wHp2P51Ys/Ed7puhDT7HMQjDRtPHeOsZjc4w0Dboiee649cVTnuLPMfkCeGRhvlimWMLk9PL2YULxwABjmtWopaGcJzUrMu2NwssDtJ8m/wC+QMgZzyvrT4JjulSRlIHG09xjI/n+lZVrDqF5Pcf2TY3V7cxqCYLIBmzzghe+fYHGK0NR06ezsP7R+12F7Eri2uFhLR3VrKeAskDgOGBPbPrjHNTy31NHVSdiGWeS3bajNh8sNwzyDk4P8hVkXay/MhViDvHbcD6j1rLW6juYgkxKhMF1K4A57H1JxQZGiO5WBJXLdgWz3HapaN4y0OnsbjcBtY/Pz14zUd2I0uNwO5GGPp7Vk2l0FGADjdnGePpT3vWZcHG5TlCDzn3qHE0Uy5HJ5TAA7gD8jE8GtWG6KyhxyrNgn64yaw/NWW3b5tjtjac/Ke5B98Y49zSxXBKGPIUdQCeTnms5ROiFQ73SJmZSxI2mQoBnH3cdR75/St9JAy9xznPXn6Vwvh28LyrvJ5yCPf1rqobjBOWxuOPoKyOrdGpsWbdGeeQ2DxzmmxSjzGDDnrz0yc0tufMg3j/WMSeuMDoKZbq020AO8gIWMDqT0H86te8+VbmUmkm5bFokLwBuGeM/Tt6CqtzIz5ckFgMfMegPcVoatbGy1CS18wOEjUnb1yR/n8KzPMDSFHGAF7HIP41Uo8uhjTqRqLmRmXsbSxBflU9iRncO4P61ztxYrGZYlbdHuEm09Q3b8MV1EhXdjocDvkD1rJuFHmSqQADkKGPscZqUtbmnOee69dXVnG08o3SCYLnGARtPH06VNbzlvsJmVcPCZNgHc8cjtWzqMKtgOPNII6jgEdTWMiJbRSeVE/LZ3g8A56frV6EzlctrIVD5wfmHfsKJH43FsA54/GoJCquFz7Z/rTLmXnGeFyPrQlfYhz0Ib2f5VG4k47jv71zOrXTYwhA54b1Hv+NaWo3R+fBGSO1cr4hvBaoyg/vW4J/vVduhzVKllc5nWrkSSsqn92vGcd/WvoX9iVzJN42Y+ljj6f6RXzBcTNO5yxIznPrX05+xB9/xr9LH/wBuK7oqyPFqT5pXPqWiiiqIPBP2zv8AkmOk/wDYai/9ET18a19k/tn/APJMdJ/7DMX/AKInr42oA7z4S/EGfwLq8vnCSfR7oYuIF52t0Eig9x0PqPoK+t9I1+1NvbXGng3FjOvnQyRnKsp7qfT1FfBler/Bb4hSaLcW/h7Vbho9KnmzBOf+XR26g/8ATNuMjsefWuLFYfn9+C1OijUt7ktj7FWRL2zMqDakgOQw/i968f18G3NwhTaUJdYwchSOoB9D1rY0jxBJeQSDTLlmQZR2A4I/vDt+VcnqMV1b3VxFeMWjZvkJPBHY/wCNedUT0bPQw+jMzUYSwWZAfLniDoe4GOQao3LGSGPk5ZQBj1rVmkMuh2yom2SF2hcngqfXHTBrMVMAoMZwTyO9YW1PXp1L7k8LiKFQ2Dg4JqSGRbhyzDMfII7bappvWFs4JP8ACRzT7VFjctnk9RWsUzrUk9zeudYvLnT7Oxu7kzW1ooWHKjcuM4+br0498D0rJ1MSTwTRQxSTSNExCRJuYgDLYA64pkkoTOCcZ6gZFZ17qE9nc29zZXElreW0izRyxdVPrzwfQjuDWqV3qTaNOL9mkmY+h3G6HYrb0b5gfWtHIMuFJJznHcVNJbpqAuNftpNPj82+ZLmxtvla3LDKuEPJVjluMgE9qiu4miO4YBHp0I9qqUeVkwqqpG/VFS/szIGliAHUkY+8O9Y0PGUGTExOP8Poa66F1lhBQchc47Y7iubvbYxXMsa/xDfGemM/578VcXY5q0OYwZbX7Kxlj+e3zlgD/qhn9R71n6raqHEyqAQuSBna4/xrsLwW0i262tuY/Lj8uVieJmH/AC02/wALEcHHHFY43Wg2MFa2OQuecD0rohOx51aldHMqBtLr3JpMqG+cgtjqRW3eaOJpGez2gkZCk4zWc9ncRErJErEjjHNbKSZw8strFNUU9wPXA6VNHGpk6MQD17VLDbSlj5MDsemNvU1dGk6hcEAx446EgACk5IuNOT2KqFQASdq9dveo5JPMCrgAg8nvjsK3LPwu8pV7pwg/2eSa37PS7GzACqgC9Xbv+NZSqxWx0U8JJ/Ec3p2m3ssZ8iFo/V2GOPYVp2Xh4Bv3srEnkhOv511ECMzoroI9yhgeqkZ7kVNbxGOOVmZXSQFVGeAe3PasJVmzsVGEEU7PTlEEaRPGUjGdq8AA9x/WpooYzdhEKu8q5iVh6dR+NMvpVtYorN4UD+QRIok2tJzk89/apNUlE2uXV08iJMfLELIoQMu0ZUgDAO0AZ7kZ71EtVcOZ7IrywpBdSzISkaYZWYcYxjYf1qvJP9hjkmHmQNbZZ2ZR8kb8HcO64NSvEHne2laVQgxGShYshJJOenyg/iM15z4x8QLdtJYWE5kt95M04JAnI4Xj+4AOB61rSouozGvXjSjczvFOrjUb0xwybrSBiI3AIMnP3yDz+Hau0/Zl/wCS5eGPrc/+ks1eYYHv+Nen/sy/8ly8MfW5/wDSWavRjHlPCnNzlzM6n9sz/kqem/8AYGh/9Hz14XbzPbyb4zzjBHqPSvdP2zP+Sp6b/wBgWH/0fPXg9DJvY6LS70qFdRnsw7Cuhs5VkERJ+dF6j0PXH+eK4G3ne3fcnI7g9DXUaZcgtGUO5D907ehrCcNbnXSq30OnilkguY7yzeWC4iJeOaAlXX1we4x1HT1Bq99rjvLua5u4yPNDO5s40iJcjIKqcKDnr0HoBWVAgml8t5CjNG5GIzJufadowORkgDPbOaSynUojAD5+eBncPT3z+tYOWtjosum50TrPDpsWq29wk8MEqxTSQ5WS0mbpFLG3IDdA/KseM0RyxCI7disWUeSsR2SAjmTPRSDgFR65HesWN0VMyD5h8hJ5OM5AHr/KnQztE7xbmwCcjdkc9BnNRJpapDimt2azxWks6eZBHuIC7icbPcHquP61b1GGeW+Y3s32i9VFRZriUSyEc7QspzkY4HPfFZCXET4KsT0XHQipTKpJUgDIPbrn1HTFCnK1huK36lq3Pl3Cpcm5jiGVkWFFaZAfRXIDY54yCe1R6gkFjMp0+/gvLcqds8AZd2Dja8bDcjjqex7Gmm8KonmMJY+AFlJOPoeoqvOsJbCSbgw5VznI9N3QirU42tYm0r3LFpcswO1uNxyccZ/wqw869drYIwfcnjrVfTYbGRZY76+k0+5VwY5ZIDNbyr/dcJ88RX+8AysMcZrTvdB1e3torv7D9rs5wSLrTibuDjIwXTJU4GcMOPY8Vok2rkqutmREyLCVL70xgqcZx2xSS3UfysSfM3A5PpgcEevv6ZqjHd4/1ZRkU4xkNj6etPFzGMbSdo5yBlt3+FS43OiNTudN4Ovgb6eMuN5i3Kc/ew2OO/Tr9K7SOcYByfl+bHYev415OrtDNFc2zeXcRNvXGO/BB7YPSu303VYL2JZIyUYHDZGNrenPbtWMo2O6hW5lY7XS51ljfaTy+SfUYrWsZRFPbzAcxSrJg9DjPB/P+VcfYXYSViflBUDkY6dePxrdhu08tQhOSfzpR01RVVKas9mauoXTXd7NcS4DyNzx2HAH5VlXTBEAT7ykde9Oe4X7zZBPbpWfd3CgFmIwCCMVUm5O7M4pRSiugSzgSnhRjnjqRisuaUCWUknDNkY7UTXB5fsM4P4Vm3NyMnqAxzhT196EVexXv2DkMXOGOM9SOcZrD1xmbUH8pXVLZkjSMD5fLOd7segGAOO5YYxitG7lB3BM9cZ9h1NVNWuJFtoLcKXgUqz7mKh2IySB3wMc1SRjUqWKxfLq2eSeSTknvVW8nC5HJAOMY6mmS3BSMknkMeo/Ks6WZVTzZFPJ+XI5/KnYx5iG/nEKNJI2W7EjHBrzXXNSa9uGCsSgPJ/vVp+KdaNxK0ELHdnDN6e1cyK6adPqzz8RWu+VDcHoOK+ov2IPv+NfpY/+3FfL9fUH7EHD+NfpY/8AtxW5yH1LRRRQB4J+2d/yTHSf+w1F/wCiJ6+Na/Qf40fDw/EvwvaaONU/swwXq3fnfZ/P3bY5E27dy4/1mc57dK8Z/wCGTW/6HVf/AAU//b6APl6g8jmvqH/hk1v+h1X/AMFP/wBvo/4ZNb/odV/8FP8A9voA8s+FPjqfSpRplxKimRv3E8nc8ARsf5H8K9MGoy38k0k33ycMPQ9//wBVTH9k1iP+R1X/AMFP/wBvrsNP+B+tWVqkI8ZWcxUAeZLozF2x6kXAzXDicNKo7wZ24fExgrTOQtgcsrAqh+b6mppLaOVyWwjoM59fau6Hwk14dfFeln66JJ/8k0rfCbX2jCN4q0ogDH/IEkz/AOlVcscFVTudqx9JHlUp/dAcb9xHXt1qhbzcMJGI59e9esD4K6yFK/8ACV6bz/1BX/8Akmq0/wACtWlKn/hLrFGU5BXRn/8Akmr+qVTppZpQXxXPOodxQBsmIjOcdDVbUlZJIiUDxEYZu1erD4KayDx4t0/A7f2M/wD8k0jfBPWGRkPizTtrDGP7Gf8A+SapYWoW80w/d/cePW9i6azYLp0aGa8kFuqN6t0wT0Ga17qAv58UjqzQu0Z256g4I9q7+b4C6pNbvC/i+z2MQeNHcEEHIIP2ngg1f/4Uzrxmkml8Y2M00hLSSSaM5Z2PViftPWn9VqB/a1G+j09DyLSZPL/dSY3KdhGccGotdtmYEqVLxnAwc/5Fern4FasZjL/wl1gGPB/4kz8/+TNPHwN1fbj/AIS2wxjH/IGf/wCSaaw0zN5nQ1Wv3HiMOZYwgIY7sEZwR3z9KrXlvIoJaI7e20ZGPpXtsf7P+px3DTJ4vsgzDaw/sZsH/wAmKsyfAvVn+94tsPw0Z/8A5Jq/YTMfr1B7nglrAWcwRjzOmxDwcema2YNPAZRclIQDtQnp7k45Ir1eX9nzUZGDf8JdZow5BXR3BB/8CKnT4Daom4jxbY5Y7if7GfOfX/j5qvYTMXjKSeh5SLeKOdkVozs5yOAAO9OjjaRtkRDNk8L/AIV6mPgJqfmtJ/wltiWbg50Z+np/x8U4fAjVt24+MLItkHP9jvn/ANKal4ebLjj6a/4Y8oeLDeXLJ8xDBCOmQev0pbZZi0tv+6MFwBHHO6B2jI9D75INesR/AvWI5EkTxjZLIj71b+xm4Of+vilHwL1YK6r4tsFDsWONGfqev/LzUfVqhbzCk+55TaOYY0inKxvA5jG35sJ2BHQ81oW7J5QYSI8K5HyDvXpFv8ENcto7iO28aWkUVwAJkXRmxIAcgH/SKjHwK1dYTGvjCyAJzkaM2f8A0oo+qyE8dR7s841CUC3AKpMceWuPm+XrwfTP41UhtZNU1KztNLjuJbsQ5njkABLr1CAe2PfivVF+BeqqUx4s0/aqhdv9jPg+5/0nrUVx8B9YmkWUeM7WKaPmKSPR2DRN/eX/AEjr9c1Sw0tmZSxtPofPnxA8Q3NpbHRlby73BjuQDkwp2i44ye5FecfSvqJv2UJGYlvGwJJySdJ7/wDf+k/4ZOb/AKHVf/BT/wDb67IQUFZHm1KjqO7Pl6vT/wBmT/kuXhj63P8A6SzV6l/wyc3/AEOq/wDgp/8At9dR8Mf2eW8D+OtM8RnxQL/7F5v+jjT/ACt++J4/vea2Mb89D0qzM8u/bM/5Knpv/YFh/wDR89eD19vfGf4Hn4leKrbWR4hGmeTZJZ+SbHz9215H3bvMXH+sxjHbrXBf8Mmt/wBDqv8A4Kf/ALfSsI+Xqu6Xdm2m2kZVj64wa+lP+GTm/wCh1X/wU/8A2+k/4ZNbGP8AhNR/4Kf/ALfScblRbTujyrTbmeze3uLe4eG4hcPFLGQGicZwR7+9VojGqKrPwSVb2JOcj35PT1r3C2/ZnvYLZYB43jdF6b9IJI9v9f0qQfs13m/cfGcBPvpB/wDj9czoybOtV4ni+mX8mn37XK29rd5hltzFcJuT94uNw9HUcg9KhhBSMI8hcACMN03jHX/65r3H/hm68xg+MLUgdP8AiTtx/wCTFPH7OV8MZ8Y2pI7nR2/+SKXsZ2sV7eB4oHVgp+8px6dB2NP8xsqWfAA3FlHIH+Fe1L+zpeqgA8XWm/cWL/2Q+SCPu4+0YwOvTPvS/wDDO1/z/wAVhaYPUf2O35f8fFL6vMPrETxOWSVAQ5DEYB6Z9j+BpPOZRmQEM3G4DK5zyT6fyr27/hne/Oc+L7TB7f2M3/yRTV/Z0vgMDxfae3/Enbj/AMmKTw8x/WIHiTXgBYp94EHAz1Pf/wCvVnQ9WvtI1FrzRr25sLwjl7dzGX/3l+6w68MP6V7E37OV80gc+MLXP/YHbn6/6RSn9nO+Jy3i+1POf+QO3/yRVKjOOxMq8JaM8X1fVrzUtXutSu1gFzLgTyW8AiRmHV2VTtLY6kYz6VX+3DIdSu1hxg9fTB969xb9nW/IQp4wtEdABvTR2BJB4J/0jrUb/s4Xju7t4vtS7tuY/wBjtyfX/j4qvZTEq0EeLxXfmXEfzRlCcNuJwBjqcc8Vr298lva3F5bllcTeXGc/IwxzuyRn2I6V6iP2b7z5f+Kvtfl6f8Sdv/kiny/s6X0pXd4vtMIMIBo7YQe3+kcVPsJdSliUndHG6Nr0E7eX50ImyuY1kDgnHqOGI9q6yz1DAGX2E/KRng/SpD+zjekg/wDCX2wI6H+yG4/8mK2LH4Ja5aQmMeMrOVSNuZNGYnHpkXA9KX1eR1RzCG0jKa9VsruHPPBzgVVu7rdhdw8sAZGOtdY/wj11pJGHirSlDknauiSYGew/0npUbfB7XWIJ8Wabkf8AUFf/AOSaFQmDx1PocJNcD7qlcD0rOecEnONuOTn73Nejn4La2cf8Vbp/H/UFf/5JpifBPWFYH/hLNOOOmdGfj/yZp+wkS8dA84bbjzpCEjBIZ24X6D1rIvryGSJ1ilDpH8p6gZ616ze/A3WLt1MnjCyUL91V0Z8D/wAmaox/s86jGJAvjG1AfqP7Hb/5IpqhIylioM8mghuNQdxawNOqHc+xc4GeAcetc38Q7w6XdfZEuIZpSn/LJs7frX0dpvwS17TfN+w+NbWHzU2Nt0ZvQgH/AI+Ooya4+T9lCSSRnk8b7nbqTpXJ/wDI9axp23MKle+x8uc87jknk0tfUH/DJrf9Dqv/AIKf/t9L/wAMmt/0Oo/8FP8A9vrY5T5er6g/YgOX8a/Sx/8Abil/4ZOb/odV/wDBT/8Ab69R+B/wlPwuOtk60NV/tLyOlp5Hl+X5n+22c+Z7YxQB6nRRRQB4n+1prOqaJ8O9LuNF1K+064fVo42ls7h4XZDDMSpZSDjIBx7CvmfRtZ+Ket2z3Gi6l471G3RzG0tncXkyKwAJUspIzgg49xX0T+2b/wAky0j/ALDUX/oieuH+EWranoX7LnjrUdCaRNQh1GTy5I/vRgxWyu49Cqlmz2xmgDzz/i8//VSf/J+uZHxA8Zld3/CYeJMHp/xNZ/8A4uvurwNp2nWiadd2niDUb6e+sFkMV1qclylwPlJnVJGYry2Pk2r82COmPgzw3pDSxxXd0o8pQPKQ/wDLQ/4VMpKKuzSlTdSXKjqNM8T+MWtxLd+LfEpZ1yE/tW4G0djw/Oa0IvEfilz/AMjX4kA5/wCYvc//ABdUUgJ5BGP4T61raXo8d6zoZF8tSvyAHdMDycegGOa43Vk3ue1DCQjHVGpo2peIbiETz+KPEzK/CqNYuunr/rKuT6lrSplfEfiME/8AUauz/wC1KvNbeWm1QFCgAKOi+1UZoSwGBg5wfpSlOVtGXChSb+FfcVxqmusxC+JvEuP+wzdcf+RKkTUddLHPiXxMeeP+Jzdc/wDkSpI7ULyMYxxTvJIPyisfaT7s6Vh6P8i+5Dor3XHz/wAVH4k68f8AE5u+n/fyrC3Gtcf8VF4lP/cau/8A45UlnBgZwM4446Ve+z4BJGBnv/Oj2k+7H9Xo3+BfcjLN3rKtg+IfEpPp/bV3/wDHKeL3VDwPEXiQt/2G7v8A+OVYuLfBDEFT6EVXEWDgHB+n6Vm6s/5mdMMNQ/59r7kXbG8v4bqOa61rxHcQKfmhbXbxQ/HqJc/lVvWNTuJhGLW78QaexGSF8Q38h/8AHpap2vkzIRLwuPujrmq02d/VmA4GeSB9aPb1ErXL+oYeUlJwX3D/ALTqZBP/AAkHiQ/9xu8/+O0+OfUiPm8QeJCev/IbvP8A45UAOSBzjpU8XC4Pr6dqwdar/M/vOmOCw/8Az7j9yJ1lvzwdf8Sf+Dy8/wDjtSo190bXfEp/7jl5/wDHagR8EjrU8eARk/Tis/b1ekn95osDht/ZR+5E8a3pcA654kI6k/27ef8Ax2rQguS2P7b8SYx/0HL3/wCO1BGp69zyauQMr4zkfU9RUvEVf5n95f1DDf8APuP3IkitJifn1rxIf+49e/8Ax2rkems5AGseJM9/+J9ff/Hqiib0Oa0bbnBz7VP1ir1k/vOargcOl/DX3ImttFRiBJq3iQ5/6j99/wDHq27PwtaS43aj4lP/AHMN/wD/AB6qlu4Rl7iuhsJtqrjpW1GvUctZP7zxsVhqcV7sV9xBL4JsxGWTUfEucf8AQxX/AP8AHq81+MPg/wAS2vh5tZ8EeJPFMclim65sF1i6k82MctIrPKTlR/COvJHTB9ytWLxDPIxzU0MQV8j8q9OEpcyknoeJNRs01qfnwPiB4yIBHi/xJzyP+Jrcf/F0v/Cf+Mv+hw8Sf+DW4/8Ai69W/aN+EEnh+8ufFPhi2LaLM3mXltFkm0cnlwP+eZJ/4Cfbp4HxjIORXetUcp03/Cf+Mv8AocPEn/g1uP8A4uvRP2evGHibVPjH4dstT8Sa3e2cpuPMgudQmljfFtKRlWYg4IB+oFeKGvTf2Z/+S4+GPrc/+ks1AH3nRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAeCftm/8ky0j/sNRf8AoievGfg98av+Fc+Fr7RH8OJqsd1ePdGRr3yQA0caFCvltn7nXPfpXs/7Zv8AyTLSP+w1F/6Inr5D0yxlv7yOGJeC3zMegHehuw4xcnZH0f4W+OdhYtcXWgfC/SdMa4wJJbe8SEzEHOCUt8t1J5rzHSbSSGzto5sbo4hFkZx8oAJ+nfNWrHTljEaqCIUGFHoPxrastNml+ZYnGMZbbxtrhq1HN2R72EwsaK5nuVbbT5pnjWJSS3yj0J+ldlomlx2MToo3SMcyOeuewzS6ZafZFBdCCqnAIyeefzrZSForKMOMOV3Y7ClGNtWb1JtvQz2t97N784rc8MeC7nXre6miCLHHmMM7YzIOwFUYVOQ3O4EdK1tG1e+0kS/YZJIfP5YdmxxnHr70QsviMKjny+5ucpcWDR3LxMGUxkoykYOR14qGS3IOQAPTFdBPHks3bPJP86oSxkvgGs3a50Qk7aml4S0jT7xp5da1FdPs4So2qcyTE8nHHAHr611h0/wFHmMahe5HBZS+T+S1x1vGvlDJA49KdIq4+7jA4Oa0jV5VaxjPDzqSuptIt+Ml8ORWkNv4cjmmmYgyXMpb5QP4QDjJNcgUAGG+971rTwKVySDVJoMMBuAB71hVfO7no4aDpR5b3KO3DkqR079acFZ1JwSPpUsiKXZSVIXjcOAaiLFVUBjtx0B/Oue3c74sFjZUBGCB15p6c9D+tNDH+EEA+ppUbjIAHGeayaN4lu3g8yUK0kcY6bpDtFdBD4a1V7JruKyM9soJ3wyLJkDuADk/TGa5+KQEANyp4xnpxWx4d1a/0W4abR7owhjmSFhujfHqvr7jmrpKm9JmOKeIS5qG/YqwDzNskLBwTg9iD6H0q4sTx8uuPr3rstMi0Lx3NKJYW0zxAE3S+URtmH98dmA4z35rkNQtZNP1O60u9c/aLdhtYZ2uCMhlB5x+lOthHBc0dUZ4TMo15eymrSQ+Nh/9atCF8cCsc5TGKswSZ6muFnfKPMjetnJOGPTpW9p86jGTnHauShl5BHUcVsWVxxnv71UZcup5eJo3R3OmXAxjPWtqMYO49K4ixuirDJHFdXY3KSrye3rXq4aqpKzPmcXQcHdF28tobuzmt7pFkt5Y2jljblXQjBB9sZr4Z+OfwsvfAOtTXlhBJJ4WuHAtZ92/yiRnyn7gg5wT1GOc5r7sjYOtZ3iPRdO13RLzS9XtUubC7TZNG3cdQfqDyD1yK9SLujzHofmmeD616d+zP/yXHwx9bn/0lmrnPiZ4F1XwF4kn07UoZDas7Gzu8ZS4jyduD/eA4KnkH8DXR/s0Y/4Xn4Yx0zc/+ks1U9APvOiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA8E/bN/5JlpH/AGGYv/RE9fP3g7ThbWhd1IaQcd/bNfSH7WFqt74J8PwP91tciJ+gt7gn+VeQaTpdxJ5AtoCsbMqqRyp5/wD1VhWl0PSy+km3N9DW8N6KupXBMiAWsQ+Y4+8fSu+XTAkeMbSSBjsBmtDw3oQsYI4wjMAPMdtvyljXQfYlIUFe+Scdcc1NOCtdnbVr626HKjTTNKwVM5UhQvU9/wAsVnX6HzI1GAPr6V2lrBLbWkt8kTFQuFdlyoGef8Kbp1xZgtLJHxC3lzqeVSEscZXp35I5x6U3Bs5/b22VzkEjhWSJJWZUZjuZRlvwpmo3kb3pe3jEduuFSPdkKMdfrVzxZqMOr30UlpAIIIAY4in/AC0Gev0rl3kaKVllJMbenUVzVNNDuormSlY0ZZgUODkjnpjis/z1edT6Hp/WqMl15G5lYYJ43Vd1uE2B8ooXmRcykDCL65PoCcH3rM6OVXsXlYbcA/NxnNDsCSOM+lc8l8VZT8zDOSN2Pyqwuoq6goGOOqt6+lGhooGpIOBVO5UqDgVFFdllXeFVgTkAZ4qx9pjK5HXFJq5a0Ma6JUAAnr271Abk7h8wK+uORVm+8u4z5RwT0OfT0rKZXWcArgHr7GsWmjpjK5qCbLAqvbIanoc4PUHqKrW7bThh371bCh+QRUPQ2Uh+7juMGpkb5t2Dkcgiq4GcZOF7ipVGCCR7496ykjoizUs7mSKeGaOV4J4WDJNH95fX68du9dV4i8SQ67pZt722ikvIyDDeRjYfckdvp09q4iM4J4qyrHHtVQrzjHl6GNXBUa9RVZrVdi5Knyhkx7+34U9c7AR1qrHMU6EkfU1Z8xWBZDjPOK5pas7LFuBz3NadpJwvOKw0bHuD3FXreXawB6fWpMa0Lo6S2mww5zW/p90UI5PrXHQzcAjHHpWxZ3GGA7VpSm4njYnD3R6BYXAYLk8Vo5BrkNOuguBnjtXRWtwHUc817WGrprU+YxFFxdzF+I/g3TfHXha50bVYwd4328w+9BKAdrqfbP4jIr5H+Behal4Z/aP0PR9btzbahavcrInY/wCizEMp7qRyCPWvt4H3riPGNnaSeO/AN+YIjfRanPAs2PnCPYXRZfoSiH8K7uZbHLY7qiiimIKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPI/2kYjN4e8NRqSpbWlGQu7H+iXPOO9Z3w+0JbS0QOu6Rg3m8dew+h68V1HxlXevg9cZJ1o49j9iu8H8Dz+FT6ZaJZKuCzMxCy7uzY5P1rGa9656OGny0Wl3/AMi/b2wEQUIQmwBUx92n3cebZiVydpCj3q1aqBBGD85wPnJ5z6+1FxtVR39W6nNWY8zuy9pSw3GjQxNGpjEYjkj7ZxyK8s1UR2mrNbfaPJhXUks59rYDwspdvy+Ue1dhc3bwEyRuwTKk7WxnnnNeaeKphca5OYmUkqiFjwGfHLY/LmoqzSjdHXgsLOU/JmdNO63stu4XYk7OrooGIweMegwR9TVHU5jPxAq7U5yOCRULtKn2iGMEpc7UlBPUISQM9upqlcMxldF+UYIC57AV50p3PoI0OXRMmt7aGS8U3gke1VQXRTh89sH64qa5vXu5JWZ5Jyx/1jttBHqR9f8A69Ubac5cls/JjB5zVuORQkChVyjiQhlBGVORkdx7Uk2xyjy6mXcoA+Am1lYhiRz+OelNIyMupAzjpgsa1L1Eubme6uHd5p3aWVv77N1P6VTmHnSFSMKen+zx2oaEpaK5lzsVZTA8i56k9qh+0upIkZmAxjBxyaS5bEjsgKxk8KxqnJl+hO5hjaD19vb60jRWRbS5Z2bdP/GVRck9B1z9eKuQtOsW54vMXHY8isySGe2YNKwVoSC5CHoTgfU+1aFtrkQB82Hbjj/e9OlUo3MZVbPQtxzIx2t8rjgB+Dn0q4hOcMNrcc1iS35vkm+zQgmMbjvYA4I69e1XBLcwwBtk1xZqAY5kQkSA46Yyc89DSlTZUa66moVJJwTketJ5/lMAyMQe4qmbzbIkZco5Pyq/Rvoam3M3DZyPXjNYygdUKqezL6TI3Q4PuanxnIHNZgO3IYdRkEdcU8uUwUck+lYtWOmNRM00z1X1PQ1NEeQMZPcVjLdycKDgk4AHetG08yXGXUDv7GsZaPU6IyvozThYGJAw5HBbuRU33W9uuaozCa2KeYuVb7pAzmrFxKsGlTXhcPHCodvZdwVvxGRQlzMipKMFdvQ0YZzwc9Kuw3OCOTx71gX3nadqdzY3AIntmXOOjowyrD1BGfxBFNS+fg7xz2FTOEoOzMFyVY80XdHaW1+Rj5vxrYttZWEDc5rzeO+cAYY4HrVhL98csee9VGco7HJWwEJ7nqP/AAkcezhq5y71X7d468FRZ6apM3/khd/41yP9ovtPJqbw7P53xD8GAnn7fMfr/oN1Xbhq051IpnlYzAU6FCclue/UUUV7p8wFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHA/FhS1z4LUMVJ1s8hcn/jxu+1S2cnlwb5Nxfk4bqcVF8WF3T+DhuK/8Tl+R1/48LviobuQW9mxQJ5yxZj/2mzgD8O9YVHZ3PQwseaFvM03u0ijJaVRgA/OcYrAu/EUJt7mRZlkQSrGgQElcnv8AX1rG1V5byHbIPk67R/EPf+dZm5DcSbgZBgMFXgccVyTxN9EezQyyOkpMl/4SO4nSeHCIHhyvGdrFucnvxmsC5U7pVb5QSp5HTIpbmJ7dGk4kRlZDt4wT09eB61Nbzo1nEsmDKQCWI5JrDmclqz1I0Y07uBjzQu7LHGWJkBUY4PQ559eKZYQSancW1tBDLLfScxxRLneqjk/QDr6fjWpJZQzwyNE+Mcr9az9F1CXQ9fs9Utghntt6jeOGRhhhjqOg/LNVHlv7xFR1HB8i1IJrMwsY5SUmIWQgDkAjIqBpBG5LBjj1GKlW5V3t3f5hGZC/GGfe7Oc/7pbAx0HFVzOGYAxMpRSSd3Bx7U2op+6RGUpR99aj5LjkqE+8PT+dULiYsJAzBRjaOMYoluQVbIfA+Ug8fhVCeVyFbam1VyMj7tBDRHLGrEbSSM/ekqtFKguHVhvQrwQOpPQD0p83y7nnKgn7vBOPwqGV/Kfz3DbRHtVVH3sdvr9aaiZznZWNO4t/tha3b7a8m2R4S0v7s7RufcSPvDIGBwMepqG001rhJw4nSSIpvdFLBUfOHKqCxUYwSBxkZp9vPcG4RnIMc4XeUwHKkj5Ce3IAOPSrzRlr37RuktnnQqlzHkeVggb8j72QGGAeOK0UTmnNodZaJF/Z0f2x/LuxucokYYYxkIx6hiAWGcZ7c1dS0t44reSD7RFG1uDJAjn5ZD1f3yAMHgc+tWrWRI18u3RlUMR8xyxXsCe9Nuo96Y34BG7IPIPb61okcsqzMS5sDPHcOZbjy3clYi2UiB+7gnnFVS93YRYaV5l3fLnGAP8AGtJYZLdws07S7+QWABb8qhmBIJaMOAeM8/pUSgi4YhxGw6i4YrJHt7cA9D/MVblu0KAnjPUjoDXOXZZHGAQRz7fSrBmEtsJEY5hQ7kP3/cn1xXNOj1R6FHFvZm/A37tpM5wQAF461KkrIpl3MAACCOQOeQ3vWZZF5QFBY8bQMYK4GTkfSpp9ywNHnNvLtbKn5WI71zSp30PRjWkjok1YT6VLE3JX7jd8/wD1qoeeW06+sm5iuotkgPICnrWSkgwqgkDO4getWbeTO7JOPTHQelZqn7N3NXKM001ubup6rLqh0ye5yLy2s/sUr4/1qq2UY++P1Jqr5u09foRWdHLjHY9qd5vOc4IzRNynqyaVKNGPLA0VuMNyODUkc59eQeKyhLgkc+5p32jGcE4pcpo2aK3DZOOecmtXwXLv+JPg4Z/5fZz/AOSV1XMfaMAnGO1bvgBw3xL8Hgf8/k5/8krmurC/xInmZm74efofTNFFFe6fFBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBxnxCgW41bwRE5wG1p+fT/AIl94ak1PT7dHSaTJG0xjH5Zp/jZQ3iDwKD/ANBqT/033lXNdti5EoZtqH7oHWsqsU1c6sLNxla+hxuqW0ZmIwAucJt/iGMc1iXXlwObdEACgZOOtdXqdtI8O+JG3oSceormdQtmEzyOCuTnjtXmVVbWx9Rg6iejZz068iNuUOSPp6VQlt3UhYssrnOe49q3LiEB1zxuBGfSs+VWWKRgMYO4DPSue57Cs1oUpnmhDqxKRtwcDJqldRRyQGWIL5gIDeuDVu5uGKNvC9Bv9h2rKlnRLqVHIAfb0NaKSMZQe5TOEfJyMfpVSR2DBdwP+124HenXG7OQwJVueeMDpVN5j5bhskM/Bz+tXE56hLIzvtDIkeOdynr7VTmkDKCxwzNubAPTt+VOZ91q6ycByGAPXI4/lUau/wDrIQWeFsD0Pb8etaLU5JNkpZmgEPCoeoxz+dQxx/apraIJsDMA2Scg5wc+vHSmzE20i/at6LjKbup9arSXLyS5AZtp+XBGT9K06HPJ6j9VDgWUiELAhuDLlzl2jlCsoB/jIIwTwcnnjFauiX8Mc00CeYLGYOcS43AnJXOPlLKMAlQATnHFZkdv9uie5DmLH31boSB0wPpnn3qrNMtsijP2hhlQo4VBj5iPU8mrjojlnFt3udRp98gjjEjY+TIzzk1YkvkD4Trjp7VwP9oMFjkkmVcx/Kc4LEHmsyHUZYp2mWXcJcsQTkMOg/GtEc8oM9LutTgijzM3yqOKzZNR8xy0BC49a86mvprlwXkO3pgnrU9tqcsKks20gd279qOUxkmtmdrM0M4eMZUhgDwe4z1/pVB7oRSJ55PmJGqBh8yzKvYjs2Cea5ufWAsgkkEJYD7wBBLY9jg49cVTutdM6Ya33ZYlm3ct7/X0NL2d9hxrOL1Z3tjqHmNbvCvlzW+AXDFjI2eGYHuFO3jsBV3zGCsIxlUAGK4Tw/fbbiMI25GYqS3BPHGfcetdvbDLZyc8ZBPt29a4q0OWR7mErc8LktrG0CkHkE55NaEBVdpyQc/lUCg7dwwR3BNLGRkgnrXPJXPRi7E0hwxBOCDj8abuGRg/jUt3G0t3biIfPcKhAz/GeMfyqlJxvU5WRGKOp6qQcEH6VKjoX7TUlaQ9Sx6dD1pvmDBwRn3yaiaUA4zknjgcVC8hwV4x65pJMTmW/Oxk5I9zXR/DeTPxR8HL2+1XB/8AJO4rjjJ8/J5zjnpXUfC9s/FfwgP+nq4/9I7iujDL96jzswf+zzPq2iiivbPjwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA5Xxn/yMXgT/sMyf+m68roLyDzoSAcHB/Ouf8Zf8jH4E/7DUn/puvK6kgGk1cabWqOZ+zO9zLlSPLBOMdeK5W9hWQzpKMI7HGR0NejyRjzy691Ix71zGo2ttNJciNvn5BX3FctemrHqYPE2k7nAXduV2IRwO47elZVx0jZgSSGVlroJsbmBbKsOc9qx7mMRwMiHLjknHNeU42Z9dQndI5u7j37iDjnGMdqwtQhMheT/AJaJ69x7V1F2m+LcSTk7cVg3kWPMVj904xjkf41Cep2TXMjn/wB4yuHcbDxx96qjpMrMqfMOm1u/0NX2TazBhwB096pXGcsuTxgbgOhrdSOGVNFP7TKmPMiBOThx834D6U0XjKR5QIKncuTx+Hoc4qZ5PMd1QhJG+9k45Heo2kjcF5Fy3GD0288fnW0WcFSLTLN7cre2JZUAlaZpNg4VW2hSQPQ4z+NUTIsbqUUjgEAY4PrRcOApeM7WL8kgde4NVZCyj7u1lJ75AOOD7mtNzCSHRzeXNOEY/vwsvA7556VQupmefI+bHAzz7nj3qe2klVsJjMgyMjhsj1/Oq0SBIztHcqGPOB61adjCSM66EjuGfOWHXvWecKT6DjHfitK8XDlVzhT+QrOnHzccZOM+taxOSpcAvyjO4ZHy8Ur9DznGB7/lTUIUc5z0pzj932BAyOM5q0zmkyrIMsTwQM8jkUxF/eDA64P1qVlOCWHbJApyqeVYDPcZ9qtPoc0o3LsFuyKsqcbm9cbWHNeh2UvmW8E24FZFyuMZGK8/juM2qQ4G4NySfx4rsdHJFha56+WHwT2P/wCuuTExTPWy2TWhvRsQPmbAb5s/0p8YZpQMHO0vkjjAGarwn5NuDySw604bgct1AwfpXE0e5zE81y4e3IwWiKsvHpyKr3dyZ7y4nYZeaVpWAGOWOTTZWAYkjg+/aqzHDEd8ZH+NF3aw1a9yXec5+8MnDVGWJ4PtwRUTt2Y8HPP/ANamuRggnnFLlByJN2WAJzg55FdV8KGz8WfCOev2m4/9I7iuPQ5ByeO/FdX8ImB+LXhLv/pNxz/253FbUF+8RwY6V6Ej65ooor1z5QKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOV8Zf8jH4E/7DUn/puvK6o1yvjL/kY/An/Yak/wDTdeV1VADGBNc5rFgY7kzxjartk88A9zXSmq18m+3cHB6fhUTimjWjU9nJM8x8R2QswkynbArGF+wLk7lI/A4P0rnJVJZyEyWOOvP0Feg+IrRZreS2ly0Ukgcqf747g+/FcbqdvsaJlDfKQ6sP4WzXk1o66H1eW15eySluczlnbapUru3D2x1rD1Fdssr84L42jqTXUSRpHIXVceYSzBeme9YmpWZRMCM4BJLDq6noPbb61yyR7kZ8yOQuF3Fmxj5s5Hr/AIVQuge643puGO4PQ5rbu4yHweX2g5AwKyb2MNy2S0fK7Tzgdv50RZEl2M5mZnO05DKBgd/f8uKhzgAKMjoB6nvmpHGZPl+7ywwOh7io2Dbs54PPPbHXiumLOGqrk2FYnaVypw24dqqLhdx9MDOM/wCRU8hBAYHqBwPSq8xwgH8TcH2rWOpyTjYhVfKkmcxq0IBRkJJ6+mP0IxUMzAByCC6YKbuMjGCfqfepZWdSpfgSN0B+7tAHB9zTbuEbV8sKd2ScHJ47fT3rRHNJGfdKcZ2j1H09azZVwuMfdINacnliXd1Vhgjdn8frVGVQ6jBPXqK0RzTjchZPkwfujGTUfIZsjAPDYbHHpVnpGe5+vSmuoJb2PGP51aZzygViOQfw6UwcYAzwe1T+WRyMDv1p1vArtukOYx2HUmtLmEoC2cZfJUHczbE9D6n8z+lehQxiPAj3CNAEB9hXL6BAJLyOQj7vzKDwFCj0+prsVUBMEEMDkn1rlrPU9TBwUYk8WNrr/EduGB4HXP51IVVkZuBjqPWoI87PQ+9WIeSFbjPWuY9Equow2R/hUEqndyAMnH9asPw5XquSDio5Rx0J7dfSgdyoQSwAGD6+/rTHPyk84Pb+tSOuFYA88d6ifngk4A7d6S1BuwjHZnht2ecV1nwfyfi54SJHP2i45/7c565B8FQW78evNdf8ICv/AAtzwiAPmE9xz/25z10UV76ODGyvRkfXlFFFekfMhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQByvjP8A5GLwJ/2GZP8A03XldTk56VynjZgviDwKT0/tqT/033ldSzbSOevFADietUYwRLcox4zkD61NLJskXnr1FVrbd5szyHLEhAPx4NS9dCktLmLr4+bem099p/nXF30zkscDaOMV3Oup5NoPPwWVTyO4zXB3cjGQ5GR147V51dWZ9JlbvFMxroq7FpRgA9ayrsoWIbOBkBu3Na19MmCMjHTp1rGuWZFOQNuOh71wSdj6WlC5zurW0hjYA4cLhSBnHoayNTEXmjyVMf7td0bDJDjgkN3BzXQXueWUdOpJ5ArOvYjKRgAd8+tRGRpOk1scwANm3AG12yQOeapyMgc7wDn5V5xW3c2wcNglXxy2KwLhHEwiuHO1TyCvX3rog+ZHBVTjuSxqSzlAGU457cVUuCyujOQxwHQ44IzWraWbrbjLq0ZBK4HA9KqXVtGWLOCssZx0JDA1rF2OScW0SmJJ4g24jDbtpGMZpi2sUkeEQYj43evNXFj3oXXcrAgBSOoFRynybVVznHRiO5PUitOY55QZiXliwywyARnAHA+lZc6qF3A43cY7g12GFAABBXoaw9Q0/buZCGBb0AwKtNmMoGNtyzEnAIwo96FUhiecg/TA9PzqRwyHnHTjjj603AxyOMYzjmtYs55QGYbAIOC3DD+lSWykyEIA3y7CcdDn/wCt+tOSPeOHAKkAH1zUkbbQQuVTHDEcnNO5i4Gz4aUG6mGSyQxqvA/vHJ/lXUxpwS3UDOT61zXhaM/6Y2D/AAKPXgV1cfEJDYPO73rCbuzuo6RGoufUsRye1TLHtCsDkYHX0zjP60wjBfPPTIHpV6BI5bK5m3qpieNEXb98tknn0UDOPeotqdHNZEOq6cY768jt3WYWyGRmQ8FRgZH4nH4VlyIT8pPQ8VcmkZZJAmVBQRkfjnFU3bc5255Oen3R9fWlJJAm2VJckkj1x61Xkyzcngdu/wCFW5yNoI5x6jNUnbbuB578VKByI2ypIPA64Pauq+DDZ+MPhMD/AJ73H/pJPXIu3IUZGepNdT8FD/xeTwp7zXH/AKRz10UV7yOLGSvSkfZNFFFegfOhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBwvxPu4rG+8EzzusaDW2Tc3TLWN2o/UityDURPsTcQzDg9twryn9r5mT4e6I6MyOutRsrKcEEW9xgiub+FnxMTU7KKy1eYR6nGFUSdpcd/Y+tY1G4u6OvD041I2e59Bzyidcrw64bH41FPdLEqkZwSSKxbDVEuBHIJMgnB+lV9TvBG7qclAuVNQ6mlzWOEbfK0bF5Naajd29tdqPIkRxycZfjv8ATNefSoTNKCzMEkZd2MbwCQDjtkCr+oztKE2ZJTnrz+FUnjmW3cJjJXjHXPrXLWqqasz2cFhXQd1LR9DEuhH5rBcY6VnXYyMKeT61p/Yp2UsVxnk5NZc6jf8AMMDPU9jXmTuz6Wg1snexi3KEbQOgyDWfL0C8dOCf5V0E8RZGLryDjise5tXVjsw49OmDWWp1tcxkXeWUhQoPvzWJew7mLqcYQLn/AGc9TXRyRENnrjg81SezaWNxtJU9T6ZFbwlocdancraUVFoBcdRnPIwPTFXXgRzuYIScZ3AVRa1UOI5hsDgBiM44rbEL7VHDZ43Lz+Bq+Y5XDoyn5cYQ7SNo6envmql1BtQgLnd6e1bEdmY49pA4GRk8+9RTxIX2dz0281pGfUydK+xyfMShTwDnKgd6gkmDAFlAO7AINdJc6X5nzJjHfFZd3pLqflz6+matVdTKeHOYuYmLPx/FnAqsseyQF+Buwf8A6xrelsGVyHzycnmoJrQqQEYlRyVY/wBa1jUOSpRZXtLXcoKoQBkYzyaZ9injVQxQybsgA8gAd+3A7VtpaMUYxK2cKBtPX1pH0+VNWBX5rW3Hzy4Kg5Hoec8kfhVqomYSota2LHh6IJahW2ks+4/lW/bjchJ5A4BNZOmx5MQ2gBlYnnpwK2oCdoyOS2QBSvctKyFdOoxjJ5yM/wD66nWR00qVGnUW4uRL5X8TSFcbwfQKPwzUSxyO6qpBlkbjJwAff2pL1Y45pBEzPHuIRmGCw6ZNMplVSDyR+neopE2kHjPUH/CpHzkZOCP9qo2c4wTx3/8ArVLDmKNxuDZP3vSqMoyAoHP1/rV66yM8jPoKz5Op6+gHoPekS5FaQ8k9wPx/Kup+B+5/jL4TbgKktyOPU2k5/pXIzHjnPJ+n411fwNnH/C5/CUJ4dpLqUjGCB9kmAz/nvXRRXvI4cXP92z7RooortPDCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDwX9stzH8NNHdeo1qI/+QJ6+WNLviCs1u+11OQO4P+NfUv7aH/JMNJ/7DUX/AKInr46tJ2t5g46dGHtSauXCbg7o+kfht8RoklFlrMojWUBFnJ+UP2J9M9K9e1KVZreOQNx03A5HtXxpZTAxq6/MjDlfUe/417F8KvGka6cmg6rcYhX/AI9LmZvuf9MmY9OeQfwrjqwtqj28NXU7XPU53keYMpxtHY8cVI9yQBjJrME+ZTnhgoVh7/8A16e0m7p97OMGuCTPfhBNK4+e4lMbZ4BNZNxGXQgfd/nWo0bYAJyG9e3tUN9EVQBBhehIrCSZ1UpKOiM0xk4B5GMc9zWbPbMCx2kFj3OPzrbgBIAOCR+pqK/tjIRt6j8axcbnVCrZ2Oda23MflJcDAPrTFtmSPbjDZ5UnitqKINBu/iQ5Ukdae0SyoHCfNgk7hTjognK7Oeks9zkOAB9MirltbhN3J28ZH9atMq7icEKvHIp5i2KJFwwHQDtVKQOmirPCCOmBiqU1uC6typ7n3rblj8xMgnBql5RDMDyOnIxVcxCpmW0bfdIxkZOD2qvNEXJbn1OAOK2GiB3BlHsexqt5ZQtu5A7HtRzEypmJJbFl6HGPSqU2mh0cAFT2IA4rpJYS3LY4HUVE8QJwRx2qomE6SZlRxNCgBQ9gCR7UajbtPYvGFO5sDAHNaywjd6ge9WreAHcSDn37VvFnDVi0jmdKhxGVODJGu0Y471pRqAQCTknn0q/NYJHKWjyokwvP60xI/nwV2gEkk+grZanGtNCqwCoCQRngDHGahuQ24Zxgc1dUgrkcDJ6gnNU7uMemQeme1UhSKLnPzHg+lRqSDgEZyKfLnv09qqvuXgZJ68e1IzuE/MXyn2yMVlXHCscZ7YrRYhiVI49xgVk6jLHBDJNM+2NfmJIpqN2ROVjL1a9is4d0x3egHVvpWx+zfO9z8e/Dc0h+ZmuiR2H+izcCvNdSvXv7kyuMICdi56CvRf2ZP+S4+GPrc/8ApLNXfTp8qPFxFb2jstj72ooorQ5gooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA8D/AG0P+SYaT/2Gov8A0RPXxnX2Z+2h/wAkw0n/ALDUX/oievjOgC7pt35DbHP7s+vQH/CtrdlCp+Zc555/GuYrQ0652kRO2P7pqZK5pCbiz2LwH45W0gg0zVXcjBEc7tlefugk9D79K9Ws7h5o0ZYwyMfmVuCpr5eGAAGGUPBGOgr1r4OeKpDctoOqyl3YeZZyu2SQBzHn26ivPrUPtI+iwGP5rQmz1lJGNoruoWRWwVb+IevtUjkNOAVxnqtW4IY5I8pjawyVq5DahmVz1A6VxtX2PR9qomJNaLuDrwBzjtUDgvMmOOMH3NdUlkpYYwc+2aWXSYpAGCAMPQcUeyYljYrSRyMtsI3Ixw4446j0+tMa3Eaog4LdTXSy2DopDqGUHKsO9QXtkzKhI2tjIPaodNpam0MWn1OZuLIgllH59KiitiT8w210xh+QB1571QuYwuNo61DjY6oYltWM1rcxqSQNuetVJYiX5APuT/KtWS3YlGibK55XtVCdGWd1JGM8A1DVzenPmdikIxnpzTZoFctgYPf3rQWJWBIXaQMe1MeEFQAcc0tkauSZiTRFfUjOMf8A16hEZZ8EEg1rzIVkKOOD0IHBqNYxCdwUNu7dRVRZlNFNYgTgdM+vWrkUBwO1NiG6fd69ABwo9q1beJCcgbj39q6YanmYjQZaWayIWlVti9cdD7exqpqtkyh/LyiOAMbq6+w3RWrwoxWN23uoAwx9/wDOKqXtohIGAQa64rQ8iU2mcB5WOoK5HJJ4NMMQmRo1G18cbjXR3Vh85RVO4nG31qkmmkwX91LJ5MVooLcZL5zhE9SSPyzVWYnURzUdjLLdLbqv71mEYHTJJwKPFegXeg3xtLiNgfXGM+mD09/XFdf4YEb+KvD9zcqqItyokD9G3DCn3AJ61o/tBXUU+p6UkU4coky+UP4QGAZ89MkjYPYNzWqgnG5yyrtVFFbHjcxVUbJVduSSTgDHWvNfEmrtql3tjytpGT5anv8A7R+tX/F2u/appLGzc/ZkYh2B++3t/s/15rma1p0lHVnLicRz+7EPfvXp/wCzL/yXLwx9bn/0lmry9q9Q/Zk/5Ll4Y+tz/wCks1bHCfe1FFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB4H+2hgfDDScnA/tmL/ANET18Z7k/vD86/UiigD8tty9mH50bl7sPzr9SaKAPzHsr9T+7mkXI6MTwfrWvaahHbzwzRXqR3ETCSOZZBuRh0P4V+kNFS43LjUcXdHy78OviTpN7pirrGr6baXkeEk824SNZP9pdx/Tt+Vd7B458I4G7xRoQI9dQi/+Kr2Wiuf6rFO9zveZTas0jySLxz4NIyfFOgrg/8AQQh/+Kqf/hO/BxKqvizQFU8HOow//FV6pRVqgl1MHjJs8tXxr4MCnPi3w6Qf4f7Sh/8Aiqgu/GPguSDbH4s8P+3/ABMYc/8AoVes0UfV4hHGTTueJTeL/CgUD/hKdBPbjUYf/iqrXPijwg0Z3eJ9CbHZdQiPP/fVe7UVm8HBnTHNasdkeCWPinwlvYN4n0ML2LahEP8A2aqd/wCI/CpuSw8SaE/uNRiP/s1fQ9FQ8DB9TWOdVoy5rHzd/wAJL4ZyceI9EC/9f8XP/j1MbxF4bRi48TaLtPUC/iP/ALNX0pRUPLoPqa/2/W/lR8z3PiPwxIOfEWj5HTF9H/8AFVTl8S+HQoX/AISDSce15Gf619SUU1l0F1GuIKv8qPlhfEXhwyBm1/SsDp/pkf8AjV638WeHUYbdf0jB4Ob2L/4qvpmirjgorqZTzupPeKPn+Lxn4XQD/io9FJ/6/ouP/Hqjm8beGe3iDR254/06L/4qvoSitlh0upyTx8pfZPKfDviv4dS6LGbrX/DaXDgiUTajCHB6Hq2a8/8AiJ4q8KXGsSJp+taLNaQxRxqY7yMhgB93r8wxwT3ya+lqK09mrWOWFZxlzHxvf+MLGa7a4bWdPaRiGGJ0wMHKgDPAHQAdBXDfEHx1LfT7LW/8+eRdss6sG2ockKp+pJJHT8TX6A0UlTSNKmJlNbWPy33KOjDH1pd6f3h+dfqPRWhzH5cb1/vD869P/ZjYH46eGMEHm5/9JZq++KKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Colonoscopic views of histologically confirmed ileocecal tuberculosis with ulcerations (A) and destroyed ileocecal valve (B and C).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harshad Devarbhavi, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_23_1398=[""].join("\n");
var outline_f1_23_1398=null;
var title_f1_23_1399="Subacute thyroiditis";
var content_f1_23_1399=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Subacute thyroiditis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/23/1399/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/23/1399/contributors\">",
"     Kenneth D Burman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/23/1399/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/23/1399/contributors\">",
"     Douglas S Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/23/1399/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/23/1399/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/23/1399/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is some controversy concerning the nomenclature used to categorize the different forms of subacute thyroiditis. However, most thyroidologists use the term subacute thyroiditis to apply specifically to subacute granulomatous thyroiditis. Other names for this disorder are subacute nonsuppurative thyroiditis, giant cell thyroiditis, painful thyroiditis, and de Quervain's thyroiditis. It is an uncommon cause of hyperthyroidism and affects women more often than men (3 to 5:1) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1399/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Subacute thyroiditis (subacute granulomatous thyroiditis) is characterized by neck pain or discomfort, a tender diffuse goiter, and a predictable course of thyroid function evolution. Hyperthyroidism is typically the presentation followed by euthyroidism, hypothyroidism, and ultimately restoration of normal thyroid function (",
"    <a class=\"graphic graphic_figure graphicRef75131 \" href=\"UTD.htm?28/16/28942\">",
"     figure 1",
"    </a>",
"    ). The diagnosis and management of subacute thyroiditis will be provided here. Other types of thyroiditis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/51/43830?source=see_link\">",
"     \"Overview of thyroiditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The best available incidence data for subacute thyroiditis comes from the Rochester Epidemiology Project in Olmsted county, Minnesota [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1399/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Between 1970 and 1997, 94 patients with subacute thyroiditis were identified. They report an incidence of 12.1 cases per",
"    <span class=\"nowrap\">",
"     100,000/year",
"    </span>",
"    with a higher incidence in females than in males (19.1 and 4.1 per",
"    <span class=\"nowrap\">",
"     100,000/year,",
"    </span>",
"    respectively). It is most common in young adulthood (24 per",
"    <span class=\"nowrap\">",
"     100,000/year)",
"    </span>",
"    and middle age (35 per",
"    <span class=\"nowrap\">",
"     100,000/year),",
"    </span>",
"    and decreases with increasing age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subacute thyroiditis is presumed to be caused by a viral infection or a postviral inflammatory process. The majority of patients have a history of an upper respiratory infection prior to the onset of thyroiditis (typically two to eight weeks beforehand). The disease was thought to have a seasonal incidence (higher in summer) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1399/abstract/4\">",
"     4",
"    </a>",
"    ], and clusters of cases have been reported in association with Coxsackievirus, mumps, measles, adenovirus, and other viral infections [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1399/abstract/1\">",
"     1",
"    </a>",
"    ]. However, in other series, there was a relatively comparable distribution of presentation throughout the year [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1399/abstract/2,5\">",
"     2,5",
"    </a>",
"    ]. Serial studies of viral antibody titers have implicated many of the same viruses, but the changes could equally be attributed to nonspecific anamnestic responses [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1399/abstract/6\">",
"     6",
"    </a>",
"    ]. Viral inclusion bodies are not seen in thyroid tissue.",
"   </p>",
"   <p>",
"    Thyroid autoimmunity does not appear to play a primary role in the disorder, but it is strongly associated with HLA-B35 in many ethnic groups [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1399/abstract/7\">",
"     7",
"    </a>",
"    ]. A unifying hypothesis might be that the disorder results from a common subclinical viral infection that provides an antigen, either of viral origin or resulting from virus-induced host tissue damage, that uniquely binds to HLA-B35 molecules on macrophages. The resulting antigen-HLA-B35 complex activates cytotoxic T lymphocytes that then damage thyroid follicular cells, because the cells have partial structural similarity with the infection-related antigen. Unlike autoimmune thyroid disease, however, the immune reaction is not self-perpetuating, so the process is limited.",
"   </p>",
"   <p>",
"    Whatever factors initiate subacute thyroiditis, the resulting thyroid inflammation damages thyroid follicles and activates proteolysis of the thyroglobulin stored within the follicles. The result is unregulated release of large amounts of thyroxine (T4) and triiodothyronine (T3) into the circulation resulting in clinical and biochemical hyperthyroidism. This state lasts only until the stores of thyroglobulin are exhausted because new hormone synthesis ceases, not only because of damage to the thyroid follicular cells but also because of inhibition of thyrotropin (TSH) secretion by the increased serum T4 and T3 concentrations.",
"   </p>",
"   <p>",
"    As the inflammation subsides, the thyroid follicles regenerate and thyroid hormone synthesis and secretion resume (",
"    <a class=\"graphic graphic_figure graphicRef75131 \" href=\"UTD.htm?28/16/28942\">",
"     figure 1",
"    </a>",
"    ). There is usually a period of rapid evolution through euthyroidism and then into hypothyroidism. The hypothyroidism lasts until the thyroid gland can generate sufficient thyroid hormone synthesis and secretion so that the patient regains normal homeostasis. Each phase typically lasts two to eight weeks with the possible exception of the initial transition through euthyroidism, which may be shorter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The thyroid is usually moderately enlarged in subacute thyroiditis. Large-needle thyroid biopsies reveal widespread infiltration with neutrophils, lymphocytes, histiocytes and giant cells, disruption and collapse of thyroid follicles, and necrosis of thyroid follicular cells. Later there may be some fibrosis, but eventually the gland becomes normal. Fine needle aspiration biopsies reveal the same inflammatory cells, plus clusters of follicular cells and masses of colloid.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H990861\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;In an analysis of 94 patients with subacute thyroiditis, pain was the presenting symptom in 96 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1399/abstract/2\">",
"     2",
"    </a>",
"    ]. The onset may be sudden or gradual and may be preceded by an upper respiratory infection. The pain may be limited to the region of the thyroid or radiate to the upper neck, jaw, throat, upper chest, or ears. Pain can be exacerbated by coughing or turning the head. As a result, some patients first consult an otolaryngologist. Fever, fatigue, malaise, anorexia, and myalgia are common [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1399/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The thyroid gland is typically slightly or moderately diffusely or asymmetrically enlarged, and nearly always tender. In some cases, the pain is so severe that the patient cannot tolerate palpation of the neck. Both thyroid lobes are involved from the beginning in most patients, but the pain, tenderness, and enlargement can be unilateral or start on one side and later spread to the other side days or even weeks (so called &ldquo;creeping thyroiditis&rdquo;) later [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1399/abstract/1\">",
"     1",
"    </a>",
"    ]. Approximately one-half of patients have symptoms and signs of hyperthyroidism, but the neck pain and tenderness usually dominate the illness, and the diagnosis should not routinely be made in their absence. Temperature elevations also can occur [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1399/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The thyroid inflammation and hyperthyroidism are transient, usually subsiding in two to eight weeks, even if the patient is not treated. It may be followed by a period of transient, usually asymptomatic hypothyroidism lasting from two to eight weeks or longer, but recovery is nearly always complete. In a follow-up study of 160 patients with subacute thyroiditis seen at the Mayo Clinic, 15 percent of patients eventually developed permanent hypothyroidism requiring",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/43/41656?source=see_link\">",
"     levothyroxine",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1399/abstract/2\">",
"     2",
"    </a>",
"    ]. Only 4 percent of the patients had a recurrence (6 to 21 years after the initial episode). In another study, recurrence occurred in 1.6 percent of patients after 13.6",
"    <span class=\"nowrap\">",
"     +/-",
"    </span>",
"    5.6 years [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1399/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the hyperthyroidism is usually mild and transient, it may rarely be associated with serious side effects such as ventricular tachycardia and thyroid storm [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1399/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to thyroid tenderness, nearly all patients have biochemical evidence of hyperthyroidism (high serum free T4 and T3 and low serum TSH concentrations) during the early stages of the illness, even though many have no symptoms of thyroid excess. The serum free T4 and T3 concentrations are usually only mildly elevated, and serum T3 is not typically disproportionately increased, as it is in some patients with Graves' hyperthyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1399/abstract/11\">",
"     11",
"    </a>",
"    ]. Hyperthyroidism is transient, lasting from two to eight weeks, and may be followed by a period of transient, usually asymptomatic, overt or subclinical hypothyroidism (high TSH and low or low-normal normal serum free T4 and T3).",
"   </p>",
"   <p>",
"    The erythrocyte sedimentation rate is usually greater than 50",
"    <span class=\"nowrap\">",
"     mm/hour",
"    </span>",
"    and may exceed 100",
"    <span class=\"nowrap\">",
"     mm/hour.",
"    </span>",
"    C-reactive protein may also be elevated [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1399/abstract/12\">",
"     12",
"    </a>",
"    ]. Other characteristic laboratory findings (although not routinely needed to confirm diagnosis) include high serum thyroglobulin concentrations due to release from the thyroid gland, mild anemia, and leukocytosis. Liver function tests are also frequently abnormal during the initial hyperthyroid phase and then typically return to normal over the next one to two months as the disease improves [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1399/abstract/13\">",
"     13",
"    </a>",
"    ]. Serum antithyroid peroxidase or antithyroglobulin antibodies are usually undetectable or present at low titer. Some patients have increases in serum antithyroid antibody concentrations during the period of transient subclinical or overt hypothyroidism, probably caused by the response to release of thyroid antigens during the preceding period of inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1399/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2861225\">",
"    <span class=\"h2\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with subacute thyroiditis and hyperthyroidism, a radioiodine or technetium imaging study will show low uptake (usually less than 1 to 3 percent) or a faint heterogeneous pattern of radionuclide uptake during the hyperthyroid phase (in the absence of previous recent exposure to high iodine-containing radiocontrast agents). On ultrasonography the thyroid appears to be normal or enlarged but is diffusely or focally hypoechogenic regardless of its size [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1399/abstract/11,14\">",
"     11,14",
"    </a>",
"    ]. Color Doppler sonography shows low flow during the hyperthyroid phase, whereas Graves&rsquo; hyperthyroidism usually shows enhanced flow [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1399/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. After recovery, thyroid ultrasonography appearance normalizes [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1399/abstract/15,17,18\">",
"     15,17,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H990834\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subacute thyroiditis is fundamentally a clinical diagnosis. In most patients, clinical manifestations (the presence of neck pain, often radiating upward to the jaw, marked thyroid tenderness, and a diffuse goiter) are sufficient to establish the diagnosis. Symptoms and signs of hyperthyroidism may or may not be present, but the serum TSH is usually suppressed (typically &lt;0.1",
"    <span class=\"nowrap\">",
"     mU/L)",
"    </span>",
"    and free T4 and T3 concentrations elevated. Thus, serum TSH, free T4, and T3 should be measured in all patients in whom there is a clinical suspicion of subacute thyroiditis. We also typically measure an erythrocyte sedimentation rate or C-reactive protein level and obtain a radioiodine or technetium imaging study. A high erythrocyte sedimentation rate",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    C-reactive protein measurement and a low radioiodine uptake (usually less than 1 to 3 percent) during the hyperthyroid phase help confirm the diagnosis.",
"   </p>",
"   <p>",
"    In patients with thyroid pain and mild hyperthyroidism, radioiodine or technetium imaging may be deferred and thyroid function monitored. If thyroid function normalizes and pain resolves within several weeks, the diagnosis of subacute thyroiditis is confirmed. For patients in whom the clinical presentation is less obvious (eg, thyroid tenderness less prominent), thyroid ultrasonography may be useful to assess for cystic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    solid masses. In addition, Doppler sonography may be used to distinguish subacute thyroiditis (decreased flow during hyperthyroid phase) from Graves&rsquo; disease (enhanced flow). Rarely, fine needle aspiration biopsy, typically under ultrasound guidance, is necessary to distinguish infection, hemorrhage, thyroid cancer, or lymphoma from subacute thyroiditis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of thyroid pain and goiter includes acute infectious (also called &ldquo;suppurative&rdquo;) thyroiditis and hemorrhage into a thyroid nodule. Both infection and hemorrhage can cause severe thyroid pain and tenderness, but the thyroid abnormalities are predominantly unilateral. It is most important to differentiate acute infectious thyroiditis from subacute thyroiditis. The diagnosis of infection should be suspected if the patient has a leukocytosis, and confirmed by ultrasonography and fine needle aspiration biopsy. Patients with acute infectious thyroiditis usually have a cystic or mixed",
"    <span class=\"nowrap\">",
"     cystic/solid",
"    </span>",
"    mass on ultrasound that may represent an abscess. A fine needle aspiration would show neutrophils and should be analyzed with stains and cultures for bacteria, fungi, and parasites, as appropriate. Although thyroid function is usually normal, on rare occasions patients with infectious thyroiditis may present with hyperthyroidism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/51/43830?source=see_link&amp;anchor=H5#H5\">",
"     \"Overview of thyroiditis\", section on 'Infectious thyroiditis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When a low radioiodine uptake is noted, but the more classic clinical (or laboratory) manifestations of subacute thyroiditis such as neck discomfort and elevated sedimentation rate are lacking, the diagnosis of subacute thyroiditis may be more difficult. In this setting, a random urine iodine measurement may be helpful to distinguish subacute thyroiditis from other causes of a low radioiodine uptake (",
"    <a class=\"graphic graphic_table graphicRef76972 \" href=\"UTD.htm?31/45/32476\">",
"     table 1",
"    </a>",
"    ). Urine iodine values are below approximately 500",
"    <span class=\"nowrap\">",
"     mcg/L",
"    </span>",
"    in patients with subacute thyroiditis. In contrast, in patients with low radioiodine uptake due to exposure to excess exogenous iodine (eg, radiocontrast materials), random urine iodine measurements are usually markedly elevated (&gt;1000",
"    <span class=\"nowrap\">",
"     mcg/L)",
"    </span>",
"    for several weeks following the exposure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/0/4103?source=see_link\">",
"     \"Disorders that cause hyperthyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Occasional patients with either chronic autoimmune thyroiditis (Hashimoto's thyroiditis) or Graves' hyperthyroidism have neck pain and tenderness. However, the pain in both conditions is much less severe than in subacute thyroiditis, while thyroid dysfunction should be much more severe. In Graves&rsquo; hyperthyroidism, radioactive iodine uptake is high, not low. Painless (silent) and postpartum thyroiditis may cause similar changes in thyroid function and are associated with low radioiodine uptake, but thyroid gland or neck tenderness is not present [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1399/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/7/24694?source=see_link\">",
"     \"Painless thyroiditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/15/248?source=see_link\">",
"     \"Postpartum thyroiditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One study suggests that there is an unusual entity of painful Hashimoto's thyroiditis characterized by chronic neck discomfort or pain [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1399/abstract/20\">",
"     20",
"    </a>",
"    ]. Patients who have elevated thyroid antibodies and fine needle aspiration and surgical pathology show Hashimoto's thyroiditis. This variant, painful Hashimoto's thyroiditis, does not respond well to corticosteroid therapy, in contrast to subacute thyroiditis.",
"   </p>",
"   <p>",
"    Rarely, even patients with thyroid nodules harboring thyroid cancer or patients with primary thyroid lymphoma may demonstrate thyroid gland discomfort or pain (so called &ldquo;malignant pseudothyroiditis&rdquo;) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1399/abstract/21\">",
"     21",
"    </a>",
"    ]. Although not every patient suspected of having subacute thyroiditis requires a thyroid ultrasound, this test can be extremely helpful in ensuring that the patient does not have one of these conditions that can mimic many of the clinical findings of subacute thyroiditis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/8/35974?source=see_link\">",
"     \"Thyroid lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Subacute thyroiditis is an uncommon cause of fever of unknown origin, and because it may cause pain in the upper neck and jaw area, it has rarely been mistaken for temporal arteritis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1399/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no trials assessing optimal treatment of subacute thyroiditis. Treatment recommendations are based upon observational data and clinical experience. Treatment of patients with subacute thyroiditis should be directed at providing relief for thyroid pain and tenderness and ameliorating symptoms of hyperthyroidism, if present. Some patients need no treatment, because their symptoms are mild or are subsiding by the time they seek medical attention and the diagnosis is established. Thyroid function tests should be monitored every two to eight weeks to confirm resolution of hyperthyroidism, detection of hypothyroidism, and subsequent normalization of thyroid function.",
"   </p>",
"   <p>",
"    In the majority of patients, however, antiinflammatory therapy with either a nonsteroidal antiinflammatory drug or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    is indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1399/abstract/23\">",
"     23",
"    </a>",
"    ]. A reasonable approach is to start with acetylsalicylic acid (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , 2600 mg daily) or a nonsteroidal antiinflammatory drug (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    1200 to 3200 mg daily) in divided doses. If there is no improvement in two or three days, the nonsteroidal antiinflammatory drug should be discontinued and prednisone (40 mg daily) initiated. Prednisone therapy should result in pain relief in one to two days; if not, the diagnosis should be questioned. In patients with severe pain, prednisone is a reasonable first-line therapy.",
"   </p>",
"   <p>",
"    Once the pain is relieved by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , an attempt should be made to find the lowest possible dose that provides adequate pain relief by reducing the dose by 5 to 10 mg every five to seven days. Should pain reoccur, increase to the prior dose and maintain that dose for approximately two weeks, then attempt to taper again. Typically a two to eight week course of prednisone is required, and occasionally the course may be even more prolonged.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     Ibuprofen",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    can cause a variety of systemic symptoms and the prescribing health care provider and patient should be familiar with its relative contraindications, medication interactions, and adverse effects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/36/5703?source=see_link\">",
"     \"NSAIDs: Therapeutic use and variability of response in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although symptomatic relief is achieved with corticosteroid therapy, it does not prevent early and late-onset thyroid dysfunction. As an example, in one retrospective community study, during long-term monitoring, patients who had received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    had a greater likelihood of developing transient hypothyroidism (25 percent) as compared with those who did not receive prednisone (10 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1399/abstract/2\">",
"     2",
"    </a>",
"    ]. Corticosteroid therapy may be associated with shorter overall disease duration [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1399/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Therapy for hyperthyroidism is not often needed because symptoms, if present, are mild and short-lived. Those few patients who have bothersome symptoms of hyperthyroidism, such as palpitations, anxiety, or tremor, may benefit from treatment with a beta blocker such as 40 to 120 mg",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    , propranolol LA 80 mg daily, or 25 to 50 mg",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    daily for a few weeks while they are thyrotoxic.",
"   </p>",
"   <p>",
"    Thionamides should not be used because hyperthyroidism is not caused by excess thyroid hormone synthesis. Radioactive iodine is neither effective nor indicated because the uptake of radioiodine is very low.",
"   </p>",
"   <p>",
"    Therapy for hypothyroidism is not often needed because symptoms, if present, are usually mild and short-lived. However, if the hypothyroidism is more pronounced (TSH &gt;10",
"    <span class=\"nowrap\">",
"     mU/L)",
"    </span>",
"    or associated with more than mild symptoms, the patient should be treated with 50 or 100 mcg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/43/41656?source=see_link\">",
"     levothyroxine",
"    </a>",
"    (T4) for six to eight weeks (with a goal TSH in the normal range). The T4 should then be discontinued, and the patient reevaluated in four to six weeks to be sure that the hypothyroidism is not permanent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?13/42/13986?source=see_link\">",
"       \"Patient information: Thyroiditis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18315772\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Subacute thyroiditis (subacute granulomatous thyroiditis) is characterized by neck pain, a tender diffuse goiter, and a predictable course of thyroid function evolution. Hyperthyroidism is typically the presentation followed by euthyroidism, hypothyroidism, and ultimately restoration of normal thyroid function (",
"      <a class=\"graphic graphic_figure graphicRef75131 \" href=\"UTD.htm?28/16/28942\">",
"       figure 1",
"      </a>",
"      ). It is presumed to be caused by a viral infection or a postviral inflammatory process. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of subacute thyroiditis is based primarily upon clinical manifestations (the presence of neck pain, often radiating upward to the jaw, marked thyroid tenderness, and a diffuse goiter). In patients with suspected subacute thyroiditis, thyroid function tests (TSH, free T4, T3) should be obtained. Although symptoms and signs of hyperthyroidism may or may not be present, the serum TSH is usually suppressed (typically &lt;0.1",
"      <span class=\"nowrap\">",
"       mU/L)",
"      </span>",
"      and free T4 and T3 concentrations elevated. Low radioiodine uptake during the hyperthyroid phase and a high erythrocyte sedimentation rate (ESR) confirm the diagnosis. (See",
"      <a class=\"local\" href=\"#H990834\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of patients with subacute thyroiditis should be directed at providing relief for thyroid pain and tenderness. Some patients need no treatment, because their symptoms are mild or are subsiding by the time they seek medical attention and the diagnosis is established. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Treatment'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      For pain relief, antiinflammatory therapy with either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (2600 mg daily) or a nonsteroidal antiinflammatory drug (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"       ibuprofen",
"      </a>",
"      1200 to 3200 mg daily in divided doses) is usually effective. If there is no improvement in pain in two or three days, the nonsteroidal antiinflammatory drug should be discontinued and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (40 mg daily) initiated. Prednisone can be used as initial therapy for patients with severe pain. Effective therapy should be continued until pain and tenderness have subsided and then gradually tapered.",
"     </li>",
"     <li>",
"      Thyroid function tests should be monitored every two to eight weeks to confirm resolution of hyperthyroidism, detection of hypothyroidism, and subsequent normalization of function. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Therapy for hyperthyroidism is not often needed because symptoms, if present, are mild and short-lived. Beta blockers may be useful to relieve bothersome palpitations or tremulousness in symptomatic hyperthyroid patients. There is no role for thionamides or radioactive iodine in the treatment of hyperthyroidism in subacute thyroiditis. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Therapy for hypothyroidism is often not needed because symptoms, if present, are mild and short-lived. However, patients with symptomatic hypothyroidism require treatment with thyroxine (T4), typically 50 or 100 mcg daily. For asymptomatic patients with a TSH level &ge;10",
"      <span class=\"nowrap\">",
"       mU/L,",
"      </span>",
"      we also suggest T4 replacement (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We continue T4 for six to eight weeks (with a goal TSH in the normal range). The T4 should then be discontinued, and the patient reevaluated in four to six weeks to be sure that the hypothyroidism is not permanent. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Lazarus JH. Silent thyroiditis and subacute thyroiditis. In: The Thyroid: A Fundamental and Clinical Text, 7th Ed, Braverman LE, Utiger RD (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 1996. p.577.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1399/abstract/2\">",
"      Fatourechi V, Aniszewski JP, Fatourechi GZ, et al. Clinical features and outcome of subacute thyroiditis in an incidence cohort: Olmsted County, Minnesota, study. J Clin Endocrinol Metab 2003; 88:2100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1399/abstract/3\">",
"      Golden SH, Robinson KA, Saldanha I, et al. Clinical review: Prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review. J Clin Endocrinol Metab 2009; 94:1853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1399/abstract/4\">",
"      Martino E, Buratti L, Bartalena L, et al. High prevalence of subacute thyroiditis during summer season in Italy. J Endocrinol Invest 1987; 10:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1399/abstract/5\">",
"      Benbassat CA, Olchovsky D, Tsvetov G, Shimon I. Subacute thyroiditis: clinical characteristics and treatment outcome in fifty-six consecutive patients diagnosed between 1999 and 2005. J Endocrinol Invest 2007; 30:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1399/abstract/6\">",
"      Volp&eacute; R, Row VV, Ezrin C. Circulating viral and thyroid antibodies in subacute thyroiditis. J Clin Endocrinol Metab 1967; 27:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1399/abstract/7\">",
"      Ohsako N, Tamai H, Sudo T, et al. Clinical characteristics of subacute thyroiditis classified according to human leukocyte antigen typing. J Clin Endocrinol Metab 1995; 80:3653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1399/abstract/8\">",
"      Nishihara E, Ohye H, Amino N, et al. Clinical characteristics of 852 patients with subacute thyroiditis before treatment. Intern Med 2008; 47:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1399/abstract/9\">",
"      Sherman SI, Ladenson PW. Subacute thyroiditis causing thyroid storm. Thyroid 2007; 17:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1399/abstract/10\">",
"      Alper AT, Hasdemir H, Akyol A, Cakmak N. Incessant ventricular tachycardia due to subacute thyroiditis. Int J Cardiol 2007; 116:e22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1399/abstract/11\">",
"      Weihl AC, Daniels GH, Ridgway EC, Maloof F. Thyroid function tests during the early phase of subacute thyroiditis. J Clin Endocrinol Metab 1977; 44:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1399/abstract/12\">",
"      Pearce EN, Bogazzi F, Martino E, et al. The prevalence of elevated serum C-reactive protein levels in inflammatory and noninflammatory thyroid disease. Thyroid 2003; 13:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1399/abstract/13\">",
"      Matsumoto Y, Amino N, Kubota S, et al. Serial changes in liver function tests in patients with subacute thyroiditis. Thyroid 2008; 18:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1399/abstract/14\">",
"      Park SY, Kim EK, Kim MJ, et al. Ultrasonographic characteristics of subacute granulomatous thyroiditis. Korean J Radiol 2006; 7:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1399/abstract/15\">",
"      Hiromatsu Y, Ishibashi M, Miyake I, et al. Color Doppler ultrasonography in patients with subacute thyroiditis. Thyroid 1999; 9:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1399/abstract/16\">",
"      Ruchala M, Szczepanek E, Sowinski J. Sonoelastography in de Quervain thyroiditis. J Clin Endocrinol Metab 2011; 96:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1399/abstract/17\">",
"      Nikolai TF, Coombs GJ, McKenzie AK. Lymphocytic thyroiditis with spontaneously resolving hyperthyroidism and subacute thyroiditis. Long-term follow-up. Arch Intern Med 1981; 141:1455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1399/abstract/18\">",
"      Brander A. Ultrasound appearances in de Quervain's subacute thyroiditis with long-term follow-up. J Intern Med 1992; 232:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1399/abstract/19\">",
"      Om&uuml;r O, Dagl&yacute;&ouml;z G, Akarca U, Ozcan Z. Subacute thyroiditis during interferon therapy for chronic hepatitis B infection. Clin Nucl Med 2003; 28:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1399/abstract/20\">",
"      Kon YC, DeGroot LJ. Painful Hashimoto's thyroiditis as an indication for thyroidectomy: clinical characteristics and outcome in seven patients. J Clin Endocrinol Metab 2003; 88:2667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1399/abstract/21\">",
"      Yang YS, Wu MZ, Cheng AL, Chang TC. Primary thyroid lymphoma mimicking subacute thyroiditis. Acta Cytol 2006; 50:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1399/abstract/22\">",
"      Cunha BA, Chak A, Strollo S. Fever of unknown origin (FUO): de Quervain's subacute thyroiditis with highly elevated ferritin levels mimicking temporal arteritis (TA). Heart Lung 2010; 39:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1399/abstract/23\">",
"      Yamamoto M, Saito S, Sakurada T, et al. Effect of prednisolone and salicylate on serum thyroglobulin level in patients with subacute thyroiditis. Clin Endocrinol (Oxf) 1987; 27:339.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7832 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.65.66-BC5B390E05-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_23_1399=[""].join("\n");
var outline_f1_23_1399=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18315772\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H990861\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2861225\">",
"      Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H990834\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18315772\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7832\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7832|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/16/28942\" title=\"figure 1\">",
"      Course of thyroiditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7832|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/45/32476\" title=\"table 1\">",
"      Causes of hyperthyroidism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/0/4103?source=related_link\">",
"      Disorders that cause hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/36/5703?source=related_link\">",
"      NSAIDs: Therapeutic use and variability of response in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/51/43830?source=related_link\">",
"      Overview of thyroiditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/7/24694?source=related_link\">",
"      Painless thyroiditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?13/42/13986?source=related_link\">",
"      Patient information: Thyroiditis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/15/248?source=related_link\">",
"      Postpartum thyroiditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/8/35974?source=related_link\">",
"      Thyroid lymphoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_23_1400="General principles of definitive fracture management";
var content_f1_23_1400=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   General principles of definitive fracture management",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/23/1400/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/23/1400/contributors\">",
"     Anthony Beutler, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/23/1400/contributors\">",
"     Stephen Titus, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/23/1400/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/23/1400/contributors\">",
"     Patrice Eiff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/23/1400/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/23/1400/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/23/1400/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 31, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immobilization provides the basis for fracture healing. For many complex and unstable fractures, immobilization is achieved by means of internal fixation. However, many stable fractures at low risk of displacement can be immobilized effectively with casting, which can be performed by orthopedists or knowledgeable primary care clinicians.",
"   </p>",
"   <p>",
"    The basic principles and techniques of casting and the follow-up care needed for patients treated in this manner are reviewed here. The assessment and initial management of acute fractures is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/58/43941?source=see_link\">",
"     \"General principles of fracture management: Bone healing and fracture description\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/58/17318?source=see_link\">",
"     \"General principles of acute fracture management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CASTING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Casting is standard treatment for many closed, nondisplaced, or reduced fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1400/abstract/1\">",
"     1",
"    </a>",
"    ]. Casts provide a stable, protected environment in which the external, periosteal callus can form and normal bone healing can proceed [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1400/abstract/2\">",
"     2",
"    </a>",
"    ]. The optimal time to place a cast is after post-traumatic swelling has resolved. This usually takes five to seven days following an injury, but varies depending upon the location and type of fracture. Most often a splint is used in the interim. Successful casting requires three things: proper materials, proper positioning, and selection and application of the appropriate type of cast.",
"   </p>",
"   <p>",
"    Fractures likely to require casting acutely include those with the following characteristics [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1400/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Reduction was required",
"     </li>",
"     <li>",
"      Two adjacent bone are involved (eg, fracture of radius and ulna)",
"     </li>",
"     <li>",
"      Segmental fractures",
"     </li>",
"     <li>",
"      Spiral fractures",
"     </li>",
"     <li>",
"      Fracture dislocations",
"     </li>",
"     <li>",
"      Fractures where muscles exert strong forces that may cause displacement",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some fractures, such as those of the proximal humerus, are not amenable to casting, while others that should be casted, such as certain ankle fractures in children, are often not [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1400/abstract/1\">",
"     1",
"    </a>",
"    ]. Nevertheless, casting remains the treatment of choice for most nonoperative fractures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Materials",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fiberglass and plaster of Paris are the two most common types of fracture \"tape\" used for casting; each has relative advantages and disadvantages. Fiberglass is lighter, stronger, more breathable, and sets more quickly than plaster (",
"    <a class=\"graphic graphic_picture graphicRef59546 \" href=\"UTD.htm?2/0/2053\">",
"     picture 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1400/abstract/3\">",
"     3",
"    </a>",
"    ]. According to a laboratory study using a prosthesis model of limb swelling, fiberglass applied with a stretch-relax technique accommodates swelling better and causes less skin surface pressure than plaster [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1400/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Application of cast'",
"    </a>",
"    below.) Fiberglass is a skin irritant, and clinicians should wear gloves when applying a fiberglass cast.",
"   </p>",
"   <p>",
"    Plaster molds more uniformly than fiberglass, which is an advantage in maintaining fracture reduction. Plaster also sets more slowly, making it easier for less experienced clinicians to apply it correctly. However, plaster tape is messier, heavier, and breaks down more easily than fiberglass tape, and it can produce a significant exothermic reaction while it sets. For these reasons, many clinicians prefer fiberglass for most casting applications.",
"   </p>",
"   <p>",
"    Protection of the skin from the overlying fiberglass or plaster is essential to prevent breakdown and related complications. Skin protection begins with the application of a stockinette, the first layer of any cast, followed by adequate but not excessive amounts of padding (",
"    <a class=\"graphic graphic_picture graphicRef66332 \" href=\"UTD.htm?42/47/43765\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef78338 \" href=\"UTD.htm?19/60/20420\">",
"     picture 3",
"    </a>",
"    ). Both stockinette and cast padding have traditionally been made of cotton, but synthetic materials are becoming available. Several forms of synthetic stockinette and padding materials are designed to allow for the cast to become wet.",
"   </p>",
"   <p>",
"    It is important to use the appropriate amount of padding, especially over bony prominences, which are susceptible to pressure and skin breakdown from the cast. Extra padding is often needed in such areas (eg, lateral epicondyle, ulnar styloid, medial and lateral malleoli). However, care must be taken to avoid excess padding, especially around the fracture site, as this can lead to a loose cast that provides inadequate immobilization [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1400/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Type of cast",
"    </span>",
"    &nbsp;&mdash;&nbsp;When selecting the appropriate cast, the clinician must determine which joints to include and how far the cast should extend. Maximal immobilization is achieved with casts that include the joints proximal and distal to the fracture site. This is important in treating any unstable fracture, such as a reduced distal radius fracture. Whenever possible, the entire length of the fractured bone should be included in the cast [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1400/abstract/1\">",
"     1",
"    </a>",
"    ]. The accompanying table describes several common casts and the fractures for which they are best suited (",
"    <a class=\"graphic graphic_table graphicRef69141 \" href=\"UTD.htm?3/1/3101\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Application of cast",
"    </span>",
"    &nbsp;&mdash;&nbsp;The key steps in the application of a fiberglass cast are outlined below. For illustrative purposes, a short arm cast with a thumb spica is described, but the basic steps apply to all fiberglass casts.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Select the appropriate padding and width for casting (fiberglass or plaster) tape. Two-inch (5 cm) tape is generally good for the hand, three-inch (7.5 cm) for the forearm, and four-inch (10 cm) for the lower extremity and upper arm (",
"      <a class=\"graphic graphic_picture graphicRef78338 \" href=\"UTD.htm?19/60/20420\">",
"       picture 3",
"      </a>",
"      ). The stockinette width is also based on the size of the limb being casted (",
"      <a class=\"graphic graphic_picture graphicRef66332 \" href=\"UTD.htm?42/47/43765\">",
"       picture 2",
"      </a>",
"      ). Cutting the stockinette slightly longer than the cast allows for the edges to be rolled back prior to the application of the final layer of casting material, providing a smooth edge to the cast.",
"     </li>",
"     <li>",
"      First apply the stockinette (",
"      <a class=\"graphic graphic_picture graphicRef50511 \" href=\"UTD.htm?4/15/4339\">",
"       picture 4",
"      </a>",
"      ). Next, apply the padding (eg, Webril&reg;) by rolling it onto the extremity in a distal to proximal direction; each layer should overlap the preceding layer by approximately 50 percent (",
"      <a class=\"graphic graphic_picture graphicRef51305 \" href=\"UTD.htm?11/18/11556\">",
"       picture 5",
"      </a>",
"      ). Additional Webril or padding should be placed over bony prominences. In general, about two layers of padding are adequate for the upper extremity; three to four layers are used for the lower extremity.",
"     </li>",
"     <li>",
"      Once the padding is in place and the limb properly positioned, moisten the casting tape (",
"      <a class=\"graphic graphic_picture graphicRef59546 \" href=\"UTD.htm?2/0/2053\">",
"       picture 1",
"      </a>",
"      ). Cool water should be used for fiberglass tape. \"Tepid\" or room temperature water works well for plaster. Warmer water will shorten the set time, but may cause skin burns.",
"     </li>",
"     <li>",
"      Roll the casting tape over the extremity moving distal to proximal (",
"      <a class=\"graphic graphic_picture graphicRef81845 \" href=\"UTD.htm?3/1/3093\">",
"       picture 6",
"      </a>",
"      ). When applying fiberglass tape, stretch and then relax the tape during application to reduce the skin surface pressure [",
"      <a class=\"abstract\" href=\"UTD.htm?1/23/1400/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Special cuts can be used to help navigate smaller areas, such as around the thumb. This helps to prevent bulking of the cast and can improve comfort.",
"     </li>",
"     <li>",
"      After the first few layers of casting tape are applied, the cast should be molded if necessary (",
"      <a class=\"graphic graphic_picture graphicRef52657 \" href=\"UTD.htm?1/20/1349\">",
"       picture 7",
"      </a>",
"      ). The goal of molding is to maintain alignment of an unstable fracture. An oval or elliptical shaped cast is better suited for maintaining fracture alignment than a perfectly cylindrical cast [",
"      <a class=\"abstract\" href=\"UTD.htm?1/23/1400/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Improper molding or any sharp indentations in the cast can cause severe complications, such as pressure sores and skin ulcers. Clinicians with little experience casting should limit molding to gently compressing the cast into an elliptical shape at the area of the fracture. The palms and heels of the hands should be used; avoid using fingers [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1400/abstract/2\">",
"     2",
"    </a>",
"    ]. This approach provides adequate molding while decreasing the risk for skin breakdown.",
"   </p>",
"   <p>",
"    Practitioners with experience casting may use a three-point molding technique. The first point of compression is directly over the apex of the fracture with the force directed opposite the direction in which the fracture is most likely to displace. The two remaining pressure points lie on the opposite side of the bone at either side of the apex. Force is maintained at these three sites until the cast has set. As described above, the palms and heels of the hand should be used to apply pressure and use of the fingers avoided.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fold the ends of the stockinette over the set casting tape and apply the final layer of tape (",
"      <a class=\"graphic graphic_picture graphicRef71485 \" href=\"UTD.htm?1/9/1170\">",
"       picture 8",
"      </a>",
"      ). In all, two layers of fiberglass tape are usually sufficient for short arm casts, three layers for long arm casts and non-weightbearing short leg casts, and four layers for weightbearing short leg casts (",
"      <a class=\"graphic graphic_picture graphicRef72212 \" href=\"UTD.htm?41/20/42304\">",
"       picture 9",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Inspect the cast to ensure that there are no rough or sharp edges protruding and that sensation and blood flow distal to the cast end are intact. Written instructions explaining proper cast care should be provided to the patient. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Information for patients'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An alternative technique for applying a fiberglass cast may be useful for less experienced clinicians [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1400/abstract/5\">",
"     5",
"    </a>",
"    ]. This approach differs in that the casting tape is not moistened before it is applied. Rather, the fiberglass tape is applied directly out of its packaging and a water based gel, such as KY Jelly&reg;, is spread evenly over each roll after it is applied. This technique allows for a longer set time and permits adjustments to be made to casting position after each roll is placed.",
"   </p>",
"   <p>",
"    The same steps described above are used when applying a short leg cast. A few special considerations for the short leg cast include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cut the stockinette on the dorsal side just over and parallel to the ankle (ie, tibiotalar) joint to prevent wrinkling, which can lead to skin irritation.",
"     </li>",
"     <li>",
"      Four inch padding is needed for lower extremity casts; apply extra padding over bony prominences (eg, malleoli, fibular head).",
"     </li>",
"     <li>",
"      Maintain the ankle in 90 degrees of dorsiflexion (ie, neutral position) to create a position of function (especially for weightbearing casts) and to prevent flexion contractures.",
"     </li>",
"     <li>",
"      Leave all five toes visible to allow for neurovascular assessment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Positioning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Casts should place the affected joints in their position of function whenever possible (",
"    <a class=\"graphic graphic_table graphicRef69141 \" href=\"UTD.htm?3/1/3101\">",
"     table 1",
"    </a>",
"    ). The wrist and hand are usually placed in a grasping position. The ankle and elbow are usually casted at 90 degrees. Sometimes these general rules are adjusted to obtain a better outcome. As an example, the wrist may be placed in a more neutral to slightly flexed position to help maintain reduction when treating a distal radius fracture.",
"   </p>",
"   <p>",
"    Changes in fracture position can occur during cast application despite an optimal reduction and excellent casting technique with proper molding. Therefore, we suggest obtaining x-rays immediately following cast application for any unstable fracture or any fracture that required reduction prior to casting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potential complications associated with fractures are reviewed separately. Complications associated with casting are discussed below. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/42/6823?source=see_link\">",
"     \"General principles of fracture management: Early and late complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While immobilization in a cast is important for maintaining reductions and provides the basis for fracture healing, it can lead to joint stiffness, muscle atrophy, and disuse syndromes, and increases the risk for thrombosis. Casts that are applied too tightly or that become too tight due to soft tissue swelling can cause vascular compromise. Skin breakdown, compression neuropathy, and acute compartment syndrome can also occur. Any patient in a cast who complains of pain, burning, tingling, or numbness should be evaluated immediately because of these potentially severe complications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/30/35305?source=see_link\">",
"     \"Approach to the diagnosis and therapy of lower extremity deep vein thrombosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/57/8090?source=see_link\">",
"     \"Acute compartment syndrome of the extremities\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42233?source=see_link\">",
"     \"Overview of lower extremity peripheral nerve syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/44/8906?source=see_link\">",
"     \"Overview of upper extremity peripheral nerve syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/3/13368?source=see_link\">",
"     \"Acute arterial occlusion of the lower extremities (acute limb ischemia)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/20/34120?source=see_link\">",
"     \"Pressure ulcers: Epidemiology, pathogenesis, clinical manifestations, and staging\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Depending upon the age and comorbidities of the patient, even routine casting may result in prolonged losses of motion and muscular strength that require treatment with physical or occupational therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1400/abstract/1\">",
"     1",
"    </a>",
"    ]. Other casting complications include skin burns, which are more likely if plaster is used with hot water [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1400/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     FOLLOW-UP VISITS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;After the initial cast is applied and fracture alignment is confirmed, the next essential step is to ensure adequate and timely follow-up. The interval between visits depends on the nature of the fracture, the type of cast, and any concerns there may be about patient compliance.",
"   </p>",
"   <p>",
"    Even in the rare instance where no follow-up is required (eg, healthy adult with a minor fibular avulsion fracture treated in a pneumatic splint), the clinician should provide clear instructions about whom to call for signs of skin breakdown, infection, neurovascular compromise, or for worsening or persistent pain. Unstable fractures or post-reduction fractures require more frequent reassessment, sometimes as often as twice a week initially to ensure that correct fracture alignment is maintained [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1400/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As a general rule, lower extremity casting involves longer immobilization times to maximize stability and strength. Upper extremity casting generally involves shorter periods of immobilization in order to retain range of motion [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1400/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Follow-up visits for stable fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial follow-up after casting of a stable fracture is usually scheduled three to seven days later, with instructions to call or return earlier for pain, swelling, or other acute symptoms. Subsequent follow-up visits vary according to the patient and cast but are usually scheduled about every two to three weeks.",
"   </p>",
"   <p>",
"    At each follow-up visit, the cast should be carefully checked for signs of wear and proper fit. The cast should be replaced if it is too loose, too tight, or excessively worn. Most weightbearing plaster casts maintain their integrity for two to three weeks, while non-weightbearing plaster casts last about four weeks. Fiberglass casts typically remain intact for two weeks longer than their plaster counterparts. These time frames are approximations and depend on patient activity, weight, and age. The casts of children and active adults should be checked more frequently to ensure proper immobilization [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1400/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Follow-up visits are ideal venues for teaching appropriate rehabilitative exercises and ensuring compliance with activity restrictions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Follow-up visits for unstable fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unstable fractures are prone to loss of reduction or malalignment while being treated in a cast. The proper times to recheck alignment depend on the fracture type and the age of the patient.",
"   </p>",
"   <p>",
"    As an example, pediatric both-bone forearm fractures are among the most unstable fractures. Since children heal at a relatively rapid rate and only small amounts of angulation are acceptable in the forearm, midshaft fractures of both the radius and ulna require radiographic follow-up two times per week until healing has occurred.",
"   </p>",
"   <p>",
"    Conversely, angulated distal radius fractures in adults need only be reassessed once every 7 to 10 days post-injury. If excessive angulation is noted at that time, the bone can be re-manipulated because fracture fragments remain relatively mobile in adults.",
"   </p>",
"   <p>",
"    Radiographs to reassess fracture alignment in unstable fractures while they are healing should be obtained in the cast. Radiographs taken in traditional plaster or fiberglass generally provide sufficient clarity to judge the alignment of long bone fractures, although evidence of healing may be obscured. Several types of casting tape offer superior radiolucency (eg, 3M Scotchcast&trade;, M-PACT OCL Polylite&trade;), which may be helpful when evaluating unstable fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1400/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Orthopedic referral",
"    </span>",
"    &nbsp;&mdash;&nbsp;Between visits, patients can develop complications that warrant orthopedic evaluation. As an example, unacceptable changes in fracture angulation may appear on follow-up radiographs and orthopedic consultation should be obtained in such cases to determine the best treatment. Any new deficit in neurovascular function requires immediate evaluation by an orthopedic surgeon.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     FRACTURE HEALING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of casting is to provide a sufficient period of immobilization such that the fracture heals properly. However, prolonged immobilization increases the risk of complications. An accurate assessment of fracture healing is essential to striking a balance between these twin considerations. Unfortunately, determining when clinical union has occurred can be problematic. Understanding the basic biology of bone healing and then relying on a combination of clinical and radiographic factors offers the best estimation of when a fracture is adequately healed [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1400/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Complications'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Biology of fracture healing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The biology of bone healing is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/58/43941?source=see_link&amp;anchor=H2#H2\">",
"     \"General principles of fracture management: Bone healing and fracture description\", section on 'Biology of bone healing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Clinical assessment of fracture healing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proper assessment of clinical union is essential to optimize fracture healing and to prevent complications from excessive immobilization. Biomechanical studies of fracture stiffness show that clinical union typically occurs one to two weeks before evidence of radiographic union [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1400/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Additionally, radiologic parameters of fracture healing have poor interobserver correlation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1400/abstract/10\">",
"     10",
"    </a>",
"    ], and tend to underestimate healing progress when compared with clinical [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1400/abstract/9\">",
"     9",
"    </a>",
"    ], biomechanical [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1400/abstract/9-11\">",
"     9-11",
"    </a>",
"    ], and histologic [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1400/abstract/11\">",
"     11",
"    </a>",
"    ] measures.",
"   </p>",
"   <p>",
"    Given the limitations of radiographic parameters, typical clinical practice is to schedule a follow-up visit around the time of expected healing, usually around four to six weeks post-injury. The cast is removed and clinical features of healing are assessed. These can include the ability to bear weight [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1400/abstract/12\">",
"     12",
"    </a>",
"    ], no tenderness to palpation at the fracture site [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1400/abstract/1\">",
"     1",
"    </a>",
"    ], and stability and absence of pain with manual stress testing [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1400/abstract/8\">",
"     8",
"    </a>",
"    ]. If the fracture demonstrates clinical healing and appropriate signs of healing are seen on radiographs, then the fracture is deemed healed and the patient begins rehabilitation. If the fracture does not demonstrate signs of clinical healing or appropriate healing is not seen on x-rays, a cast is reapplied. Alternatively, a functional splint or brace, which allows for some gentle range of motion exercises to be done out of the device, can be used. The fracture is then reassessed in two weeks.",
"   </p>",
"   <p>",
"    Fracture healing depends on multiple biologic and biomechanical factors and some patients may need to be recasted several times. If a fracture is not clinically healed four weeks after the expected time of healing, additional confirmation of bony healing should be sought through advanced imaging (MRI or CT scanning) and consultation with an orthopedic surgeon.",
"   </p>",
"   <p>",
"    As a general rule, lower extremity casting involves longer immobilization times to maximize stability and strength. Upper extremity casting generally involves shorter periods of immobilization in order to retain range of motion [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1400/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H64687106\">",
"    <span class=\"h1\">",
"     ADJUNCTIVE THERAPY FOR FRACTURE HEALING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H64687126\">",
"    <span class=\"h2\">",
"     Overview and basic measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of adjunctive therapies are used to aid fracture healing. While a detailed discussion is beyond the scope of this review, a brief description of some of the more commonly mentioned therapies is included here. Pain management for patients with fractures and the effects of specific drugs on fracture healing are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/58/17318?source=see_link&amp;anchor=H7#H7\">",
"     \"General principles of acute fracture management\", section on 'Pain management'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/42/6823?source=see_link&amp;anchor=H21949930#H21949930\">",
"     \"General principles of fracture management: Early and late complications\", section on 'Nonunion and malunion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For all patients with fractures, regardless of the site, it is important to ensure good nutrition, including adequate intake of vitamin D and calcium, to maximize fracture healing. Although evidence exists to support the role of vitamin D in fracture prevention, there is no high quality evidence to support the use of supplemental vitamin D for the treatment of acute fractures. However, prescribing supplemental vitamin D in this setting seems a reasonable practice given the prevalence of vitamin D deficiency in the general population and the low potential for side effects or toxicity. A daily dose of 1000 international units during fracture healing is reasonable. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36586?source=see_link&amp;anchor=H11#H11\">",
"     \"Vitamin supplementation in disease prevention\", section on 'Vitamin D'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/3/39990?source=see_link\">",
"     \"Overview of vitamin D\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cigarette smoking and excessive alcohol use impairs fracture healing. Patients should be encouraged to stop smoking and limit alcohol consumption. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/42/6823?source=see_link&amp;anchor=H21949930#H21949930\">",
"     \"General principles of fracture management: Early and late complications\", section on 'Nonunion and malunion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H64687240\">",
"    <span class=\"h2\">",
"     Pharmacologic adjuncts",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24490553\">",
"    <span class=\"h3\">",
"     Systemic therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;A wide range of pharmacologic treatments to accelerate fracture healing are being studied. Such treatments include growth hormone (GH), bone morphogenetic proteins (BMP), parathyroid hormone (PTH), platelet-derived growth factor, and bisphosphonates. Most studies are preliminary and the appropriate role for these therapies in the treatment of acute fractures remains speculative [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1400/abstract/13-16\">",
"     13-16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24490560\">",
"    <span class=\"h3\">",
"     Local therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Locally injected or applied treatments to improve fracture healing, such as platelet-rich therapies, are under investigation. However, studies are preliminary and the appropriate role for such therapies in the treatment of acute fractures remains speculative [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1400/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H64687190\">",
"    <span class=\"h2\">",
"     Prevention of complex regional pain syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complex Regional Pain Syndrome (CRPS), also known as Reflex Sympathetic Dystrophy, is a complex disorder of the extremities characterized by localized pain, swelling, limited range of motion, vasomotor instability, skin changes, and bone demineralization. Fractures, with or without a nerve injury, are a common inciting event. Measures to prevent this debilitating syndrome, including supplemental vitamin C, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/62/6122?source=see_link\">",
"     \"Prevention and management of complex regional pain syndrome in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/37/32344?source=see_link\">",
"     \"Etiology, clinical manifestations, and diagnosis of complex regional pain syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H64687354\">",
"    <span class=\"h2\">",
"     Nonpharmacologic adjuncts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several nonpharmacologic interventions have been used to aid fracture healing. Among these are electromagnetic stimulation (&ldquo;bone stimulators&rdquo;) and ultrasound. Electromagnetic stimulation is used most often to hasten healing after internal fixation or bone grafting has been performed for fractures that failed to heal with standard treatment (ie, nonunions) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1400/abstract/18\">",
"     18",
"    </a>",
"    ]. Although the United States Food and Drug Administration has approved low intensity pulsed ultrasound for the treatment of acute fractures and nonunions, debate continues about the quality of the evidence supporting this intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1400/abstract/19\">",
"     19",
"    </a>",
"    ]. A systematic review confirmed that the available studies are heterogeneous, but concluded that the evidence does not support routine use of ultrasound for fracture healing [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1400/abstract/20\">",
"     20",
"    </a>",
"    ]. Large controlled trials are needed to determine the value of these treatments.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?10/51/11058?source=see_link\">",
"       \"Patient information: Cast and splint care (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?25/21/25937?source=see_link\">",
"       \"Patient information: Cast and splint care (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Casts provide a stable, protected environment in which the external periosteal callus can form and normal bone healing can proceed. The optimal time to place a cast is after post-traumatic swelling has resolved, which usually takes five to seven days. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fiberglass and plaster of Paris are the two most common types of fracture \"tape\" used for casting. Fiberglass is lighter, stronger, more breathable, and sets more quickly than plaster. Plaster molds more uniformly and may be easier for less experienced clinicians to use. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Materials'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The steps involved in applying a cast are described in the text; common casts and their application are summarized in the accompanying table (",
"      <a class=\"graphic graphic_table graphicRef69141 \" href=\"UTD.htm?3/1/3101\">",
"       table 1",
"      </a>",
"      ). For proper cast application, it is important that the clinician do the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Protect the skin with a stockinette, the first layer of any cast, and adequate but not excessive amounts of padding.",
"     </li>",
"     <li>",
"      Use extra padding over bony prominences.",
"     </li>",
"     <li>",
"      Ensure maximal immobilization for unstable fractures by including the joints proximal and distal to the fracture site in the cast.",
"     </li>",
"     <li>",
"      Casts should place the affected joints in their position of function (ie, neutral position) whenever possible. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Application of cast'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Casting has a number of potential complications, including pressure sores, neurovascular compromise, acute compartment syndrome, and disuse atrophy. Therefore, any patient in a cast who complains of pain, burning, tingling, or numbness should be evaluated immediately. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The intervals between follow-up visits depend on the nature of the fracture, the type of cast, and any concerns there may be about patient compliance. Children with unstable fractures need to be reexamined frequently, in some cases as often as two times each week; responsible adults with stable minor fractures may require only one follow-up visit. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Follow-up visits'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A combination of clinical and radiographic factors offers the best estimation of fracture healing. Assessment of healing is usually performed around the time when union would normally be expected. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Clinical assessment of fracture healing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All patients with fractures require good nutrition, including adequate intake of vitamin D and calcium, to maximize fracture healing. A number of adjunctive therapies for fracture healing are available but few rigorous studies have been performed and the appropriate role of such treatments remains to be determined. (See",
"      <a class=\"local\" href=\"#H64687106\">",
"       'Adjunctive therapy for fracture healing'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Eiff MP, Hatch RL, Calmbach WL. General principles of fracture care. In: Fracture Management for Primary Care, 2nd, WB Saunders, Philadelphia 2003. p.4.",
"    </li>",
"    <li>",
"     Connolly JF, Mendes M, Browner BD. Principles of closed management of common fractures. In: Skeletal Trauma, Browner BD, Jupiter JB, Levine AM, et al.  (Eds), WB Saunders, Philadelphia 1992. p.215.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1400/abstract/3\">",
"      Mihalko WM, Beaudoin AJ, Krause WR. Mechanical properties and material characteristics of orthopaedic casting material. J Orthop Trauma 1989; 3:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1400/abstract/4\">",
"      Davids JR, Frick SL, Skewes E, Blackhurst DW. Skin surface pressure beneath an above-the-knee cast: plaster casts compared with fiberglass casts. J Bone Joint Surg Am 1997; 79:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1400/abstract/5\">",
"      Smith GD, Hart RG, Tsai TM. Fiberglass cast application. Am J Emerg Med 2005; 23:347.",
"     </a>",
"    </li>",
"    <li>",
"     Harkess JW, Ramsey WC. Principles of fractures and dislocations. In: Rockwood and Greens's Fractures in Adults, 4th, Rockwood CA, Green DP.  (Eds), Lippincott-Raven, Philadelphia 1996. p.48.",
"    </li>",
"    <li>",
"     Mazzola TJ. Splinting and Casting. In: Sports Medicine Resource Manual, 1st, Seidenberg P, Beutler AL.  (Eds), Saunders, Philadelphia 2007. p.152.",
"    </li>",
"    <li>",
"     McGowan HJ. General principles of fracture management. In: Sports Medicine Resource Manual, 1st, Seidenberg P, Beutler AL.  (Eds), Saunders, Philadelphia 2007. p.147.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1400/abstract/9\">",
"      Claes L, Grass R, Schmickal T, et al. Monitoring and healing analysis of 100 tibial shaft fractures. Langenbecks Arch Surg 2002; 387:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1400/abstract/10\">",
"      McClelland D, Thomas PB, Bancroft G, Moorcraft CI. Fracture healing assessment comparing stiffness measurements using radiographs. Clin Orthop Relat Res 2007; 457:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1400/abstract/11\">",
"      Blokhuis TJ, de Bruine JH, Bramer JA, et al. The reliability of plain radiography in experimental fracture healing. Skeletal Radiol 2001; 30:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1400/abstract/12\">",
"      Joslin CC, Eastaugh-Waring SJ, Hardy JR, Cunningham JL. Weight bearing after tibial fracture as a guide to healing. Clin Biomech (Bristol, Avon) 2008; 23:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1400/abstract/13\">",
"      Garrison KR, Shemilt I, Donell S, et al. Bone morphogenetic protein (BMP) for fracture healing in adults. Cochrane Database Syst Rev 2010; :CD006950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1400/abstract/14\">",
"      Ellegaard M, J&oslash;rgensen NR, Schwarz P. Parathyroid hormone and bone healing. Calcif Tissue Int 2010; 87:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1400/abstract/15\">",
"      Graham S, Leonidou A, Lester M, et al. Investigating the role of PDGF as a potential drug therapy in bone formation and fracture healing. Expert Opin Investig Drugs 2009; 18:1633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1400/abstract/16\">",
"      Tran GT, Pagkalos J, Tsiridis E, et al. Growth hormone: does it have a therapeutic role in fracture healing? Expert Opin Investig Drugs 2009; 18:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1400/abstract/17\">",
"      Griffin XL, Wallace D, Parsons N, Costa ML. Platelet rich therapies for long bone healing in adults. Cochrane Database Syst Rev 2012; 7:CD009496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1400/abstract/18\">",
"      Griffin XL, Costa ML, Parsons N, Smith N. Electromagnetic field stimulation for treating delayed union or non-union of long bone fractures in adults. Cochrane Database Syst Rev 2011; :CD008471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1400/abstract/19\">",
"      Busse JW, Kaur J, Mollon B, et al. Low intensity pulsed ultrasonography for fractures: systematic review of randomised controlled trials. BMJ 2009; 338:b351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1400/abstract/20\">",
"      Griffin XL, Smith N, Parsons N, Costa ML. Ultrasound and shockwave therapy for acute fractures in adults. Cochrane Database Syst Rev 2012; 2:CD008579.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 236 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-201.211.0.116-E346565194-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_23_1400=[""].join("\n");
var outline_f1_23_1400=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CASTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Materials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Type of cast",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Application of cast",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Positioning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      FOLLOW-UP VISITS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Follow-up visits for stable fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Follow-up visits for unstable fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Orthopedic referral",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      FRACTURE HEALING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Biology of fracture healing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Clinical assessment of fracture healing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H64687106\">",
"      ADJUNCTIVE THERAPY FOR FRACTURE HEALING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H64687126\">",
"      Overview and basic measures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H64687240\">",
"      Pharmacologic adjuncts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24490553\">",
"      - Systemic therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24490560\">",
"      - Local therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H64687190\">",
"      Prevention of complex regional pain syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H64687354\">",
"      Nonpharmacologic adjuncts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/236\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/236|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/0/2053\" title=\"picture 1\">",
"      Fiberglass fx tape",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/47/43765\" title=\"picture 2\">",
"      Stockinette types",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/60/20420\" title=\"picture 3\">",
"      Fracture padding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/15/4339\" title=\"picture 4\">",
"      Stockinette short arm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/18/11556\" title=\"picture 5\">",
"      Padding short arm cast",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/1/3093\" title=\"picture 6\">",
"      Casting tape short arm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/20/1349\" title=\"picture 7\">",
"      Molding short arm cast",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/9/1170\" title=\"picture 8\">",
"      Stockinette folded",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/20/42304\" title=\"picture 9\">",
"      Short arm cast 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/236|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/1/3101\" title=\"table 1\">",
"      Common casts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/3/13368?source=related_link\">",
"      Acute arterial occlusion of the lower extremities (acute limb ischemia)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/57/8090?source=related_link\">",
"      Acute compartment syndrome of the extremities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/30/35305?source=related_link\">",
"      Approach to the diagnosis and therapy of lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/37/32344?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of complex regional pain syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/58/17318?source=related_link\">",
"      General principles of acute fracture management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/58/43941?source=related_link\">",
"      General principles of fracture management: Bone healing and fracture description",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/42/6823?source=related_link\">",
"      General principles of fracture management: Early and late complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42233?source=related_link\">",
"      Overview of lower extremity peripheral nerve syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/44/8906?source=related_link\">",
"      Overview of upper extremity peripheral nerve syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/3/39990?source=related_link\">",
"      Overview of vitamin D",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/21/25937?source=related_link\">",
"      Patient information: Cast and splint care (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/51/11058?source=related_link\">",
"      Patient information: Cast and splint care (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/20/34120?source=related_link\">",
"      Pressure ulcers: Epidemiology, pathogenesis, clinical manifestations, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/62/6122?source=related_link\">",
"      Prevention and management of complex regional pain syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36586?source=related_link\">",
"      Vitamin supplementation in disease prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_23_1401="Left ventricular hypertrophy and arrhythmia";
var content_f1_23_1401=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Left ventricular hypertrophy and arrhythmia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/23/1401/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/23/1401/contributors\">",
"     Philip J Podrid, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/23/1401/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/23/1401/contributors\">",
"     George L Bakris, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/23/1401/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/23/1401/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/23/1401/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 14, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data, primarily from the Framingham Heart Study, have identified electrocardiographic left ventricular hypertrophy (LVH) as a blood pressure-independent risk for sudden cardiac death (SCD) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1401/abstract/1,2\">",
"     1,2",
"    </a>",
"    ], acute myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1401/abstract/3\">",
"     3",
"    </a>",
"    ], and other cardiovascular morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1401/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/34/17959?source=see_link\">",
"     \"Clinical implications and treatment of left ventricular hypertrophy in hypertension\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/13/3285?source=see_link\">",
"     \"Electrocardiographic diagnosis of left ventricular hypertrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These relationships can be illustrated by the following findings in patients with a definite electrocardiographic pattern of LVH:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A 59 percent overall mortality at 12 years [",
"      <a class=\"abstract\" href=\"UTD.htm?1/23/1401/abstract/2\">",
"       2",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      A threefold increase in the risk of developing overt coronary heart disease at 14 years, even after adjustments for concomitant hypertension are made [",
"      <a class=\"abstract\" href=\"UTD.htm?1/23/1401/abstract/3\">",
"       3",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      A sixfold increase in sudden cardiac death among men and a threefold increase in women [",
"      <a class=\"abstract\" href=\"UTD.htm?1/23/1401/abstract/3\">",
"       3",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      A 10-fold increase in congestive heart failure at 16 years [",
"      <a class=\"abstract\" href=\"UTD.htm?1/23/1401/abstract/4\">",
"       4",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Echocardiographic studies, which more reliably document the presence of LVH, have confirmed and expanded the above observations [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1401/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. For each 50",
"    <span class=\"nowrap\">",
"     g/m2",
"    </span>",
"    increase in left ventricular mass, the relative risk of death from cardiovascular disease is 1.73 in men and 2.12 in women. The echocardiogram has also established other important features of LVH, particularly an eccentric or concentric pattern [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1401/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review the evidence linking hypertension and LVH to ventricular arrhythmia and sudden cardiac death. The pathogenesis of LVH in hypertension is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/52/18247?source=see_link\">",
"     \"Definition and pathogenesis of left ventricular hypertrophy in hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     LEFT VENTRICULAR HYPERTROPHY AND ARRHYTHMIAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;LVH has been associated with both ventricular and supraventricular arrhythmias.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Ventricular arrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with electrocardiographic evidence of LVH have a higher prevalence and greater complexity of ventricular premature beats and more serious arrhythmias than patients without LVH or normotensive subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1401/abstract/8-15\">",
"     8-15",
"    </a>",
"    ]. This association is independent of the etiology of LVH [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1401/abstract/16\">",
"     16",
"    </a>",
"    ]. Ventricular arrhythmia is also increased in patients with echocardiographically demonstrated LVH compared with normal subjects or hypertensive patients without LVH [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1401/abstract/11,17-20\">",
"     11,17-20",
"    </a>",
"    ]. In a study of men over age 70, the presence of LVH, even in the absence of a history of hypertension, was associated with increased rates of ventricular arrhythmia [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1401/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The frequency and complexity of ventricular premature beats (VPBs), also referred to as ventricular premature complexes (VPCs), premature ventricular beats (PVBs), or premature ventricular complexes (PVCs), is related to the severity of LVH as well as chamber volume and indices of left ventricular contractility [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1401/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. As an example, one study of 49 patients without coronary artery disease found that the frequency and complexity of ventricular arrhythmias were significantly related to the presence of LVH, defined either by thickness of the interventricular septum or posterior left ventricular wall &ge;1.2 cm or by left ventricular mass [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1401/abstract/17\">",
"     17",
"    </a>",
"    ]. For every 1 mm increase in wall thickness, there was a two to three fold increase in the occurrence and complexity of VPBs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Sudden cardiac death",
"    </span>",
"    &nbsp;&mdash;&nbsp;LVH is a risk factor for sudden cardiac death (SCD) as well as overall cardiovascular mortality.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a nationwide study of SCD occurring in persons aged 15 to 35 years in Ireland between 2005 and 2007, 10 percent (12 of 116 autopsy-adjudicated cases) had evidence of LVH which did not meet the criteria for another diagnosis (ie, hypertrophic cardiomyopathy) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/23/1401/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a report from the Framingham Heart Study which evaluated the relationship between left ventricular mass and hypertrophy and SCD in 3661 subjects over the age of 40 who were followed for 14 years, the prevalence of LVH was 22 percent and the risk factor-adjusted hazard ratio for SCD was significantly increased (adjusted hazard ratio 2.16, 95% CI 1.22-3.81) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/23/1401/abstract/23\">",
"       23",
"      </a>",
"      ]. For each 50",
"      <span class=\"nowrap\">",
"       g/m2",
"      </span>",
"      increment in left ventricular mass, the risk factor-adjusted hazard ratio for sudden death was 1.45.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Comorbid diseases may account for part of the prognostic variability of LVH. In particular, coronary heart disease, which frequently coexists with hypertensive LVH, may predispose susceptible individuals to arrhythmias and sudden death.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Supraventricular arrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are limited data regarding the interrelationship between LVH and supraventricular arrhythmias. One echocardiographic study of 78 patients with borderline hypertension found that those with LVH had more frequent supraventricular premature beats compared to normotensive controls or borderline hypertensive patients without LVH [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1401/abstract/24\">",
"     24",
"    </a>",
"    ]. Hypertensive patients with LVH also have an increased incidence of runs of supraventricular tachycardia [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1401/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Atrial fibrillation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relationship between LVH and atrial fibrillation (AF) is well established. Data from the Framingham study provide evidence of an increased prevalence of AF among patients with hypertensive cardiovascular disease as compared with control subjects with a risk ratio of about 2.0 [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1401/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The importance of LVH in the development AF was further illustrated in a study of 2482 subjects with essential hypertension followed for up to 16 years [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1401/abstract/26\">",
"     26",
"    </a>",
"    ]. During follow-up, 61 patients developed AF (0.46 per 100 person years). Among the cardiovascular risk factors studied, multivariate analysis revealed age and LV mass to be the only independent predictors of developing AF. For every one standard deviation increase on left ventricular mass, the risk of AF was increased 1.20 times.",
"   </p>",
"   <p>",
"    Additional predictors for AF in hypertensive patients include [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1401/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age",
"     </li>",
"     <li>",
"      The level of diurnal and nocturnal systolic blood pressure during 24 hour monitoring",
"     </li>",
"     <li>",
"      Left atrial diameter",
"     </li>",
"     <li>",
"      Left ventricular mass",
"     </li>",
"     <li>",
"      The maximum duration and dispersion of the P wave on the ECG",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the majority of patients with hypertension and LVH have intermittent AF, chronic or permanent AF develops in about 33 percent of patients. Independent predictors of permanent AF are age, left ventricular mass, and left atrial diameter [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1401/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additionally, there appears to be an increased risk of sudden cardiac death (SCD) in patients with ECG evidence of LVH who develop AF. Among a cohort of 8831 hypertensive patients with baseline sinus rhythm and ECG evidence of LVH who were followed for an average of 4.7 years, 701 (7.9 percent) patients developed AF, and 151 patients (1.7 percent) experienced SCD [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1401/abstract/28\">",
"     28",
"    </a>",
"    ]. Multivariate analysis revealed a greater than threefold increased risk of SCD among patients who developed AF (hazard ratio 3.1 compared with those who remained in sinus rhythm, 95% CI 1.9-5.2).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ELECTROPHYSIOLOGIC MECHANISM LINKING LVH AND VENTRICULAR DYSRHYTHMIAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Little is known about the physiologic mechanisms accounting for ventricular arrhythmia in LVH. Several theories have been proposed, although it seems likely that the arrhythmogenicity of LVH is multifactorial in origin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Ischemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;LVH and hypertension without LVH are commonly associated with myocardial ischemia; in addition, microvascular angina can occur in patients with hypertension even in the absence of LVH [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1401/abstract/29-33\">",
"     29-33",
"    </a>",
"    ]. Several factors can contribute to the development of myocardial ischemia:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A reduction in subendocardial blood flow due to the increase in left ventricular end-diastolic blood pressure. The repolarization changes seen with LVH reflect this reduction in subendocardial blood flow. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/13/3285?source=see_link&amp;anchor=H6#H6\">",
"       \"Electrocardiographic diagnosis of left ventricular hypertrophy\", section on 'Repolarization abnormalities'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Increased peripheral vascular resistance and an overall reduction in coronary artery blood flow resulting from augmented vasoconstrictor tone and the increased",
"      <span class=\"nowrap\">",
"       wall/lumen",
"      </span>",
"      ratio.",
"     </li>",
"     <li>",
"      Failure of the coronary arteries to grow at a rate sufficient to compensate for the muscular hypertrophy, resulting in decreased coronary reserve and chronic ischemia, a well-recognized stimulus for arrhythmias of all type [",
"      <a class=\"abstract\" href=\"UTD.htm?1/23/1401/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Increased oxygen demand due to the rise in wall tension.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Electrophysiologic abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;The irregular hypertrophy pattern and local areas of fibrosis in LVH can impede the homogeneous propagation of the electric impulse throughout the myocardium and its subsequent recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1401/abstract/7,34-36\">",
"     7,34-36",
"    </a>",
"    ]. Fibrosis is one of the deleterious anatomic abnormalities associated with LVH, and may be the main substrate for the development of ventricular arrhythmias, particularly reentrant arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1401/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Eccentric hypertrophy (ie, hypertrophy affecting one region of the left ventricular myocardium, usually the septum, more than other regions) has been associated with more severe ventricular arrhythmias, while concentric hypertrophy (ie, uniform hypertrophy affecting all walls of the left ventricle) is more closely related to ischemic events resulting from abnormal coronary autoregulation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1401/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Experimental models have detected changes in the membrane of the hypertrophied myocardial cell which result in electrophysiologic alterations that are involved in the pathophysiology of LVH-related arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1401/abstract/34,37,38\">",
"     34,37,38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lengthening of the action potential duration (APD) for which the mechanism is not yet understood [",
"      <a class=\"abstract\" href=\"UTD.htm?1/23/1401/abstract/39,40\">",
"       39,40",
"      </a>",
"      ]. In addition, an increase in APD dispersion, manifest on the ECG as QT dispersion, has been described [",
"      <a class=\"abstract\" href=\"UTD.htm?1/23/1401/abstract/41\">",
"       41",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/33/10778?source=see_link\">",
"       \"QT dispersion: Clinical applications\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Significant reductions in action potential upstroke velocity and impulse conduction velocity, which may vary within regions of the myocardium dependent upon the degree of hypertrophy and fibrosis [",
"      <a class=\"abstract\" href=\"UTD.htm?1/23/1401/abstract/42,43\">",
"       42,43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Slowing of membrane repolarization or recovery manifest as an increase in QT interval duration. Similar to impulse conduction velocity, the recovery times within the myocardium may vary as a result of hypertrophy and fibrosis [",
"      <a class=\"abstract\" href=\"UTD.htm?1/23/1401/abstract/14,37\">",
"       14,37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The abnormalities in impulse conduction and myocardial repolarization result in the generation of reentry mechanisms, which are facilitated by the presence of interstitial fibrosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/62/42984?source=see_link\">",
"       \"Reentry and the development of cardiac arrhythmias\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The hypertrophied myocardium is capable of generating early and delayed afterdepolarizations, leading to triggered activity [",
"      <a class=\"abstract\" href=\"UTD.htm?1/23/1401/abstract/44,45\">",
"       44,45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      T wave or repolarizing alternans (TWA), which reflects beat to beat variability in the timing or morphology of repolarization, indicates repolarizing heterogeneity and has been associated with an increased risk for sudden death. The prevalence of TWA is increased in those with LVH [",
"      <a class=\"abstract\" href=\"UTD.htm?1/23/1401/abstract/46\">",
"       46",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/48/5898?source=see_link\">",
"       \"T wave (repolarization) alternans: Clinical aspects\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Abnormalities of the hypertrophied myocardial cell",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hypertrophied cardiac myocyte is electrophysiologically different from and more arrhythmogenic than the normal myocyte [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1401/abstract/34,47\">",
"     34,47",
"    </a>",
"    ]. A number of structural changes that occur in hypertrophy have been related to the susceptibility of the hypertrophied myocardium to arrhythmias. As an example, low resistance pathways of the intercalated discs of the hypertrophic myocardium undergo changes that increase the surface of the gap region involved in cell-to-cell communication [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1401/abstract/48\">",
"     48",
"    </a>",
"    ]. Other changes include dilatation of the transverse tubule system, which is involved in the transmission of the surface action potential to the sarcomere, and an increase in the number of mitochondria, which are responsible for the cell energy status [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1401/abstract/48\">",
"     48",
"    </a>",
"    ]. Whether these structural changes correlate with the above electrophysiologic abnormalities is not known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Fluctuations in arterial blood pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Excessive fluctuation in arterial pressure, as occurs in severe hypertension, may be arrhythmogenic via changes the loading conditions of the left ventricle [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1401/abstract/49-51\">",
"     49-51",
"    </a>",
"    ]. The cardiac myocyte is capable of reacting to a variety of external stimuli modifying its structural and functional behavior [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1401/abstract/52\">",
"     52",
"    </a>",
"    ]. Stretch-activated channels in the cytoplasmic membrane detect external physical stimuli, such as pressure changes, giving rise to a sequence of intracellular ionic events that affect the electrical stability of the cell. Mechanical stretching of the myocyte, as with a pharmacologic stressor, reduces the electric threshold and increases the frequency of ventricular arrhythmia (electromechanical feedback) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1401/abstract/50\">",
"     50",
"    </a>",
"    ]. Conversely, acute reductions in afterload, resulting from electrically inactive drugs such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21302?source=see_link\">",
"     nitroprusside",
"    </a>",
"    , significantly diminish the prevalence of arrhythmias in patients with a high basal rate of ventricular arrhythmia [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1401/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Increased sympathetic activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased activity of the sympathetic nervous system and the renin-angiotensin system has been implicated in the pathogenesis of essential hypertension. One study found that abnormal circadian blood pressure variations, as assessed by 24-hour blood pressure monitoring, correlated with the presence of echocardiographic LVH [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1401/abstract/53\">",
"     53",
"    </a>",
"    ]. Thus, at any given level of blood pressure,",
"    <span class=\"nowrap\">",
"     sympathetic/parasympathetic",
"    </span>",
"    imbalance may influence the development of LVH and the occurrence of atrial and ventricular arrhythmias. In addition, sympathetic stimulation exerts a direct proarrhythmic effect by enhancing automaticity [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1401/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/5/42070?source=see_link\">",
"     \"Enhanced cardiac automaticity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The renin-angiotensin system has been implicated in the pathogenesis of LVH [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1401/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. However, the evidence that cellular angiotensin levels exert direct arrhythmogenic effects is less conclusive. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36825?source=see_link\">",
"     \"Actions of angiotensin II on the heart\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Electrolyte abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although not directly related to hypertrophy, hypokalemia (particularly when the plasma potassium concentration is less than 3",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    or hypomagnesemia resulting from diuretic therapy in patients with hypertension may be arrhythmogenic by enhancing automaticity (particularly in association with an increase in sympathetic tone), by prolonging repolarization and the QT interval, or by increasing triggered activity [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1401/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. However, the data about the role of hypokalemia in spontaneous ventricular arrhythmia are contradictory [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1401/abstract/60-62\">",
"     60-62",
"    </a>",
"    ]. There is evidence that diuretic therapy in patients with hypertension increases the incidence of sudden death probably due to hypokalemia (",
"    <a class=\"graphic graphic_figure graphicRef68346 \" href=\"UTD.htm?10/23/10621\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1401/abstract/63-65\">",
"     63-65",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/2/9258?source=see_link\">",
"     \"Clinical manifestations and treatment of hypokalemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     VENTRICULAR ARRHYTHMIA AND SUDDEN CARDIAC DEATH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fact that both ventricular ectopy and SCD occur with increased frequency in patients with LVH [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1401/abstract/23\">",
"     23",
"    </a>",
"    ] does not prove that VPBs in an individual patient herald ventricular fibrillation (VF) or other fatal electric events. It seems logical but remains unproven that, in a population documented to be at increased risk of SCD, such as patients with LVH, those with the greatest degree of electric instability are likely to be at highest risk.",
"   </p>",
"   <p>",
"    However, several studies have suggested that complex ventricular ectopy is predictive [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1401/abstract/66-68\">",
"     66-68",
"    </a>",
"    ]. As an example, the Framingham Heart Study evaluated 671 men and women with LVH on echocardiography; after a six year follow-up, all-cause mortality was increased in those with complex or frequent ventricular arrhythmia compared to subjects without this arrhythmia (38 versus 12 percent in men and 22 versus 11 percent in women) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1401/abstract/66\">",
"     66",
"    </a>",
"    ]. However, the increased mortality was only marginally significant after adjusting for clinical factors.",
"   </p>",
"   <p>",
"    An uncontrolled study included 554 elderly patients (average age 84) who were followed for an average of 27 months [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1401/abstract/67\">",
"     67",
"    </a>",
"    ]. Hypertensive patients with coronary disease and episodes of nonsustained VT on ambulatory monitoring who had echocardiographic LVH were significantly more likely to experience VF or SCD than their counterparts who did not have VT or those with VT who did not have LVH (57 versus 20 and 20 percent, P&lt;0.001).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     EFFECT OF REGRESSION OF LVH ON VENTRICULAR ECTOPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, lowering the BP with antihypertensive agents, weight loss, or dietary sodium restriction decreases cardiac mass in patients with LVH [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1401/abstract/1,13-15\">",
"     1,13-15",
"    </a>",
"    ]. This effect is related both to the antihypertensive response and, to some degree, to the type of therapy used [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1401/abstract/69\">",
"     69",
"    </a>",
"    ]. The degree of regression appears to be most prominent with ACE inhibitors and calcium channel blockers, particularly the nondihydropyridines, and may not occur with direct vasodilators (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/5/32848?source=see_link\">",
"     minoxidil",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1401/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/34/17959?source=see_link\">",
"     \"Clinical implications and treatment of left ventricular hypertrophy in hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Regression of LVH appears to be associated with a reduction in ventricular arrhythmia. In animal models, regression of hypertrophy normalized action potential duration and dispersion of refractoriness and decreased vulnerability to inducible polymorphic VT and ventricular fibrillation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1401/abstract/14,38\">",
"     14,38",
"    </a>",
"    ]. A number of observations are consistent with similar benefit in humans given a number of different antihypertensive drugs:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Regression of LVH with three months of treatment with a calcium channel blocker decreased ventricular arrhythmia in association with a reduction in left ventricular mass [",
"      <a class=\"abstract\" href=\"UTD.htm?1/23/1401/abstract/71\">",
"       71",
"      </a>",
"      ]. In contrast, patients treated with a diuretic had no decrease in either left ventricular mass or ventricular ectopy.",
"     </li>",
"     <li>",
"      Among 46 hypertensive patients randomly assigned to therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"       enalapril",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"       hydrochlorothiazide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"       atenolol",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      , all drugs significantly lowered blood pressure. At six months, LV mass index and ventricular ectopy were reduced by enalapril, atenolol, and verapamil. In contrast, hydrochlorothiazide did not reduce LV mass or arrhythmia [",
"      <a class=\"abstract\" href=\"UTD.htm?1/23/1401/abstract/72\">",
"       72",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a small randomized trial, hypertensive patients with LVH were assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"       captopril",
"      </a>",
"      or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?1/23/1401/abstract/73\">",
"       73",
"      </a>",
"      ]. Captopril therapy was associated with a marked reduction in LVH and a marked reduction in ventricular ectopy, whereas the placebo group showed progression of LVH without change in ventricular ectopy.",
"     </li>",
"     <li>",
"      In another small randomized trial of 45 hypertensive patients,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/56/903?source=see_link\">",
"       isradipine",
"      </a>",
"      (a calcium channel blocker), spirapril (an ACE inhibitor), and the combination produced an equivalent degree of LVH regression and reduction in ventricular ectopy [",
"      <a class=\"abstract\" href=\"UTD.htm?1/23/1401/abstract/74\">",
"       74",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon these data, it seems safe to assume that the decrease in ventricular ectopy associated with regression of LVH is not related to a direct antiarrhythmic effect of antihypertensive therapy but to its effects on hemodynamics and perhaps neurohormonal activation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     REGRESSION OF LVH AND THE RISK OF SUDDEN CARDIAC DEATH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies of the effects of the regression of LVH on cardiovascular morbidity and mortality are limited; they generally support but do not prove an improvement in outcome beyond that associated with the reduction in blood pressure alone [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1401/abstract/7,75,76\">",
"     7,75,76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reports from the Framingham Heart Study showed that regression of LVH, as assessed by electrocardiographic criteria, was associated with reductions in the risk of SCD, acute myocardial infarction, and congestive heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1401/abstract/7,23,77\">",
"     7,23,77",
"    </a>",
"    ]. Among subjects with LVH, the likelihood of a cardiovascular event (cardiac death, myocardial infarction, stroke, angina, or need for coronary revascularization) over a 10-year period was significantly lower in patients with LVH regression compared to those in whom LVH persisted at the end of follow-up (3 versus 25 percent). Furthermore, patients with a normal left ventricular mass at baseline who did not develop LVH after 10 years had a significantly lower percentage of events than those who developed LVH (5.1 versus 31.6 percent).",
"   </p>",
"   <p>",
"    Further support for the benefit of LVH regression on SCD comes from a post hoc analysis of the LIFE trial [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1401/abstract/78\">",
"     78",
"    </a>",
"    ]. This study enrolled 9193 patients with hypertension and ECG evidence of LVH and randomly assigned them to treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/35/26168?source=see_link\">",
"     losartan",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1401/abstract/79\">",
"     79",
"    </a>",
"    ]. Over a mean follow-up of 4.8 years, absence of ECG evidence of LVH while on-treatment was associated with a significant reduction in the risk of SCD, independent of treatment modality, blood pressure reduction, and other cardiovascular risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1401/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     LVH AND ARRHYTHMIAS IN ATHLETES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Molecular biology techniques are providing strong evidence that not all types of pathologic LVH are equivalent and that the patterns of functional and structural adaptation of the heart differ depending upon the pathogenetic mechanism. As an example, ventricular hypertrophy frequently occurs in trained athletes. The LVH is typically concentric with isometric exercise and eccentric with endurance sports [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1401/abstract/80-82\">",
"     80-82",
"    </a>",
"    ]. The mechanisms accounting for LVH in these situations and the consequences of LVH are quite different from those in hypertensive LVH [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1401/abstract/83,84\">",
"     83,84",
"    </a>",
"    ]. Both systolic and diastolic function are generally maintained in LVH occurring in athletes [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1401/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hypertrophy may also be present in the right ventricle, an abnormality that may be best demonstrated on cardiac MRI. There appears to be a correlation between the degree of hypertrophy of both ventricles and exercise capacity [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1401/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The arrhythmias that are seen in athletes who do not have associated cardiac abnormalities are similar in type and frequency to those that occur in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?1/23/1401/abstract/86\">",
"     86",
"    </a>",
"    ]. Some of the arrhythmias, such as sinus bradycardia and sinus arrhythmia, are the result of enhanced vagal tone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23192?source=see_link\">",
"     \"Arrhythmia in athletes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/36/13898?source=see_link\">",
"     \"Risk of sudden cardiac death in athletes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;LVH is a common cardiac complication of sustained arterial hypertension or significant aortic stenosis. It is also a blood pressure-independent risk factor for sudden death, acute myocardial infarction, and other cardiovascular morbidity and mortality. Ventricular ectopy and more serious arrhythmias are common in patients with LVH, although it remains uncertain is whether patients with LVH and ventricular arrhythmia are at a higher risk for SCD than those without ventricular ectopy.",
"   </p>",
"   <p>",
"    The degree of hypertrophy can be reduced by specific antihypertensive therapy, although not all antihypertensive drugs are equipotent in this regard. Regression of LVH diminishes LVH-associated arrhythmias and appears to reduce the risk of SCD.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/1\">",
"      Kannel WB, Gordon T, Offutt D. Left ventricular hypertrophy by electrocardiogram. Prevalence, incidence, and mortality in the Framingham study. Ann Intern Med 1969; 71:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/2\">",
"      Kannel WB, Doyle JT, McNamara PM, et al. Precursors of sudden coronary death. Factors related to the incidence of sudden death. Circulation 1975; 51:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/3\">",
"      Kannel WB, Gordon T, Castelli WP, Margolis JR. Electrocardiographic left ventricular hypertrophy and risk of coronary heart disease. The Framingham study. Ann Intern Med 1970; 72:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/4\">",
"      Kannel WB, Castelli WP, McNamara PM, et al. Role of blood pressure in the development of congestive heart failure. The Framingham study. N Engl J Med 1972; 287:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/5\">",
"      Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322:1561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/6\">",
"      Casale PN, Devereux RB, Milner M, et al. Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med 1986; 105:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/7\">",
"      Koren MJ, Devereux RB, Casale PN, et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991; 114:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/8\">",
"      Messerli FH, Ventura HO, Elizardi DJ, et al. Hypertension and sudden death. Increased ventricular ectopic activity in left ventricular hypertrophy. Am J Med 1984; 77:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/9\">",
"      McLenachan JM, Henderson E, Morris KI, Dargie HJ. Ventricular arrhythmias in patients with hypertensive left ventricular hypertrophy. N Engl J Med 1987; 317:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/10\">",
"      Aronow WS, Epstein S, Schwartz KS, Koenigsberg M. Correlation of complex ventricular arrhythmias detected by ambulatory electrocardiographic monitoring with echocardiographic left ventricular hypertrophy in persons older than 62 years in a long-term health care facility. Am J Cardiol 1987; 60:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/11\">",
"      Levy D, Anderson KM, Savage DD, et al. Risk of ventricular arrhythmias in left ventricular hypertrophy: the Framingham Heart Study. Am J Cardiol 1987; 60:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/12\">",
"      Siegel D, Cheitlin MD, Black DM, et al. Risk of ventricular arrhythmias in hypertensive men with left ventricular hypertrophy. Am J Cardiol 1990; 65:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/13\">",
"      Vester EG, Kuhls S, Ochiulet-Vester J, et al. Electrophysiological and therapeutic implications of cardiac arrhythmias in hypertension. Eur Heart J 1992; 13 Suppl D:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/14\">",
"      Rials SJ, Wu Y, Ford N, et al. Effect of left ventricular hypertrophy and its regression on ventricular electrophysiology and vulnerability to inducible arrhythmia in the feline heart. Circulation 1995; 91:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/15\">",
"      Martins JB, Kim W, Marcus ML. Chronic hypertension and left ventricular hypertrophy facilitate induction of sustained ventricular tachycardia in dogs 3 hours after left circumflex coronary artery occlusion. J Am Coll Cardiol 1989; 14:1365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/16\">",
"      Spacek R, Gregor P. Ventricular arrhythmias in myocardial hypertrophy of various origins. Can J Cardiol 1997; 13:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/17\">",
"      Ghali JK, Kadakia S, Cooper RS, Liao YL. Impact of left ventricular hypertrophy on ventricular arrhythmias in the absence of coronary artery disease. J Am Coll Cardiol 1991; 17:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/18\">",
"      Schmieder RE, Messerli FH. Determinants of ventricular ectopy in hypertensive cardiac hypertrophy. Am Heart J 1992; 123:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/19\">",
"      Novo S, Barbagallo M, Abrignani MG, et al. Increased prevalence of cardiac arrhythmias and transient episodes of myocardial ischemia in hypertensives with left ventricular hypertrophy but without clinical history of coronary heart disease. Am J Hypertens 1997; 10:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/20\">",
"      Mammarella A, Paradiso M, Basili S, et al. Morphologic left ventricular patterns and prevalence of high-grade ventricular arrhythmias in the normotensive and hypertensive elderly. Adv Ther 2000; 17:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/21\">",
"      Andr&eacute;n B, Lind L, Hedenstierna G, Lithell H. Impaired systolic and diastolic function and ventricular arrhythmia are common in normotensive healthy elderly men with left ventricular hypertrophy. Coron Artery Dis 1999; 10:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/22\">",
"      Margey R, Roy A, Tobin S, et al. Sudden cardiac death in 14- to 35-year olds in Ireland from 2005 to 2007: a retrospective registry. Europace 2011; 13:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/23\">",
"      Haider AW, Larson MG, Benjamin EJ, Levy D. Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. J Am Coll Cardiol 1998; 32:1454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/24\">",
"      Melina D, Colivicchi F, Guerrera G, et al. Prevalence of left ventricular hypertrophy and cardiac arrhythmias in borderline hypertension. Am J Hypertens 1992; 5:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/25\">",
"      Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med 1982; 306:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/26\">",
"      Verdecchia P, Reboldi G, Gattobigio R, et al. Atrial fibrillation in hypertension: predictors and outcome. Hypertension 2003; 41:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/27\">",
"      Ciaroni S, Cuenoud L, Bloch A. Clinical study to investigate the predictive parameters for the onset of atrial fibrillation in patients with essential hypertension. Am Heart J 2000; 139:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/28\">",
"      Okin PM, Bang CN, Wachtell K, et al. Relationship of Sudden Cardiac Death to New-Onset Atrial Fibrillation in Hypertensive Patients with Left Ventricular Hypertrophy. Circ Arrhythm Electrophysiol 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/29\">",
"      O'Gorman DJ, Sheridan DJ. Abnormalities of the coronary circulation associated with left ventricular hypertrophy. Clin Sci (Lond) 1991; 81:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/30\">",
"      Houghton JL, Prisant LM, Carr AA, et al. Relationship of left ventricular mass to impairment of coronary vasodilator reserve in hypertensive heart disease. Am Heart J 1991; 121:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/31\">",
"      Lucarini AR, Picano E, Salvetti A. Coronary microvascular disease in hypertensives. Clin Exp Hypertens A 1992; 14:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/32\">",
"      Houghton JL, Carr AA, Prisant LM, et al. Morphologic, hemodynamic and coronary perfusion characteristics in severe left ventricular hypertrophy secondary to systemic hypertension and evidence for nonatherosclerotic myocardial ischemia. Am J Cardiol 1992; 69:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/33\">",
"      Harrison DG, Marcus ML, Dellsperger KC, et al. Pathophysiology of myocardial perfusion in hypertension. Circulation 1991; 83:III14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/34\">",
"      Swynghedauw B, Chevalier B, Charlemagne D, et al. Cardiac hypertrophy, arrhythmogenicity and the new myocardial phenotype. II. The cellular adaptational process. Cardiovasc Res 1997; 35:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/35\">",
"      Levy D, Anderson KM, Plehn J, et al. Echocardiographically determined left ventricular structural and functional correlates of complex or frequent ventricular arrhythmias on one-hour ambulatory electrocardiographic monitoring. Am J Cardiol 1987; 59:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/36\">",
"      McLenachan JM, Dargie HJ. Ventricular arrhythmias in hypertensive left ventricular hypertrophy. Relationship to coronary artery disease, left ventricular dysfunction, and myocardial fibrosis. Am J Hypertens 1990; 3:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/37\">",
"      Kulan K, Ural D, Komsuolu B, et al. Significance of QTc prolongation on ventricular arrhythmias in patients with left ventricular hypertrophy secondary to essential hypertension. Int J Cardiol 1998; 64:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/38\">",
"      Rials SJ, Wu Y, Xu X, et al. Regression of left ventricular hypertrophy with captopril restores normal ventricular action potential duration, dispersion of refractoriness, and vulnerability to inducible ventricular fibrillation. Circulation 1997; 96:1330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/39\">",
"      Cameron JS, Myerburg RJ, Wong SS, et al. Electrophysiologic consequences of chronic experimentally induced left ventricular pressure overload. J Am Coll Cardiol 1983; 2:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/40\">",
"      Nordin C, Siri F, Aronson RS. Electrophysiologic characteristics of single myocytes isolated from hypertrophied guinea-pig hearts. J Mol Cell Cardiol 1989; 21:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/41\">",
"      Gillis AM, Mathison HJ, Kulisz E, Lester WM. Dispersion of ventricular repolarization and ventricular fibrillation in left ventricular hypertrophy: influence of selective potassium channel blockers. J Pharmacol Exp Ther 2000; 292:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/42\">",
"      Tritthart H, Luedcke H, Bayer R, et al. Right ventricular hypertrophy in the cat--an electrophysiological and anatomical study. J Mol Cell Cardiol 1975; 7:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/43\">",
"      Keung EC, Aronson RS. Non-uniform electrophysiological properties and electrotonic interaction in hypertrophied rat myocardium. Circ Res 1981; 49:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/44\">",
"      Ben-David J, Zipes DP, Ayers GM, Pride HP. Canine left ventricular hypertrophy predisposes to ventricular tachycardia induction by phase 2 early afterdepolarizations after administration of BAY K 8644. J Am Coll Cardiol 1992; 20:1576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/45\">",
"      Charpentier F, Baudet S, Le Marec H. Triggered activity as a possible mechanism for arrhythmias in ventricular hypertrophy. Pacing Clin Electrophysiol 1991; 14:1735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/46\">",
"      Hennersdorf MG, Niebch V, Perings C, Strauer BE. T wave alternans and ventricular arrhythmias in arterial hypertension. Hypertension 2001; 37:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/47\">",
"      Toyoshima H, Park YD, Ishikawa Y, et al. Effect of ventricular hypertrophy on conduction velocity of activation front in the ventricular myocardium. Am J Cardiol 1982; 49:1938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/48\">",
"      Leyton RA, Sonnenblick EH. The ultrastructure of the failing heart. Am J Med Sci 1969; 258:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/49\">",
"      Sideris DA, Kontoyannis DA, Michalis L, et al. Acute changes in blood pressure as a cause of cardiac arrhythmias. Eur Heart J 1987; 8:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/50\">",
"      Sideris DA, Toumanidis ST, Kostis EB, et al. Arrhythmogenic effect of high blood pressure: some observations on its mechanism. Cardiovasc Res 1989; 23:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/51\">",
"      James MA, Jones JV. Systolic wall stress and ventricular arrhythmia: the role of acute change in blood pressure in the isolated working rat heart. Clin Sci (Lond) 1990; 79:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/52\">",
"      Bustamante JO, Ruknudin A, Sachs F. Stretch-activated channels in heart cells: relevance to cardiac hypertrophy. J Cardiovasc Pharmacol 1991; 17 Suppl 2:S110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/53\">",
"      Verdecchia P, Schillaci G, Guerrieri M, et al. Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension. Circulation 1990; 81:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/54\">",
"      Schwartz PJ, La Rovere MT, Vanoli E. Autonomic nervous system and sudden cardiac death. Experimental basis and clinical observations for post-myocardial infarction risk stratification. Circulation 1992; 85:I77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/55\">",
"      Anderson JL, Rodier HE, Green LS. Comparative effects of beta-adrenergic blocking drugs on experimental ventricular fibrillation threshold. Am J Cardiol 1983; 51:1196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/56\">",
"      Paul M, Ganten D. The molecular basis of cardiovascular hypertrophy: the role of the renin-angiotensin system. J Cardiovasc Pharmacol 1992; 19 Suppl 5:S51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/57\">",
"      Sadoshima J, Xu Y, Slayter HS, Izumo S. Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell 1993; 75:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/58\">",
"      Evans SJ, Levi AJ, Jones JV. Wall stress induced arrhythmia is enhanced by low potassium and early left ventricular hypertrophy in the working rat heart. Cardiovasc Res 1995; 29:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/59\">",
"      Evans SJ, Levi AJ, Jones JV. Low magnesium enhances the pro-arrhythmic effect of low potassium in the hypertrophied rat heart but not in the normal rat heart. J Hypertens 1996; 14:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/60\">",
"      Holland OB, Kuhnert L, Pollard J, et al. Ventricular ectopic activity with diuretic therapy. Am J Hypertens 1988; 1:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/61\">",
"      Tsuji H, Venditti FJ Jr, Evans JC, et al. The associations of levels of serum potassium and magnesium with ventricular premature complexes (the Framingham Heart Study). Am J Cardiol 1994; 74:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/62\">",
"      Siegel D, Hulley SB, Black DM, et al. Diuretics, serum and intracellular electrolyte levels, and ventricular arrhythmias in hypertensive men. JAMA 1992; 267:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/63\">",
"      Siscovick DS, Raghunathan TE, Psaty BM, et al. Diuretic therapy for hypertension and the risk of primary cardiac arrest. N Engl J Med 1994; 330:1852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/64\">",
"      Hoes AW, Grobbee DE, Lubsen J, et al. Diuretics, beta-blockers, and the risk for sudden cardiac death in hypertensive patients. Ann Intern Med 1995; 123:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/65\">",
"      Warram JH, Laffel LM, Valsania P, et al. Excess mortality associated with diuretic therapy in diabetes mellitus. Arch Intern Med 1991; 151:1350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/66\">",
"      Bikkina M, Larson MG, Levy D. Asymptomatic ventricular arrhythmias and mortality risk in subjects with left ventricular hypertrophy. J Am Coll Cardiol 1993; 22:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/67\">",
"      Aronow WS, Epstein S, Koenigsberg M, Schwartz KS. Usefulness of echocardiographic left ventricular hypertrophy, ventricular tachycardia and complex ventricular arrhythmias in predicting ventricular fibrillation or sudden cardiac death in elderly patients. Am J Cardiol 1988; 62:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/68\">",
"      Saadehm Anm Joes JV. Predictors of sudden cardiac death in never previously treated patients with essential hypertension: long-term follow up. J Hum Hypertens 2001; 15:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/69\">",
"      Cruickshank JM, Lewis J, Moore V, Dodd C. Reversibility of left ventricular hypertrophy by differing types of antihypertensive therapy. J Hum Hypertens 1992; 6:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/70\">",
"      Dahl&ouml;f B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hypertens 1992; 5:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/71\">",
"      Messerli FH, Nunez BD, Nunez MM, et al. Hypertension and sudden death. Disparate effects of calcium entry blocker and diuretic therapy on cardiac dysrhythmias. Arch Intern Med 1989; 149:1263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/72\">",
"      Novo S, Abrignani MG, Novo G, et al. Effects of drug therapy on cardiac arrhythmias and ischemia in hypertensives with LVH. Am J Hypertens 2001; 14:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/73\">",
"      Gonz&aacute;lez-Fern&aacute;ndez RA, Rivera M, Rodr&iacute;guez PJ, et al. Prevalence of ectopic ventricular activity after left ventricular mass regression. Am J Hypertens 1993; 6:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/74\">",
"      Manolis AJ, Beldekos D, Handanis S, et al. Comparison of spirapril, isradipine, or combination in hypertensive patients with left ventricular hypertrophy: effects on LVH regression and arrhythmogenic propensity. Am J Hypertens 1998; 11:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/75\">",
"      Koren MJ, Devereux RB. Mechanism, effects, and reversal of left ventricular hypertrophy in hypertension. Curr Opin Nephrol Hypertens 1993; 2:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/76\">",
"      Yurenev AP, Dyakonova HG, Novikov ID, et al. Management of essential hypertension in patients with different degrees of left ventricular hypertrophy. Multicenter trial. Am J Hypertens 1992; 5:182S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/77\">",
"      Levy D, Salomon M, D'Agostino RB, et al. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation 1994; 90:1786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/78\">",
"      Wachtell K, Okin PM, Olsen MH, et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study. Circulation 2007; 116:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/79\">",
"      Dahl&ouml;f B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/80\">",
"      Fagard RH. Impact of different sports and training on cardiac structure and function. Cardiol Clin 1997; 15:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/81\">",
"      Pluim BM, Zwinderman AH, van der Laarse A, van der Wall EE. The athlete's heart. A meta-analysis of cardiac structure and function. Circulation 2000; 101:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/82\">",
"      Abernethy WB, Choo JK, Hutter AM Jr. Echocardiographic characteristics of professional football players. J Am Coll Cardiol 2003; 41:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/83\">",
"      Cuspidi C, Lonati L, Sampieri L, et al. Similarities and differences in structural and functional changes of left ventricle and carotid arteries in young borderline hypertensives and in athletes. J Hypertens 1996; 14:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/84\">",
"      Di Bello V, Pedrinelli R, Giorgi D, et al. Ultrasonic videodensitometric analysis of two different models of left ventricular hypertrophy. Athlete's heart and hypertension. Hypertension 1997; 29:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/85\">",
"      Scharhag J, Schneider G, Urhausen A, et al. Athlete's heart: right and left ventricular mass and function in male endurance athletes and untrained individuals determined by magnetic resonance imaging. J Am Coll Cardiol 2002; 40:1856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/23/1401/abstract/86\">",
"      Zehender M, Meinertz T, Keul J, Just H. ECG variants and cardiac arrhythmias in athletes: clinical relevance and prognostic importance. Am Heart J 1990; 119:1378.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 966 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.81.197.98-C80C007BE0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_23_1401=[""].join("\n");
var outline_f1_23_1401=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      LEFT VENTRICULAR HYPERTROPHY AND ARRHYTHMIAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Ventricular arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Supraventricular arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ELECTROPHYSIOLOGIC MECHANISM LINKING LVH AND VENTRICULAR DYSRHYTHMIAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Ischemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Electrophysiologic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Abnormalities of the hypertrophied myocardial cell",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Fluctuations in arterial blood pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Increased sympathetic activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Electrolyte abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      VENTRICULAR ARRHYTHMIA AND SUDDEN CARDIAC DEATH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      EFFECT OF REGRESSION OF LVH ON VENTRICULAR ECTOPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      REGRESSION OF LVH AND THE RISK OF SUDDEN CARDIAC DEATH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      LVH AND ARRHYTHMIAS IN ATHLETES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/966\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/966|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/23/10621\" title=\"figure 1\">",
"      Thiazides and cardiac arrest",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36825?source=related_link\">",
"      Actions of angiotensin II on the heart",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23192?source=related_link\">",
"      Arrhythmia in athletes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/34/17959?source=related_link\">",
"      Clinical implications and treatment of left ventricular hypertrophy in hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/2/9258?source=related_link\">",
"      Clinical manifestations and treatment of hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/52/18247?source=related_link\">",
"      Definition and pathogenesis of left ventricular hypertrophy in hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/13/3285?source=related_link\">",
"      Electrocardiographic diagnosis of left ventricular hypertrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/5/42070?source=related_link\">",
"      Enhanced cardiac automaticity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/33/10778?source=related_link\">",
"      QT dispersion: Clinical applications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/62/42984?source=related_link\">",
"      Reentry and the development of cardiac arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/36/13898?source=related_link\">",
"      Risk of sudden cardiac death in athletes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/48/5898?source=related_link\">",
"      T wave (repolarization) alternans: Clinical aspects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_23_1402="Immune globulin: Drug information";
var content_f1_23_1402=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Immune globulin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?15/54/16230?source=see_link\">",
"    see \"Immune globulin: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/55/15226?source=see_link\">",
"    see \"Immune globulin: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F15601262\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      FDA Updates Immune Globulin Product Safety Information",
"     </span>",
"     <span class=\"collapsible-date\">",
"      November 2012",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       The Food and Drug Administration (FDA) has issued an updated Safety Communication regarding thrombotic events and hemolysis potentially associated with the administration of human immune globulin. Because thrombosis has previously been identified as a potential risk following human immune globulin administration, the agency continues to investigate whether specific characteristics of these products account for an increased risk. FDA scientists and product manufacturers have examined different lots of immune globulin products and found elevated levels of the activated clotting factor XIa in certain lots produced by different manufacturers. Higher levels of factor XIa were associated with a greater incidence of arterial and venous clot formation in patients receiving these products.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Acute intravascular hemolysis or delayed hemolytic anemia can also occur after immune globulin therapy. In some cases, this happens because immune globulins contain blood group antibodies that can act as hemolysins by coating red blood cells, causing a positive direct antibody (Coombs) test result and hemolysis. Isolated cases of hemolysis-related renal dysfunction/failure or disseminated intravascular coagulation have also been reported following treatment with immune globulins.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Further information may be found at",
"       <a href=\"file://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ucm327934.htm?source=govdelivery\" target=\"_blank\">",
"        file://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ucm327934.htm?source=govdelivery",
"       </a>",
"       .",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F11513229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F11513233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Bivigam&trade;;",
"     </li>",
"     <li>",
"      Carimune&reg; NF;",
"     </li>",
"     <li>",
"      Flebogamma&reg; DIF;",
"     </li>",
"     <li>",
"      GamaSTAN&trade; S/D;",
"     </li>",
"     <li>",
"      Gammagard S/D&reg;;",
"     </li>",
"     <li>",
"      Gammagard&reg; Liquid;",
"     </li>",
"     <li>",
"      Gammaked&trade;;",
"     </li>",
"     <li>",
"      Gammaplex&reg;;",
"     </li>",
"     <li>",
"      Gamunex&reg;-C;",
"     </li>",
"     <li>",
"      Hizentra&reg;;",
"     </li>",
"     <li>",
"      Octagam&reg;;",
"     </li>",
"     <li>",
"      Privigen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F11513234\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Gamastan S/D;",
"     </li>",
"     <li>",
"      Gamimune&reg; N;",
"     </li>",
"     <li>",
"      Gammagard Liquid;",
"     </li>",
"     <li>",
"      Gammagard S/D;",
"     </li>",
"     <li>",
"      Gamunex&reg;;",
"     </li>",
"     <li>",
"      Hizentra&reg;;",
"     </li>",
"     <li>",
"      IGIVnex&reg;;",
"     </li>",
"     <li>",
"      Privigen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F11513238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Blood Product Derivative;",
"     </li>",
"     <li>",
"      Immune Globulin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F11513277\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note: Some clinicians may administer  IVIG formulations FDA approved only for intravenous administration as a subcutaneous infusion based on clinical judgment and patient tolerability.",
"     </b>",
"     Also, some clinicians dose IVIG on ideal body weight or an adjusted ideal body weight in morbidly obese patients (Siegel, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      B-cell chronic lymphocytic leukemia (CLL) (Gammagard S/D&reg;):",
"     </b>",
"     I.V.: 400 mg/kg every 3-4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chronic inflammatory demyelinating polyneuropathy (CIDP) (Gammaked&trade;, Gamunex-C&reg;):",
"     </b>",
"     I.V.: Loading dose: 2000 mg/kg (given in divided doses over 2-4 consecutive days); Maintenance: 1000 mg/kg every 3 weeks. Alternatively, administer 500 mg/kg/day for 2 consecutive days every 3 weeks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hepatitis A (GamaSTAN&trade; S/D):",
"     </b>",
"     I.M.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Pre-exposure prophylaxis upon travel into endemic areas (hepatitis A vaccine preferred):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     0.02",
"     <b>",
"      mL",
"     </b>",
"     /kg for anticipated risk of exposure &lt;3 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     0.06",
"     <b>",
"      mL",
"     </b>",
"     /kg for anticipated risk of exposure &ge;3 months; repeat every 4-6 months.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Postexposure prophylaxis:",
"     </i>",
"     0.02",
"     <b>",
"      mL",
"     </b>",
"     /kg given within 14 days of exposure and/or prior to manifestation of disease; not needed if at least 1 dose of hepatitis A vaccine was given at &ge;1 month before exposure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Immunoglobulin deficiency (GamaSTAN&trade; S/D):",
"     </b>",
"     I.M.: 0.66",
"     <b>",
"      mL",
"     </b>",
"     /kg (minimum dose should be 100 mg/kg) every 3-4 weeks. Administer a double dose at onset of therapy; some patients may require more frequent injections.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Immune (idiopathic) thrombocytopenic purpura (ITP):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Carimune&reg; NF: I.V.: Initial: 400 mg/kg/day for 2-5 days; Maintenance: 400 mg/kg as needed to maintain platelet count &ge;30,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     and/or to control significant bleeding; may increase dose if needed (range: 800-1000 mg/kg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gammagard S/D&reg;: I.V.: 1000 mg/kg; up to 3 additional doses may be given based on patient response and/or platelet count.",
"     <b>",
"      Note:",
"     </b>",
"     Additional doses should be given on alternate days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gammaked&trade;, Gamunex-C&reg;: I.V.: 1000 mg/kg/day for 2 consecutive days (second dose may be withheld if adequate platelet response in 24 hours)",
"     <b>",
"      or",
"     </b>",
"     400 mg/kg once daily for 5 consecutive days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gammaplex&reg;, Privigen&reg;: I.V.: 1000 mg/kg/day for 2 consecutive days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kawasaki syndrome (Gammagard S/D&reg;):",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gammagard S/D&reg;: 1000 mg/kg as a single dose",
"     <b>",
"      or",
"     </b>",
"     400 mg/kg/day for 4 consecutive days. Begin within 7 days of onset of fever.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      AHA guidelines",
"     </i>",
"     (2004): 2000 mg/kg as a single dose within 10 days of disease onset",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Must be used in combination with aspirin: 80-100 mg/kg/day orally, divided every 6 hours for up to 14 days (until fever resolves for at least 48 hours); then decrease dose to 3-5 mg/kg/day once daily. In patients without coronary artery abnormalities, give lower dose for 6-8 weeks. In patients with coronary artery abnormalities, low-dose aspirin should be continued indefinitely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Measles:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     GamaSTAN&trade; S/D: I.M.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Immunocompetent: 0.25",
"     <b>",
"      mL",
"     </b>",
"     /kg given within 6 days of exposure followed by live attenuated measles vaccine in 5-6 months when indicated (CDC, 1998)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Immunocompromised children: 0.5",
"     <b>",
"      mL",
"     </b>",
"     /kg (maximum dose: 15",
"     <b>",
"      mL",
"     </b>",
"     ) immediately following  exposure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gammaked&trade;, Gamunex-C&reg;, Octagam&reg;: I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Prophylaxis in patients with primary humoral immunodeficiency (",
"     <b>",
"      ONLY",
"     </b>",
"     if routine dose is &lt;400 mg/kg): &ge;400 mg/kg immediately before expected exposure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Treatment in patients with primary immunodeficiency: 400 mg/kg administered as soon as possible after exposure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hizentra&reg;: SubQ infusion: Measles exposure in patients with primary humoral immunodeficiency: Weekly dose: &ge;200 mg/kg for 2 consecutive weeks for patients at risk of measles exposure (eg, during an outbreak; travel to endemic area). In patients who have been exposed to measles, administer the minimum dose as soon as possible following exposure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Multifocal motor neuropathy (MMN) (Gammagard&reg; liquid):",
"     </b>",
"     I.V.: 500-2400 mg/kg/month based upon response",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Primary humoral immunodeficiency disorders:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.V. infusion dosing:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Bivigam&trade;, Gammaplex&reg;: I.V.: 300-800 mg/kg every 3-4 weeks; dose adjusted based on monitored trough serum IgG concentrations and clinical response",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Carimune&reg; NF: I.V.: 400-800 mg/kg every 3-4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Flebogamma&reg; DIF, Gammagard&reg; Liquid, Gammagard S/D&reg;, Gammaked&trade;, Gamunex-C&reg;, Octagam&reg;: I.V.: 300-600 mg/kg every 3-4 weeks; dose adjusted based on monitored trough serum IgG concentrations and clinical response",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Privigen&reg;: I.V.: 200-800 mg/kg every 3-4 weeks; dose adjusted based on monitored trough serum IgG concentrations and clinical response",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Switching to weekly subcutaneous infusion dosing:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Gammagard&reg; Liquid, Gammaked&trade;, Gamunex-C&reg;: SubQ infusion: Begin 1 week after last I.V. dose. Use the following equation to calculate initial dose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Initial weekly dose (g) = [1.37 x IGIV dose (g)] divided by [I.V. dose interval (weeks)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     For subsequent dose adjustments, refer to product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Hizentra&reg;: SubQ infusion: Begin 1 week after last I.V. dose.",
"     <b>",
"      Note:",
"     </b>",
"     Patient should have received an I.V. immune globulin routinely for at least 3 months before switching to SubQ. Use the following equation to calculate initial dose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Initial weekly dose (g) = [1.53 x IGIV dose (g)] divided by [I.V. dose interval (weeks)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     For subsequent dose adjustments, refer to product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Rubella (GamaSTAN&trade; S/D):",
"     </b>",
"     I.M.: Prophylaxis during pregnancy: 0.55",
"     <b>",
"      mL",
"     </b>",
"     /kg within 72 hours of exposure (CDC, 1998)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Varicella (GamaSTAN&trade; S/D):",
"     </b>",
"     I.M.: Prophylaxis: 0.6-1.2",
"     <b>",
"      mL",
"     </b>",
"     /kg (varicella zoster immune globulin preferred) within 72 hours of exposure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Unlabeled uses:",
"      </i>",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Acquired hypogammaglobulinemia secondary to malignancy (unlabeled use):",
"     </b>",
"     Adults: 400 mg/kg/dose every 3 weeks; reevaluate every 4-6 months (Anderson, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Guillain-Barr&eacute; syndrome (unlabeled use):",
"     </b>",
"     Children and Adults: Various regimens have been used, including:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     400 mg/kg/day for 5 days  (Hughes, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     400 mg/kg/day for 6 days (Patwa, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     2000 mg/kg in divided doses administered over 2-5 days (Feasby, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Hematopoietic stem cell transplantation with hypogammaglobulinemia (CDC guidelines, 2000; unlabeled use):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children: 400 mg/kg per month; increase dose or frequency to maintain IgG levels &gt;400 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adolescents and Adults: 500 mg/kg/week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      HIV-associated thrombocytopenia (unlabeled use):",
"     </b>",
"     Adults: 1000 mg/kg/day for 2 days (Anderson, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Lambert-Eaton myasthenic syndrome (LEMS) (unlabeled use):",
"     </b>",
"     Adults: 1000 mg/kg/day for 2 days (Bain, 1996; Patwa, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Multiple sclerosis (relapsing-remitting, when other therapies cannot be used) (unlabeled use):",
"     </b>",
"     Children and Adults: 1000 mg/kg per month, with or without an induction of 400 mg/kg/day for 5 days (Feasby, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Myasthenia gravis (severe exacerbation) (unlabeled use):",
"     </b>",
"     Children and Adults: 2000 mg/kg per treatment course over 2-5 days (Feasby, 2007; Patwa, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Refractory dermatomyositis/polymyositis (unlabeled uses):",
"     </b>",
"     Children and Adults: 2000 mg/kg per treatment course administered over 2-5 days (Feasby, 2007)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F11513276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/55/15226?source=see_link\">",
"      see \"Immune globulin: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"     <b>",
"      Note:",
"     </b>",
"     Gammaplex&reg; is",
"     <b>",
"      not",
"     </b>",
"     indicated for use in children. Gammagard&reg; liquid is",
"     <b>",
"      not",
"     </b>",
"     indicated for use in children with multifocal motor neuropathy (MMN).",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F11513278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F11513279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     I.V.: Use with caution due to risk of immune globulin-induced renal dysfunction; the rate of infusion and concentration of solution should be minimized.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     I.M., SubQ infusion: No dosage adjustment provided in the manufacturer&rsquo;s labeling; risk of immune globulin-induced renal dysfunction has not been identified with I.M. and SubQ infusion administration.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15897621\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.M., I.V., SubQ infusion: No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F11513299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Carimune&reg; NF: 3 g, 6 g, 12 g [contains sucrose]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gammagard S/D&reg;: 2.5 g [DSC] [contains albumin (human), glucose, glycine, natural rubber/natural latex in packaging, polyethylene glycol, polysorbate 80; IgA &lt;2.2 mcg/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gammagard S/D&reg;: 5 g [contains albumin (human), glucose, glycine, natural rubber/natural latex in packaging, polyethylene glycol, polysorbate 80; IgA &lt;1 mcg/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gammagard S/D&reg;: 5 g [DSC] [contains albumin (human), glucose, glycine, natural rubber/natural latex in packaging, polyethylene glycol, polysorbate 80; IgA &lt;2.2 mcg/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gammagard S/D&reg;: 10 g [contains albumin (human), glucose, glycine, natural rubber/natural latex in packaging, polyethylene glycol, polysorbate 80; IgA &lt;1 mcg/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gammagard S/D&reg;: 10 g [DSC] [contains albumin (human), glucose, glycine, natural rubber/natural latex in packaging, polyethylene glycol, polysorbate 80; IgA &lt;2.2 mcg/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bivigam&trade;: 10% [100 mg/mL] (50 mL, 100 mL) [sucrose free; contains glycine, polysorbate 80]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Flebogamma&reg; DIF: 5% [50 mg/mL] (10 mL, 50 mL, 100 mL, 200 mL, 400 mL); 10% [100 mg/mL] (100 mL, 200 mL) [contains polyethylene glycol, sorbitol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     GamaSTAN&trade; S/D: 15% to 18% [150 to 180 mg/mL] (2 mL, 10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gammagard&reg; Liquid: 10% [100 mg/mL] (10 mL, 25 mL, 50 mL, 100 mL, 200 mL, 300 mL) [sucrose free; contains glycine]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gammaked&trade;: 10% [100 mg/mL] (10 mL, 25 mL, 50 mL, 100 mL, 200 mL) [sucrose free; contains glycine]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gammaplex&reg;: 5% [50 mg/mL] (50 mL, 100 mL, 200 mL) [sucrose free; contains glycine, natural rubber/natural latex in packaging, polysorbate 80, sorbitol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gamunex&reg;-C: 10% [100 mg/mL] (10 mL, 25 mL, 50 mL, 100 mL, 200 mL) [contains glycine]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hizentra&reg;: 20% [200 mg/mL] (5 mL, 10 mL, 20 mL) [contains L-proline, polysorbate 80]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Octagam&reg;: 5% [50 mg/mL] (20 mL, 50 mL, 100 mL, 200 mL) [sucrose free; contains maltose, sodium 30 mmol/L]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Privigen&reg;: 10% [100 mg/mL] (50 mL, 100 mL, 200 mL) [sucrose free; contains L-proline]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F11513236\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F15841018\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bivigam&trade;: FDA approved December 2012; anticipated availability is currently undetermined. Consult prescribing information for additional information.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F11513282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     If plasmapheresis employed for treatment of condition, administer immune globulin",
"     <b>",
"      after",
"     </b>",
"     completion of plasmapheresis session.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;\">",
"     I.M.: Administer I.M. in the anterolateral aspects of the upper thigh or deltoid muscle of the upper arm. Avoid gluteal region due to risk of injury to sciatic nerve. Divide doses &gt;10 mL and inject in multiple sites.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     GamaSTAN&trade; S/D is for I.M. administration only.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     I.V. infusion: Infuse over 2-24 hours; administer in separate infusion line from other medications; if using primary line, flush with NS or D",
"     <sub>",
"      5",
"     </sub>",
"     W (product specific; consult  product prescribing information) prior to administration. Decrease dose, rate and/or concentration of infusion in patients who may be at risk of renal failure. Decreasing the rate or stopping the infusion may help relieve some adverse effects (flushing, changes in pulse rate, changes in blood pressure). Epinephrine should be available during administration. For initial treatment or in the elderly, a lower concentration and/or a slower rate of infusion should be used. Initial rate of administration and titration is specific to each IVIG product. Refrigerated product should be warmed to room temperature prior to infusion. Some products require filtration; refer to individual product labeling. Antecubital veins should be used, especially with concentrations &ge;10% to prevent injection site discomfort.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Bivigam&trade; 10%: Primary humoral immunodeficiency: Initial (first 10 minutes): 0.5 mg/kg/minute (0.3",
"     <b>",
"      mL",
"     </b>",
"     /kg/",
"     <b>",
"      hour",
"     </b>",
"     ); Maintenance: Increase every 20 minutes (if tolerated) by 0.8 mg/kg/minute (0.48",
"     <b>",
"      mL",
"     </b>",
"     /kg/",
"     <b>",
"      hour)",
"     </b>",
"     up to 6 mg/kg/minute (3.6",
"     <b>",
"      mL",
"     </b>",
"     /kg/",
"     <b>",
"      hour",
"     </b>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Carimune&reg; NF: Refer to product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Flebogamma&reg; DIF 10%: Primary humoral immunodeficiency: Initial: 1 mg/kg/minute (0.6",
"     <b>",
"      mL",
"     </b>",
"     /kg/",
"     <b>",
"      hour",
"     </b>",
"     ); Maintenance: Increase slowly (if tolerated) up to 8 mg/kg/minute (4.8",
"     <b>",
"      mL",
"     </b>",
"     /kg/",
"     <b>",
"      hour",
"     </b>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Gammagard&reg; Liquid 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Multifocal motor neuropathy (MMN): Initial: 0.8 mg/kg/minute (0.5",
"     <b>",
"      mL/",
"     </b>",
"     kg/",
"     <b>",
"      hour",
"     </b>",
"     ); Maintenance: Increase gradually (if tolerated) up to 9 mg/kg/minute (5.4",
"     <b>",
"      mL",
"     </b>",
"     /kg/",
"     <b>",
"      hour",
"     </b>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Primary humoral immunodeficiency: Initial (first 30 minutes): 0.8 mg/kg/minute (0.5",
"     <b>",
"      mL",
"     </b>",
"     /kg/",
"     <b>",
"      hour",
"     </b>",
"     ); Maintenance: Increase every 30 minutes (if tolerated) up to: 8 mg/kg/minute (5",
"     <b>",
"      mL",
"     </b>",
"     /kg/",
"     <b>",
"      hour",
"     </b>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Gammagard S/D&reg;: 5% solution: Initial: 0.5",
"     <b>",
"      mL",
"     </b>",
"     /kg/",
"     <b>",
"      hour",
"     </b>",
"     ; may increase (if tolerated) to a maximum rate of 4",
"     <b>",
"      mL",
"     </b>",
"     /kg/",
"     <b>",
"      hour",
"     </b>",
"     . If 5% solution is tolerated at maximum rate, may administer 10% solution with an initial rate of 0.5",
"     <b>",
"      mL",
"     </b>",
"     /kg/",
"     <b>",
"      hour",
"     </b>",
"     ; may increase (if tolerated) to a maximum rate of 8",
"     <b>",
"      mL/",
"     </b>",
"     kg/",
"     <b>",
"      hour",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Gammaked&trade; 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     CIDP: Initial (first 30 minutes): 2 mg/kg/minute (1.2",
"     <b>",
"      mL",
"     </b>",
"     /kg/",
"     <b>",
"      hour",
"     </b>",
"     ); Maintenance: Increase gradually (if tolerated) up to 8 mg/kg/minute (",
"     <b>",
"      4.8 mL/kg/hour",
"     </b>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Primary humoral immunodeficiency or ITP: Initial (first 30 minutes): 1 mg/kg/minute (0.6",
"     <b>",
"      mL",
"     </b>",
"     /kg/",
"     <b>",
"      hour",
"     </b>",
"     ); Maintenance: Increase gradually (if tolerated) up to 8 mg/kg/minute (4.8",
"     <b>",
"      mL",
"     </b>",
"     /kg/",
"     <b>",
"      hour",
"     </b>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Gammaplex 5%: Primary humoral immunodeficiency or ITP: Initial (first 15 minutes): 0.5 mg/kg/minute (0.6",
"     <b>",
"      mL",
"     </b>",
"     /kg/",
"     <b>",
"      hour",
"     </b>",
"     ); Maintenance: Increase every 15 minutes (if tolerated) up to 4 mg/kg/minute (4.8",
"     <b>",
"      mL",
"     </b>",
"     /kg/",
"     <b>",
"      hour",
"     </b>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Gamunex&reg;-C 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     CIDP: Initial (first 30 minutes): 2 mg/kg/minute (1.2",
"     <b>",
"      mL",
"     </b>",
"     /kg/",
"     <b>",
"      hour",
"     </b>",
"     ); Maintenance: Increase gradually (if tolerated) up to 8 mg/kg/minute (4.8",
"     <b>",
"      mL",
"     </b>",
"     /kg/",
"     <b>",
"      hour",
"     </b>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Primary humoral immunodeficiency or ITP: Initial (first 30 minutes): 1 mg/kg/minute (0.6",
"     <b>",
"      mL",
"     </b>",
"     /kg/",
"     <b>",
"      hour",
"     </b>",
"     ); Maintenance: Increase gradually (if tolerated) up to 8 mg/kg/minute (4.8",
"     <b>",
"      mL",
"     </b>",
"     /kg/",
"     <b>",
"      hour",
"     </b>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Octagam&reg; 5%: Primary humoral immunodeficiency: Initial (first 30 minutes): 0.5 mg/kg/minute (0.6",
"     <b>",
"      mL",
"     </b>",
"     /kg/",
"     <b>",
"      hour",
"     </b>",
"     ); Maintenance: Double infusion rate (if tolerated) every 30 minutes up to a maximum rate of &lt; 3.33 mg/kg/minute (4.2",
"     <b>",
"      mL",
"     </b>",
"     /kg/",
"     <b>",
"      hour",
"     </b>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Privigen&reg; 10%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     ITP: Initial: 0.5 mg/kg/minute (0.3",
"     <b>",
"      mL",
"     </b>",
"     /kg/",
"     <b>",
"      hour",
"     </b>",
"     ); Maintenance: Increase gradually (if tolerated) up to 4 mg/kg/minute (2.4",
"     <b>",
"      mL",
"     </b>",
"     /kg/",
"     <b>",
"      hour",
"     </b>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Primary humoral immunodeficiency: Initial: 0.5 mg/kg/minute (0.3",
"     <b>",
"      mL",
"     </b>",
"     /kg/",
"     <b>",
"      hour",
"     </b>",
"     ); Maintenance: Increase gradually (if tolerated) up to 8 mg/kg/minute (4.8",
"     <b>",
"      mL",
"     </b>",
"     /kg/",
"     <b>",
"      hour",
"     </b>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     SubQ infusion: Initial dose should be administered in a healthcare setting capable of providing monitoring and treatment in the event of hypersensitivity. Using aseptic technique, follow the infusion device manufacturer&rsquo;s instructions for filling the reservoir and preparing the pump. Remove air from administration set and needle by priming. Appropriate injection sites include the abdomen, thigh, upper arm, lower back, and/or lateral hip; dose may be infused into multiple sites (spaced &ge;2 inches apart) simultaneously. After the sites are clean and dry, insert subcutaneous needle and prime administration set. Attach sterile needle to administration set, gently pull back on the syringe to assure a blood vessel has not been inadvertently accessed (do not use needle and tubing if blood present). Repeat for each injection site; deliver the dose following instructions for the infusion device. Rotate the site(s) weekly. Treatment may be transitioned to the home/home care setting in the absence of adverse reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Gammagard&reg; Liquid:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Injection sites: &le;8 simultaneous injection sites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Initial infusion rate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">",
"     &lt;40 kg: 15 mL/hour per injection site (maximum volume: 20 mL per injection site)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">",
"     &ge;40 kg: 20 mL/hour per injection site (maximum volume: 30 mL per injection site)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Maintenance infusion rate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">",
"     &lt;40 kg: 15-20 mL/hour per injection site (maximum volume: 20 mL per injection site)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">",
"     &ge;40 kg: 20-30 mL/hour per injection site (maximum volume: 30 mL per injection site)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Gammaked&trade;, Gamunex-C&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Injection sites: &le;8 simultaneous injection sites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Recommended infusion rate: 20 mL/hour per injection site",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Hizentra&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Injection sites: &le;4 simultaneous injection sites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Maximum infusion rate: First infusion: 15 mL/hour per injection site; subsequent infusions: 25 mL/hour per injection site (maximum: 50 mL/hour for all simultaneous sites combined)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Maximum infusion volume: First 4 infusions: 15 mL per injection site; subsequent infusions: 20 mL per injection site (maximum: 25 mL per site as tolerated)",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F11513264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable (variable/product dependent) in D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      15",
"     </sub>",
"     W, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Fluconazole, sargramostim.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F11513241\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Treatment of primary humoral immunodeficiency syndromes (congenital agammaglobulinemia, severe combined immunodeficiency syndromes [SCIDS], common variable immunodeficiency, X-linked immunodeficiency, Wiskott-Aldrich syndrome) (Bivigam&trade;, Carimune&reg; NF, Flebogamma&reg; DIF, Gammagard&reg; Liquid, Gammagard S/D&reg;, Gammaked&trade;, Gammaplex&reg;, Gamunex&reg;-C, Hizentra&reg;, Octagam&reg;, Privigen&reg;)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Treatment of acute and chronic immune (idiopathic) thrombocytopenic purpura (ITP) (Carimune&reg; NF, Gammagard S/D&reg;, Gammaked&trade;, Gammaplex&reg; [chronic only], Gamunex&reg;-C, Privigen&reg; [chronic only])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) (Gammaked&trade;, Gamunex&reg;-C)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Treatment of multifocal motor neuropathy (MMN) (Gammagard&reg; Liquid)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Prevention of coronary artery aneurysms associated with Kawasaki syndrome (in combination with aspirin) (Gammagard S/D&reg;)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Prevention of bacterial infection in patients with hypogammaglobulinemia and/or recurrent bacterial infections with B-cell chronic lymphocytic leukemia (CLL) (Gammagard S/D&reg;)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Prevention of serious infection in immunoglobulin deficiency (select agammaglobulinemias) (GamaSTAN&trade; S/D)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Provision of  passive immunity in the following susceptible individuals (GamaSTAN&trade; S/D):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatitis A: Pre-exposure prophylaxis; postexposure: within 14 days and/or prior to manifestation of disease",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Measles: For use within 6 days of exposure in an unvaccinated person, who has not previously had measles",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rubella: Postexposure prophylaxis (within 72 hours) to reduce the risk of infection and fetal damage in exposed pregnant women who will not consider therapeutic abortion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Varicella: For immunosuppressed patients when varicella zoster immune globulin is not available",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F11513242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acquired hypogammaglobulinemia secondary to malignancy; Guillain-Barr&eacute; syndrome; hematopoietic stem cell transplantation (HSCT), to prevent bacterial infections among allogeneic recipients with severe hypogammaglobulinemia (IgG &lt;400 mg/dL) at &lt;100 days post transplant (CDC guidelines); HIV-associated thrombocytopenia; multiple sclerosis (relapsing, remitting when other therapies cannot be used); Lambert-Eaton myasthenic syndrome (LEMS); myasthenia gravis; refractory dermatomyositis/polymyositis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F11513231\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Gamimune&reg; N may be confused with CytoGam&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Immune globulin (intravenous) may be confused with hepatitis B immune globulin",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F11513250\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not always defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Chest tightness (7%), hypertension (5% to 6%), angioedema, edema, flushing of the face, hypotension, palpitation, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Headache (16% to 48%), fever (6% to 16%), chills (3% to 6%), dizziness (1% to 6%), malaise (1%), anxiety, aseptic meningitis syndrome, drowsiness, fatigue, irritability, lethargy, lightheadedness, migraine, pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Bruising, contact dermatitis, eczema, erythema, hyperhidrosis, petechiae, pruritus, purpura, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperglycemia (neuromuscular disease: 1%) dehydration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea (3% to 18%), anorexia (neuromuscular disease: 1%), abdominal cramps, abdominal pain, diarrhea, discomfort, dyspepsia, gastroenteritis, sore throat, toothache, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, autoimmune hemolytic anemia, hematocrit decreased, hematoma, hemolysis (mild), hemorrhage, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Bilirubin increased, LDH increased, liver function test increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Muscle stiffness at I.M. site; pain, swelling, redness or irritation at the infusion site",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle spasm (MMN 7%), weakness (1%; MMN: 7%), arthralgia (1%), back or hip pain, leg cramps, muscle cramps, myalgia, neck pain, rigors",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Conjunctivitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Ear pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Acute renal failure, acute tubular necrosis, anuria, BUN increased, creatinine increased, oliguria, proximal tubular nephropathy, osmotic nephrosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Oropharyngeal pain (7%), asthma aggravated, bronchitis, cough, dyspnea, epistaxis, nasal congestion, pharyngeal pain, pharyngitis, rhinitis, rhinorrhea, sinus headache, sinusitis, upper respiratory infection, wheezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis, diaphoresis, flu-like syndrome, hypersensitivity reactions, infusion reaction, thermal burn",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Apnea, ARDS, autoimmune pure red cell aplasia (PRCA) exacerbation, bronchopneumonia, bullous dermatitis, cardiac arrest, coma, Coombs' test positive, cyanosis, epidermolysis, erythema multiforme, heart failure, hepatic dysfunction, hypoxemia, leukopenia, loss of consciousness, MI, pancytopenia, phlebitis, pulmonary edema, pulmonary embolism, seizures, Stevens-Johnson syndrome, stroke, thromboembolism, transfusion-related acute lung injury (TRALI), vascular collapse",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F11513246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to immune globulin or any component of the formulation; IgA deficiency (with antibodies against IgA and history of hypersensitivity); hyperprolinemia (Hizentra&reg;, Privigen&reg;); isolated IgA deficiency (GamaSTAN&trade; S/D); severe thrombocytopenia or coagulation disorders where I.M. injections are contraindicated (GamaSTAN&trade; S/D)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F11513247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylaxis/hypersensitivity reactions: Hypersensitivity and anaphylactic reactions can occur; a severe fall in blood pressure may rarely occur with anaphylactic reaction; immediate treatment (including epinephrine 1:1000) should be available.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aseptic meningitis: Aseptic meningitis syndrome (AMS) has been reported with immune globulin administration (rare); may occur with high doses (&ge;1-2 g/kg [product-dependent]) and/or rapid infusion. Syndrome usually appears within several hours to 2 days following treatment; usually resolves within several days after product is discontinued. Patients with a migraine history may be at higher risk for AMS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hematoma: Increased risk of hematoma formation when administered subcutaneously for the treatment of ITP.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hemolysis: Intravenous immune globulin has been associated with antiglobulin hemolysis; monitor for signs of hemolytic anemia. Risk factors associated with hemolysis include high doses (&ge;2 g/kg) given either as a single administration or divided over several days, and non-O blood type.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperproteinemia: Hyperproteinemia, increased serum viscosity, and hyponatremia may occur; distinguish hyponatremia from pseudohyponatremia to prevent volume depletion, a further increase in serum viscosity and a higher risk of thrombotic events.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infusion reactions: Patients should be monitored for adverse events during and after the infusion. Stop administration with signs of infusion reaction (fever, chills, nausea, vomiting, and rarely shock). Risk may be increased with initial treatment, when switching brands of immune globulin, and with treatment interruptions of &gt;8 weeks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pulmonary edema: Monitor for transfusion-related acute lung injury (TRALI); noncardiogenic pulmonary edema has been reported with intravenous immune globulin use. TRALI is characterized by severe respiratory distress, pulmonary edema, hypoxemia, and fever in the presence of normal left ventricular function. Usually occurs within 1-6 hours after infusion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment:",
"     <b>",
"      [U.S. Boxed Warning]: I.V. administration only: Acute renal dysfunction (increased serum creatinine, oliguria, acute renal failure, osmotic nephrosis) can rarely occur and has been associated with fatalities; usually within 7 days of use (more likely with products stabilized with sucrose). Use with caution in the elderly, patients with renal disease, diabetes mellitus, volume depletion, sepsis, paraproteinemia, and nephrotoxic medications due to risk of renal dysfunction.",
"     </b>",
"     In patients at risk of renal dysfunction, the rate of infusion and concentration of solution should be minimized. Discontinue if renal function deteriorates.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thrombotic events: Thrombotic events have been reported with administration of intravenous immune globulin and subcutaneous immune globulin; use with caution in patients with a history of atherosclerosis or cardiovascular and/or thrombotic risk factors, advanced age, impaired cardiac output, or patients with known/suspected hyperviscosity. Consider a baseline assessment of blood viscosity in patients at risk for hyperviscosity such as those with cryoglobulins, fasting chylomicronemia/severe hypertriglyceridemia, or monoclonal gammopathies. In patients at risk of thrombotic events, the rate of infusion should be minimized.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fluid overload: High-dose regimens (1 g/kg for 1-2 days) are not recommended for individuals with fluid overload or where fluid volume may be of concern.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypovolemia: Patients should not be volume depleted prior to initiation of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; IgA deficiency: Increased risk of hypersensitivity, especially in patients with anti-IgA antibodies; use is contraindicated in patients with IgA deficiency (with antibodies against IgA and history of hypersensitivity) or isolated IgA deficiency (GamaSTAN&trade; S/D).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; ITP, chronic: Consider risk versus benefit for high-dose regimen in patients with increased risk of thrombosis, hemolysis, acute kidney injury, or volume overload.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; may be at increased risk for renal dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Human plasma: Product of human plasma; may potentially contain infectious agents which could transmit disease. Screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces the risk. Infections thought to be transmitted by this product should be reported to the manufacturer.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Latex: Packaging of some products may contain natural latex/natural rubber.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; L-proline: Hizentra&reg; and Privigen&reg; contain the stabilizer L-proline and are contraindicated in patients with hyperprolinemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Maltose: Some products may contain maltose, which may result in falsely-elevated blood glucose readings. Maltose-containing products are contraindicated with patients with corn allergy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Polysorbate 80: Some products may contain polysorbate 80.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Skin testing: Skin testing should not be performed with GamaSTAN&trade; S/D as local irritation can occur and be misinterpreted as a positive reaction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sodium: Some products may contain sodium.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sorbitol: Some products may contain sorbitol; do not use in patients with fructose intolerance.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Subcutaneous administration: Some clinicians may administer intravenous immune globulin products as a subcutaneous infusion based on patient tolerability and clinical judgment. SubQ infusion should begin 1 week after the last I.V. dose; dose should be individualized based on clinical response and serum IgG trough concentrations. Consider premedicating with acetaminophen and diphenhydramine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sucrose: Some products may contain sucrose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Administration: Patients should be adequately hydrated prior to intravenous therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vaccinations: Response to live vaccinations may be impaired.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299513\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F11513254\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immune Globulins may diminish the therapeutic effect of Vaccines (Live).  Management: Live organism vaccination should be withheld for up to 6 months following immune globulin administration.  Live vaccine given immediately prior to immune globulin may require repeat vaccination.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Yellow Fever Vaccine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F11513243\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F11513244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies have not been conducted. Immune globulins cross the placenta in increased amounts after 30 weeks gestation. Intravenous immune globulin has been recommended for use in fetal-neonatal alloimmune thrombocytopenia and pregnancy-associated ITP. May also be used in postexposure prophylaxis for rubella (within 72 hours) to reduce the risk of infection and fetal damage in exposed pregnant women who will not consider therapeutic abortion.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F11513245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F11513281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some products may contain sodium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Bivigam Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 gm/50 mL (50 mL): $719.76",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 g/100 mL (100 mL): $1439.52",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Flebogamma DIF Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5 g/10 mL (10 mL): $49.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5 gm/50 mL (50 mL): $247.98",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 g/100 mL (100 mL): $495.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 gm/50 mL (50 mL): $495.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 g/100 mL (100 mL): $991.92",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 g/200 mL (200 mL): $991.92",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 g/200 mL (200 mL): $1983.84",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 g/400 mL (400 mL): $1983.84",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Flebogamma Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5 g/10 mL (10 mL): $48.38",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5 gm/50 mL (50 mL): $241.92",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 g/100 mL (100 mL): $483.84",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 g/200 mL (200 mL): $967.68",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Gammagard Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 g/10 mL (10 mL): $145.57",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5 g/25 mL (25 mL): $363.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 gm/50 mL (50 mL): $727.86",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 g/100 mL (100 mL): $1455.72",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 g/200 mL (200 mL): $2911.44",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 g/300 mL (300 mL): $4367.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Gammaked Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 g/10 mL (10 mL): $141.21",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5 g/25 mL (25 mL): $353.02",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 gm/50 mL (50 mL): $706.05",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 g/100 mL (100 mL): $1412.10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 g/200 mL (200 mL): $2824.19",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Gammaplex Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5 gm/50 mL (50 mL): $355.68",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 g/100 mL (100 mL): $711.36",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 g/200 mL (200 mL): $1422.72",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Gamunex-C Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 g/10 mL (10 mL): $120.68",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5 g/25 mL (25 mL): $301.72",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 gm/50 mL (50 mL): $603.42",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 g/100 mL (100 mL): $1206.84",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 g/200 mL (200 mL): $2413.68",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Hizentra 20% Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 g/5 mL (5 mL): $151.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 g/10 mL (10 mL): $302.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 g/20 mL (20 mL): $604.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Octagam Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 g/20 mL (20 mL): $133.28",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5 gm/50 mL (50 mL): $333.22",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 g/100 mL (100 mL): $666.42",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 g/200 mL (200 mL): $1332.84",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 g/500 mL (500 mL): $3332.10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Privigen Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 gm/50 mL (50 mL): $700.13",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 g/100 mL (100 mL): $1400.26",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 g/200 mL (200 mL): $2800.51",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Carimune NF Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3 g (1): $318.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6 g (1): $636.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     12 g (1): $1272.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Gammagard S/D Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5 g (1): $339.58",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 g (1): $679.14",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 g (1): $1358.28",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Gammagard S/D Less IgA Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 g (1): $778.14",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 g (1): $1556.28",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F11513287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Renal function, urine output, IgG concentrations, hemoglobin and hematocrit, platelets (in patients with ITP); infusion- or injection-related adverse reactions, anaphylaxis, signs and symptoms of hemolysis; blood viscosity (in patients at risk for hyperviscosity); presence of antineutrophil antibodies (if TRALI is suspected); volume status; neurologic symptoms (if AMS suspected); clinical response",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     For patients at high risk of hemolysis (dose &ge;2 g/kg, given as a single dose or divided over several days, and non-O blood type): Hemoglobin or hematocrit prior to and 36 to 96 hours postinfusion.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     SubQ infusion: Monitor IgG trough levels every 2-3 months before/after conversion from I.V.; subcutaneous infusions provide more constant IgG levels than usual I.V. immune globulin treatments.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F11513265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Replacement therapy for primary and secondary immunodeficiencies, and IgG antibodies against bacteria, viral, parasitic and mycoplasma antigens; interference with F",
"     <sub>",
"      c",
"     </sub>",
"     receptors on the cells of the reticuloendothelial system for autoimmune cytopenias and ITP; provides passive immunity by increasing the antibody titer and antigen-antibody reaction potential",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F11513267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: I.V.: Provides immediate antibody levels",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: I.M., I.V.: Immune effect: 3-4 weeks (variable)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.05-0.13 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Intravascular portion (primarily): Healthy subjects: 41% to 57%; Patients with congenital humoral immunodeficiencies: ~70%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: I.M.: ~23 days; I.V.: IgG (variable among patients): Healthy subjects: 14-24 days; Patients with congenital humoral immunodeficiencies: 26-40 days; hypermetabolism associated with fever and infection have coincided with a shortened half-life",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Plasma: SubQ: Gammagard&reg; Liquid: 2.9 days; Hizentra&reg;: 2.9 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Serum: I.M.: ~48 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Subcommittee on Hyperbilirubinemia, &ldquo;Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2004, 114(1):297-316.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/23/1402/abstract-text/15231951/pubmed\" id=\"15231951\" target=\"_blank\">",
"        15231951",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anderson D, Ali K, Blanchette V, et al, &ldquo;Guidelines on the Use of Intravenous Immune Globulin for Hematologic Conditions,&rdquo;",
"      <i>",
"       Transfus Med Rev",
"      </i>",
"      , 2007, 21(2 Suppl 1):9-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/23/1402/abstract-text/17397769/pubmed\" id=\"17397769\" target=\"_blank\">",
"        17397769",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      ASHP Commission on Therapeutics, &ldquo;ASHP Therapeutic Guidelines for Intravenous Immune Globulin,&rdquo;",
"      <i>",
"       Am J Hosp Pharm",
"      </i>",
"      , 1992, 49(3):652-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/23/1402/abstract-text/1598949/pubmed\" id=\"1598949\" target=\"_blank\">",
"        1598949",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bain PG, Motomura M, Newsom-Davis J, et al, &ldquo;Effects of Intravenous Immunoglobulin on Muscle Weakness and Calcium-Channel Autoantibodies in the Lambert-Eaton Myasthenic Syndrome,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 1996, 47(3):678-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/23/1402/abstract-text/8797464/pubmed\" id=\"8797464\" target=\"_blank\">",
"        8797464",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Blanchette VS, Luke B, Andrew M, et al, &ldquo;A Prospective Randomized Trial of High-Dose Intravenous Immune Globulin G Therapy, Oral Prednisone Therapy, and No Therapy in Childhood Acute Immune Thrombocytopenic Purpura,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1993, 123(6):989-95.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/23/1402/abstract-text/8229536/pubmed\" id=\"8229536\" target=\"_blank\">",
"        8229536",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      British Committee for Standards in Haematology General Haematology Task Force,  &ldquo;Guidelines for the Investigation and Management of Idiopathic Thrombocytopenic Purpura in Adults, Children and in Pregnancy,&rdquo;",
"      <i>",
"       Br J Haematol",
"      </i>",
"      , 2003,  120(4):574-96.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/23/1402/abstract-text/12588344/pubmed\" id=\"12588344\" target=\"_blank\">",
"        12588344",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Guidelines for Preventing Opportunistic Infections Among HIV-Infected Persons - 2002 Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      ,  2002, 51(RR-8):1-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/23/1402/abstract-text/12081007/pubmed\" id=\"12081007\" target=\"_blank\">",
"        12081007",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Guidelines  for Preventing Opportunistic Infections Among Hematopoietic Stem Cell Transplant Recipients: Recommendations of CDC, the Infectious Disease Society of America, and the American Society of Blood and Marrow Transplantation,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2000, 49(RR-10):1-125.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/23/1402/abstract-text/11718124/pubmed\" id=\"11718124\" target=\"_blank\">",
"        11718124",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Measles, Mumps, and Rubella - Vaccine Use and Strategies for Elimination of Measles, Rubella, and Congenital Rubella Syndrome and Control of Mumps: Recommendations of the Advisory Committee on Immunization Practices (ACIP),\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 1998, 47(RR-8):1-57. Available at",
"      <a href=\"file://www.cdc.gov/mmwr/PDF/rr/rr4708.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/mmwr/PDF/rr/rr4708.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/23/1402/abstract-text/9639369/pubmed\" id=\"9639369\" target=\"_blank\">",
"        9639369",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Prevention of Hepatitis A Through Active or Passive Immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP),&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2006, 55(RR-7):1-23. Available at",
"      <a href=\"file://www.cdc.gov/mmwr/PDF/rr/rr5507.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/mmwr/PDF/rr/rr5507.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/23/1402/abstract-text/16708058/pubmed\" id=\"16708058\" target=\"_blank\">",
"        16708058",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cherin P, Herson S, Wechsler B, et al, &ldquo;Efficacy of Intravenous Gammaglobulin Therapy in Chronic Refractory Polymyositis and Dermatomyositis: An Open Study With 20 Adult Patients,&rdquo;",
"      <i>",
"       Am J Med",
"      </i>",
"      , 1991, 91(2):162-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/23/1402/abstract-text/1714235/pubmed\" id=\"1714235\" target=\"_blank\">",
"        1714235",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dalakas MC, &ldquo;Intravenous Immunoglobulin In Autoimmune Neuromuscular Diseases,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2004, 291(19):2367-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/23/1402/abstract-text/15150209/pubmed\" id=\"15150209\" target=\"_blank\">",
"        15150209",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dalakas MC and Hohlfeld R, &ldquo;Polymyositis and Dermatomyositis,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2003, 362(9388):971-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/23/1402/abstract-text/14511932/pubmed\" id=\"14511932\" target=\"_blank\">",
"        14511932",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dalakas MC, Illa I, Dambrosia JM, et al, &ldquo;A Controlled Trial of High-Dose Intravenous Immune Globulin Infusions as Treatment for Dermatomyositis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1993, 329(27):1993-2000.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/23/1402/abstract-text/8247075/pubmed\" id=\"8247075\" target=\"_blank\">",
"        8247075",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dattani SJ and Connelly JF, &ldquo;Oral Immunoglobulins for Gastroenteritis,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1996, 30(11):1323-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/23/1402/abstract-text/8913416/pubmed\" id=\"8913416\" target=\"_blank\">",
"        8913416",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Eijkhout HW, van Der Meer JW, Kallenberg CG, et al, &ldquo;The Effect of Two Different Dosages of Intravenous Immunoglobulin on the Incidence of Recurrent Infections In Patients With Primary Hypogammaglobulinemia. A Randomized, Double-Blind, Multicenter Crossover Trial,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2001, 135(3):165-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/23/1402/abstract-text/11487483/pubmed\" id=\"11487483\" target=\"_blank\">",
"        11487483",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Feasby T, Banwell B, Benstead T, et al, &ldquo;Guidelines on the Use of Intravenous Immune Globulin for Neurologic Conditions,&rdquo;",
"      <i>",
"       Transfus Med Rev",
"      </i>",
"      , 2007, 21(2 Suppl 1):57-107.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/23/1402/abstract-text/17397768/pubmed\" id=\"17397768\" target=\"_blank\">",
"        17397768",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gottstein R and Cooke RW, &ldquo;Systematic Review of Intravenous Immunoglobulin in Haemolytic Disease of the Newborn,&rdquo;",
"      <i>",
"       Arch Dis Child Fetal Neonatal Ed",
"      </i>",
"      ,  2003, 88(1):F6-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/23/1402/abstract-text/12496219/pubmed\" id=\"12496219\" target=\"_blank\">",
"        12496219",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Grillo JA, Gorson, KC, Ropper AH, et al, &ldquo;Rapid Infusion of Intravenous Immune Globulin in Patients With Neuromuscular Disorders,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 2001, 57:1699-1701.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/23/1402/abstract-text/11706114/pubmed\" id=\"11706114\" target=\"_blank\">",
"        11706114",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gurcan HM and Ahmed AR, &ldquo;Efficacy of Various Intravenous Immunoglobulin Therapy Protocols in Autoimmune and Chronic Inflammatory Disorders,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2007, 41(5):812-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/23/1402/abstract-text/17440006/pubmed\" id=\"17440006\" target=\"_blank\">",
"        17440006",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hilgartner MW and Bussel J, &ldquo;Use of Intravenous Gamma Globulin for the Treatment of Autoimmune Neutropenia of Childhood and Autoimmune Hemolytic Anemia,&rdquo;",
"      <i>",
"       Am J Med",
"      </i>",
"      , 1987, 83(4A):25-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/23/1402/abstract-text/3118705/pubmed\" id=\"3118705\" target=\"_blank\">",
"        3118705",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hughes RA, Bouche P, Cornblath DR, et al, &ldquo;European Federation of Neurological Societies/Peripheral Nerve Society Guideline on Management of Chronic Inflammatory Demyelinating   Polyradiculoneuropathy: Report of a Joint Task Force of the European Federation of Neurological  Societies and the Peripheral Nerve Society,&rdquo;",
"      <i>",
"       Eur J Neurol",
"      </i>",
"      , 2006,  13(4):326-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/23/1402/abstract-text/16643309/pubmed\" id=\"16643309\" target=\"_blank\">",
"        16643309",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hughes RA, Wijdicks EF, Barohn R, et al, &ldquo;Practice Parameter: Immunotherapy for Guillain-Barr&eacute; Syndrome: Report of the Quality Standards Subcommittee of the American Academy of Neurology,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 2003, 61(6):736-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/23/1402/abstract-text/14504313/pubmed\" id=\"14504313\" target=\"_blank\">",
"        14504313",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kuwabara S, &ldquo;Guillain-Barr&eacute; Syndrome: Epidemiology, Pathophysiology and Management,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 2004, 64(6):597-610.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/23/1402/abstract-text/15018590/pubmed\" id=\"15018590\" target=\"_blank\">",
"        15018590",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Morrell A, &ldquo;Pharmacokinetics of Intravenous Immunoglobulin Preparations,&rdquo;",
"      <i>",
"       Intravenous Immunoglobulins in Clinical Practice",
"      </i>",
"      , Lee ML and Strand V eds, New York, NY: Marcel Dekker, Inc, 1997, 1-18.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      NIH Consensus Conference, &ldquo;Intravenous Immunoglobulin, Prevention and Treatment of Disease,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1990, 264(24):3189-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/23/1402/abstract-text/2255028/pubmed\" id=\"2255028\" target=\"_blank\">",
"        2255028",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Newburger JW, Takahashi M, Gerber MA, et al, &ldquo;Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Statement for Health Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2004,  114(6):1708-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/23/1402/abstract-text/15574639/pubmed\" id=\"15574639\" target=\"_blank\">",
"        15574639",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Orange JS, Hossny EM, Weiler CR, et al, &ldquo;Use of Intravenous Immunoglobulin in Human Disease: A Review of Evidence by Members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology,&rdquo;",
"      <i>",
"       J Allergy Clin Immunol",
"      </i>",
"      , 2006, 117(4 Suppl):525-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/23/1402/abstract-text/16580469/pubmed\" id=\"16580469\" target=\"_blank\">",
"        16580469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Patwa HS, Chaudhry V, Katzberg H, et al, &ldquo;Evidence-Based Guideline: Intravenous Immunoglobulin in the Treatment of Neuromuscular Disorders: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 2012, 78(13):1009-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/23/1402/abstract-text/22454268/pubmed\" id=\"22454268\" target=\"_blank\">",
"        22454268",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Siegel J, &ldquo;Immunoglobulins and Obesity,&rdquo;",
"      <i>",
"       Pharmacy Practice News",
"      </i>",
"      ,  2010, 37:1.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Skvaril F and Gardi A, &ldquo;Differences Among Available Immunoglobulin Preparations for Intravenous Use,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1988, 7:543-48.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;University Hospital Consortium Expert Panel for Off-Label Use of Polyvalent Intravenously Administered Immunoglobulin Preparations Consensus Statement,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1995, 273(23):1865-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/23/1402/abstract-text/7776504/pubmed\" id=\"7776504\" target=\"_blank\">",
"        7776504",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van Schaik IN, Winer JB, de Haan R, et al,  &ldquo;Intravenous Immunoglobulin for Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Systematic Review,&rdquo;",
"      <i>",
"       Lancet Neurol",
"      </i>",
"      , 2002, 1(8):491-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/23/1402/abstract-text/12849334/pubmed\" id=\"12849334\" target=\"_blank\">",
"        12849334",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16471 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-EF0CD76C64-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_23_1402=[""].join("\n");
var outline_f1_23_1402=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15601262\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11513229\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11513233\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11513234\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11513238\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11513277\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11513276\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11513278\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11513279\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15897621\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11513299\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11513236\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15841018\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11513282\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11513264\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11513241\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11513242\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11513231\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11513250\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11513246\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11513247\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299513\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11513254\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11513243\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11513244\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11513245\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11513281\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322887\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11513287\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11513265\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11513267\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16471\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16471|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?15/54/16230?source=related_link\">",
"      Immune globulin: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/55/15226?source=related_link\">",
"      Immune globulin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_23_1403="Age of fontanelle closure";
var content_f1_23_1403=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F57361&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F57361&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Age of Fontanelle closure",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Fontanelle",
"       </td>",
"       <td class=\"subtitle1\">",
"        Closure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Posterior",
"       </td>",
"       <td>",
"        Two months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anterior lateral",
"       </td>",
"       <td>",
"        Three months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Posterior lateral",
"       </td>",
"       <td>",
"        One year",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anterior",
"       </td>",
"       <td>",
"        Two years",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_23_1403=[""].join("\n");
var outline_f1_23_1403=null;
var title_f1_23_1404="Types genital tract anomalies";
var content_f1_23_1404=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F50939&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F50939&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Acien classification of genital tract anomalies",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"1\">",
"        Agenesis or hypoplasia of the entire urogenital ridge",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        Unicornuate uterus with uterine, tubal, ovarian, and renal agenesis on the contralateral side",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"1\">",
"        Mesonephric anomalies with",
"absence of both opening of the Wolffian duct to the urogenital sinus",
"and ureteral bud sprouting leading to utero-vaginal duplicity and a",
"blind hemivagina ipsilateral with renal agenesis:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unilateral hematocolpos",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        Gartner's pseudocyst on the anterolateral wall of the vagina",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        Partial reabsorption of intervaginal septum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        Vaginal",
"or complete cervico-vaginal unilateral agenesis, ipsilateral with the",
"renal agenesis, and (1) with no communication, or (2) with",
"communication between both hemiuteri",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Isolated M&uuml;llerian anomalies:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        M&uuml;llerian ducts: unicornuate (generally, with rudimentary uterine horn), bicornuate, septate and didelphys uterus.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        M&uuml;llerian tubercle: cervico-vaginal atresia and segmentary anomalies such as transverse vaginal septum.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        M&uuml;llerian tubercle and ducts: (uni- or bilateral) Mayer-Rokitansky-Kuster-Hauser syndrome.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Anomalies of the urogenital sinus:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cloacal anomalies etc.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Malformative combinations:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        Wolfian, M&uuml;llerian and cloacal anomalies.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Acien, P, Acien, M, Sanchez-Ferrer, M. Human Reproduction 2004; 19:2377.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_23_1404=[""].join("\n");
var outline_f1_23_1404=null;
var title_f1_23_1405="PCO2 and HCO3 reabsorption";
var content_f1_23_1405=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F75228&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F75228&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    PCO2 and bicarbonate reabsorption",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 292px; height: 233px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Relationship between arterial PCO2 and HCO3- reabsorption. Note the curve is steepest in the physiologic range (PCO2 of 15 to 90 mmHg).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Rector, FC Jr, Seldin, DW, Roberts, AD Jr, Smith, JS, J Clin Invest 1960; 39:1706, by copyright permission of the American Society for Clinical Investigation.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_23_1405=[""].join("\n");
var outline_f1_23_1405=null;
var title_f1_23_1406="Increased inspiratory flow rate";
var content_f1_23_1406=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F50636&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F50636&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Increased inspiratory flow rate",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 327px; height: 474px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The changes in arterial oxygen tension (PaO2, top) and venous admixture (QVA/QT, bottom) on increasing inspiratory flow (VI) from 40 to 70 and 100 L/min in patients with chronic obstructive pulmonary disease (COPD) and in patients with other causes of respiratory failure. As VI increased, PaO2 increased and QVA/QT decreased in patients with COPD; no change was noted in patients with other causes of respiratory failure.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Connors, AF, McCaffree, DR, Gray, BA, Am Rev Respir Dis 1981; 124:537.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_23_1406=[""].join("\n");
var outline_f1_23_1406=null;
var title_f1_23_1407="Capillary loop changes JDM";
var content_f1_23_1407=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F57651&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F57651&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pre-ungual capillary loop changes in a patient with juvenile dermatomyositis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 211px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ross Petty, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_23_1407=[""].join("\n");
var outline_f1_23_1407=null;
